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WITNESS SEMINARS: 
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, as part of the Academic Unit of the Wellcome Institute for the History 
of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential beneﬁts 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic afﬁliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome 
Trust continues to fund the Witness Seminar programme via its support for the 
Wellcome Trust Centre.
The Witness Seminar is a particularly specialized form of oral history, where 
several people associated with a particular set of circumstances or events are 
invited to come together to discuss, debate, and agree or disagree about their 
memories. To date, the History of Twentieth Century Medicine Group has 
held 40 such meetings, most of which have been published, as listed on pages 
xi–xix.
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been 
agreed, suitable participants are identiﬁed and invited. This inevitably leads to 
further contacts, and more suggestions of people to invite. As the organization 
of the meeting progresses, a ﬂexible outline plan for the meeting is devised, 
usually with assistance from the meeting’s chairman, and some participants are 
invited to ‘set the ball rolling’ on particular themes, by speaking for a short 
period to initiate and stimulate further discussion.
1  The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.
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Each meeting is fully recorded, the tapes are transcribed and the unedited 
transcript is immediately sent to every participant. Each is asked to check his 
or her own contributions and to provide brief biographical details. The editors 
turn the transcript into readable text, and participants’ minor corrections and 
comments are incorporated into that text, while biographical and bibliographical 
details are added as footnotes, as are more substantial comments and additional 
material provided by participants. The ﬁnal scripts are then sent to every 
contributor, accompanied by forms assigning copyright to the Wellcome Trust.2 
Copies of all additional correspondence received during the editorial process 
are deposited with the records of each meeting in Archives and Manuscripts, 
Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and signiﬁcance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
Members of the Programme Committee of the
History of Twentieth Century Medicine Group, 2005–06
Dr Tilli Tansey – Historian of Modern Medical Science,Wellcome Trust Centre for the 
History of Medicine at UCL (WTCHM) and Chair
Sir Christopher Booth – WTCHM, former Director, Clinical Research Centre, 
Northwick Park Hospital, London
Dr Robert Bud – Principal Curator of Medicine and Manager of Electronic Content, 
Science Museum, London
Dr Daphne Christie – Senior Research Assistant, WTCHM, and Organizing Secretary
Dr John Ford – Retired General Practitioner, Tunbridge Wells
Professor Mark Jackson – Centre for Medical History, Exeter
Professor Ian McDonald – WTCHM, former Professor of Neurology, Institute of 
Neurology, London
Dr Helga Satzinger – WTCHM
Professor Lawrence Weaver – Professor of Child Health, University of Glasgow, and 
Consultant Paediatrician in the Royal Hospital for Sick Children, Glasgow
2  Sir Iain Chalmers authorizes the Wellcome Trust to publish his work and to report or reproduce it in any 
form or media, including offprints, provided that it is understood that the Wellcome Trust’s right to do so 
is nonexclusive.
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INTRODUCTION
The reader may wonder why someone who is currently Director of Oxfam GB is 
writing this introduction. There are two reasons. For many years I was engaged 
in healthcare and believed passionately that we needed to be clear what is good 
evidence about clinical care and then to make sure the knowledge is used in 
practice. Early on, it also became clear to me that information alone was rarely 
sufﬁcient for people to change their practice: the whole wonderful complexity of 
wider culture and beliefs, individuals and their place in social systems comes into 
play. Despite many studies showing consistently that disseminating evidence is 
not enough, there were and still are, many people who ignore this evidence itself 
and are then surprised that change does not happen. 
My second reason for writing this introduction is my own experience. In the 
mid-1980s I went into premature labour, eventually giving birth at 29 weeks’ 
gestation. For the time I was lucky. Because I was a member of the National 
Perinatal Epidemiology Unit advisory committee, I was aware of evidence on 
corticosteroids, lucky too in having an obstetrician who knew the evidence. Both 
of us took it as a matter of course that I should receive corticosteroids. Despite 
the prematurity, I delivered a baby who never needed artiﬁcial ventilation and 
who is, as I write, a healthy 19-year-old. This itself illustrates another point, just 
how important it is that patients should, if they want it, have access to good 
information and should feel able to be involved in decisions about their own 
care. My experience was an excellent example of patient–doctor partnership. 
Fortunately, in recent years, patient involvement has stopped being frowned 
upon and clinicians from all professions are learning how valuable it can be to 
have the patient as a partner.
The use of corticosteroids for women at risk of giving birth prematurely in order 
to reduce respiratory distress in their newborn babies is a fascinating case study 
of change. The corticosteroids Witness Seminar is an intriguing account, ﬁrstly 
of how the discovery was made, particularly the crossover links from animal 
to human studies. Yes, there was a discussion in a tearoom, which led to the 
discovery (pages 5, 20). It may seem serendipitous but one does feel that, with 
the number of people interested in the various facets, it was an idea whose time 
had come and sooner or later the connections would be made. Then there are 
the accounts of those early trials and the difﬁculties in getting people to change 
practice. This part of the story illustrates the importance of good randomized 
controlled trials, with patient numbers and protocols that are robust enough to 
xxii
withstand challenge. For the challenge certainly did come, for those who knew 
some evidence from very poorly researched trials and from those who, through 
their own personal experience, had a powerful inclination not to believe the 
proper trials. The witness evidence illustrates dramatically how one powerful 
experience (a death or near miss perhaps unrelated to the issue at stake) can 
inﬂuence a leading ﬁgure and, because of the personal authority of such 
individuals, prevent change from happening for a long time (see page 64).
Prenatal corticosteroids are now accepted practice and are included in all the 
guidelines, but it is worrying that so many babies would have died, and so many 
parents and babies suffered because the evidence was not put into practice for 
so long. The good news is that there has been a paradigm shift, I believe, in the 
acceptance of evidence-based healthcare. There has also been a dramatic change 
in understanding about what is good evidence, not least through the work of the 
Cochrane Collaboration. Beware though any complacency; remember change 
is so much a matter of culture, beliefs and individual experience. 
Barbara Stocking 
Oxfam GB
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Dr Edmund Hey: I was always taught to check my references before I stand up 
to speak. Most of us haven’t had a chance to check any of our references, but 
it may be that after today’s meeting, some of us will go scurrying away to do 
just that. 
I was provoked into checking up what Wellcome History of Medicine people 
had to say about Sir Peter Medawar and his statement that most scientiﬁc papers 
are a fraud.1 I would encourage you to read what he actually wrote, because it 
isn’t quite how it gets quoted nowadays. It was an unscripted talk, which I 
ﬁnd quite amazing, on the Third Programme [Radio 3] – yes, it was called the 
Third Programme – back in 1963. Since we are in reminiscing mood, I had 
just started my ﬁrst job as a Medical Research Council (MRC) physiologist/
clinician/animal-worker, working with Kenneth Cross. I heard Medawar’s talk 
on the day [it was given] and it had an absolutely profound effect on me. I 
thought I might read a bit of it, but then I found another talk in which he was 
actually interviewed defending this, just three years later. I think we will come 
back to this at the end of the day. 
The issue is what he meant about research being fraudulent. I will just read 
a couple of sentences. The interviewer [Dr John Watkins] says, ‘Arising out 
of your paper, “Is the scientiﬁc paper a fraud?”, which was written under the 
inﬂuence of Karl Popper’s ideas on scientiﬁc method, your answer was “Yes, it is 
a fraud” in the sense that it systematically conceals or distorts the way in which 
the ideas were thought out or developed. Have any of your scientiﬁc papers 
been, in this sense, fraudulent?’ And Peter Medawar replied: 
A good many of my scientiﬁc papers have been moderately fraudulent. 
Let me put it this way:…I have never pretended that the research I 
reported in the scientiﬁc paper was done in the inductive style – that is 
to say by the vacuous collection of facts which then tumbled somehow 
or other into place. I think I have adopted a compromise. I have not 
practised what I have preached, but then I am not the ﬁrst person to 
fail to do so.
1 Pyke (1990): 228–33, originally published in The Listener 70 (12 September 1963). Freely available 
online at www.dpi.inpe.br/cursos/ser212/artigos/ medawar_paper_fraud.pdf (visited 2 August 2005). See 
also ‘What is a Witness Seminar?’, introduction by Tilli Tansey to Tansey et al. (eds) (1997): i–v, freely 
available online at www.ucl.ac.uk/histmed following the links to Publications/Wellcome Witnesses.
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What he goes on to puzzle about is what it is that is the creative inspirational 
act at the beginning of that. He comes to the conclusion that he just hadn’t the 
faintest idea. He says: 
All that we know about it is that, whatever precedes the entry of an idea 
into the mind, isn’t known consciously. It is something subconscious. 
There is a piecing together and a putting together of something in the 
mind, but the process by which we do it is totally unknown.2 
I am not sure that’s true. Sir Peter Medawar was a Nobel Prizewinner. He knew 
more about this than most. He made many very brilliant discoveries himself. 
But I will come back at the end of the afternoon and ask whether it is not fairly 
clear how Mont Liggins came to make the discovery he did. The papers he 
wrote describe the process very succinctly. If we can agree about this we are then 
left to spend most of today realizing that great ideas are 1 per cent inspiration 
and 99 per cent perspiration. I suspect we are going to wonder why we went on 
to perspire quite as heavily as we did over this particular inspiration, and why it 
is that some of us are still mopping our brow and realizing that we still haven’t 
got things sorted. 
I think that we should start by asking Mel Avery, who has come all the way from 
Boston – although I think she’s been on the Rhine until a few days ago – to 
set the scene, because 30, 40 years ago clinicians and physiologists and animal 
research workers were much closer together than they often are nowadays. 
Certainly in the UK it’s very uncommon for you to meet a person who spends 
some days in the lab and some days on the farm or in the animal laboratory. But 
you can tell us your story, because years ago much of what we understand now 
about the lung came from the combination of those interests, didn’t it?
Dr Mary Ellen (Mel) Avery:  I bring you a personal view of the discovery of aspects 
of maturation of the lung in the preterm infant by antenatal glucocorticoids. 
The story really began with Professor G C (Mont) Liggins, an obstetrician 
in Auckland. I am happy to acknowledge that he has been a most generous 
supporter and friend and we were in close touch during the 1960s and 1970s, 
when this story evolved. 
2 ‘My Life in Science’, a transcript of an interview with Sir Peter Medawar conducted by David Wilson and 
Dr John Watkins, was broadcast on the BBC Third Programme [now Radio 3] on 25 April 1966. Published 
in Pyke (1990): 1–14. Quotes from pages 5–6 of the 1991 paperback edition.
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I was asked to give a personal point of view and I will tell you how I got into the 
act. The studies of sheep were initiated largely, I think, in this country, England, 
with Sir Joseph Barcroft and Don Barron also working with Maureen Young.3 I 
was ﬁnishing a fellowship supported by the National Institutes of Health (NIH) 
from 1957 to 1959 and then a fellowship from the Markle Foundation. So I was 
set free. I decided to go to the UK, because I had been associated with Clement 
Smith and knew that he felt great fondness for English research and animal 
research in particular, and, of course, within a month that was followed by time 
with Leonard Strang at University College Hospital.4 
My research fellows at Johns Hopkins set out to map the course of events in the 
developing lung of the fetal lamb, the animal of choice. I have often wondered 
why, and I think it’s because babies and lambs are about the same size at birth 
and the equipment you had for one worked for the other. I don’t know if that is 
quite true or not, but those are my thoughts on the matter.
I became interested in other things, but the group in the lab continued and 
the names that come into mind include Florence Moog, a brilliant anatomist 
and embryologist who was studying the intestine of mice in St Louis.5 We were 
both members of the same study section at NIH, so this was a coffee break 
conversation: ‘What do you do?’ ‘What do I do?’ She tells me she can accelerate 
the maturation of the intestine of suckling mice measured by the appearance of 
alkaline phosphatase in the duodenum after administration of glucocorticoid 
to the mother.
That was 1962. Then we said we have to know about the normal appearance of 
various enzymes and so on in the developing lamb. That’s when all the people 
in the laboratory – which then numbered 15 or 20 – produced a paper about 
the timing of various enzymes and other events in the normal lamb lungs.6 I 
went to New Zealand in 1968 as a guest of the Society of Obstetricians and 
3 See, for example, Barcroft (1946); Meschia et al. (1965); Young (1992). Professor Maureen Young wrote: 
‘Mel Avery certainly heard about the animal work in England from me, but I told her after the meeting 
on 15 June 2004 that she was not correct in presuming that I had used the lovely preparations so soon in 
my career! I had been mostly associated with human babies before 1960.’ Letter to Mrs Lois Reynolds, 
9 August 2005.
4 Smith (1945); Strang (1977). For Professor Sir Robert Boyd’s appreciation of Strang’s work on the 
adaptation of the fetal lung to air breathing, see Christie and Tansey (eds) (2001): 16, fn.
5 Moog (1953).
6 Buckingham and Avery (1962). 
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the Paediatric Society.7 Mont Liggins was there and after I said that lambs were 
perfectly normal by 147 days’ gestation, Mont said, ‘What if I told you we can 
identify accelerated maturation in the lambs’ lungs at 115 days?’ That’s too big 
[a difference] to be an error. Were New Zealand lambs that different from the 
lambs in the USA? I didn’t believe that, neither did he. It appeared that, in fact, 
glucocorticoids could accelerate lung maturation of lambs.8 
The story of the glucocorticoids moved ahead when Liggins and Howie proposed 
a randomized controlled trial [of glucocortico-steroids], and it was obvious that 
the effect was reproducible. I would also like to pay tribute to Sue Buckingham, 
a fellow at the Columbia Presbyterian Medical School, probably well known to 
you. She presented a paper on the effects on mice at the Federation of American 
Societies for Experimental Biology meeting.9 She made the point in 1968 
and I thought it was frivolous. Then we had a series of observations, not well 
put together at that time, but conﬁrmed over and over, that glucocorticoids 
accelerated maturation, not only of Moog’s mice intestine, but also of the fetal 
lung. By then I had ﬁnished my fellowship – Sue, alas, died shortly after that 
meeting, which was a great tragedy, for her contribution was valuable. 
This is the story in which I had ﬁrst-hand involvement, but I have never got 
over wanting to know what the long-term outcome of anything that’s invasive 
would be. Others at Columbia were saying, ‘Never should a premature baby be 
allowed to die without a course of glucocorticoids’. It was a sad commentary in 
retrospect. It didn’t seem to make much difference one way or another, except 
in the context of accelerating maturation of the fetal lung and intestine. There 
are still those who are worried about long-term outcomes and I think we will 
hear more about that from some of the participants here. I, too, have been 
concerned that there has been a temptation to assume that if a little bit is good, 
more is better, and give more than one dose: ‘Just let’s try it, postnatally, maybe 
we don’t need to give it prenatally, we will give it postnatally and we will give 
bigger doses, because you might get a bigger effect.’ 
Hey: I don’t think we will take questions at this stage, because Mel has just set 
the scene. She’s been very modest, our main American witness, and she will be 
7 Dr Ross Howie wrote: ‘The date was 1968 as I remember (the occasion was the opening of the new 
Christchurch Women’s Hospital), but Mel Avery will conﬁrm.’ E-mail to Mrs Lois Reynolds, 22 August 
2005. Conﬁrmed by Mel Avery, note on draft transcript, 17 August 2005.
8 Liggins (1969).
9 Buckingham et al. (1968).
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able to tell us a lot more later about the way in which things rolled out. We shall 
want to hear from her about when the collaborative [US NIH Collaborative 
Group] trial was done and how it was done, and why it was done the way it 
was.10 But that’s a long way down the line this afternoon. What we should do 
now, before we have our ﬁrst break for discussion and questions, is to hear from 
Jane Harding, who works in the room Ross [Howie] once worked in. I get the 
impression she almost had to sit on the papers that he had left behind, because 
he had left rather a lot, and it’s surprising how much more is still coming out 
of those papers. So we haven’t got Ross here in person, but you might just hear 
his voice.
Professor Jane Harding: It’s a great honour for me to be here. I am sorry that 
Mont Liggins and Ross Howie are not well enough to attend. They would both 
wish to be here and although the programme suggests that I might speak on 
their behalf, I wouldn’t dare. I will tell you a little of what they have told me 
and, later on perhaps, my own involvement in the continuation of this story 30 
years later. 
10 Collaborative Group on Antenatal Steroid Therapy (1981).
Figure 1: L to R: Ross Howie and Mont Liggins, c. 1972.
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I will start by reading from a letter written by Mont Liggins to Iain Chalmers 
earlier this year and I quote:11 
When I returned to a position as a Senior Lecturer in Obstetrics and 
Gynaecology at the National Women’s Hospital in 1959, I asked my 
friend Bill Liley, of fetal transfusion fame,12 how to choose a topic. He 
said to look for a major problem that was potentially solvable. The major 
problem was easy: prematurity stood out above everything else. I naively 
thought that all I had to do was solve the ancient question of what 
controlled the onset of labour at term and the reason for premature 
onset would become apparent. 
Mont then described how he worked on his idea that the onset of labour was 
controlled by the fetus not the mother, and how he spent a sabbatical period at 
the veterinary school at the University of California at Davis, to assess the role 
of cortisol13 in initiating parturition in sheep. I return to his letter: 
Back in Auckland I needed a lab and money. The hospital gave me 
an abandoned shed; the Wellcome Trust gave me money.14 The ﬁrst 
experiments were to test the idea that the effects of the pituitary were 
mediated by the fetal adrenal [gland]. Infusion of cortisol or ACTH 
[adrenocorticotrophic hormone] caused premature labour at any 
gestational age. 
From that point in the story I invite you to listen to Mont’s own words describing 
the application of these ﬁndings to the lung. The recording you will hear was 
made in April last year [2003], as part of a recording of an oral history project 
undertaken by the place at which I now work, the Liggins Institute. It is named 
after him, and we asked Mont to record his life story. He agreed that I could 
play a part of it to you, as it relates to this story.15
11 Letter from Professor Sir Graham (Mont) Liggins to Sir Iain Chalmers, 6 April 2004. Reproduced in full 
in Appendix 1, pages 85–8.
12 Liley (1964).
13 Cortisol is the naturally occurring glucocorticoid in humans and sheep.
14 The Wellcome Trust gave more than £40 000 in grants and supplements for research assistance to 
Professor Liggins over eight years from 1968 to 1976. See Appendix 3, pages 97–9.
15 Professor Sir Graham Liggins wrote: ‘The tape is held by The Director, Liggins Institute.’ Letter to Mrs 
Lois Reynolds, n.d., received 25 August 2005. An audiotape of Liggins’ 1989 James Young Simpson Lecture 
given at the Silver Jubilee Congress of Obstetrics and Gynaecology, has been donated by Sir Iain Chalmers, 
which will be deposited along with the records and tapes from this meeting in GC/253, Archives and 
Manuscripts, Wellcome Library, London.
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Mont Liggins [from a tape recording]: I had always been meticulous in doing 
a complete autopsy of all the lambs that I delivered, weighed organs – helped, 
I must say, by my secretary who used to come in and help me when she was in 
the ofﬁce. And I remember one morning, there was a lamb lying in a cage with 
its mother. A lamb that had been infused as a fetus with cortisol. And to my 
surprise this lamb was still breathing, not very healthy breathing, but it was alive 
and breathing. It had no right to be. It was so premature that its lungs should 
have been just like liver, and quite uninﬂatable. And this struck me as surprising, 
and when we came to do the autopsy the lungs were partly inﬂated and this 
was absolutely surprising. So, weighing this up I postulated that the cortisol 
had accelerated the maturation of enzymes in the lung that caused accelerated 
maturation. Now, at that time my facilities were fully occupied in studying the 
question of parturition and I didn’t have time to pursue this lung problem any 
further.16 But it so happened that Mary Ellen Avery, who was a big name in 
respiratory distress syndrome [RDS] and lung problems, and the discoverer of 
the fact that surfactant was necessary for the maintenance of lung expansion, 
was visiting New Zealand.17 So we were both going to a meeting in Christchurch 
where I described my ﬁndings in a series of lambs with expanded lungs. 
She couldn’t get back to the US fast enough to set up experiments in rabbits 
– giving cortisol to fetal rabbits – and produced the deﬁnitive paper on the 
effects of corticosteroids on lung maturation.18 So, as far as I was concerned, it 
rested at that point and I thought, ‘Well, if it works in animals, why shouldn’t it 
work in human babies?’ As far as we knew, lungs in human babies had the same 
enzymes as animal lungs. Should we not do a clinical trial and put it to the test? 
So I was gossiping with Ross Howie, our paediatric colleague, and Ross is a very 
meticulous guy; and Ross and I, with most input from Ross, wrote the protocol 
for doing a controlled clinical trial of corticosteroids in preterm infants. That 
protocol I might say has been cited as one of the earliest and best controlled 
trial protocols.19
Harding: One of the things that I noted in this recording, and in my many 
discussions with the principal players, was how they always give the credit 
16 See Appendix 1, pages 85–8.
17 Avery and Mead (1959); Kotas and Avery (1971); Motoyama et al. (1971). See also Avery et al. (1981).
18 deLemos et al. (1970); Avery (2000).
19 Liggins (2003); Liggins and Howie (1972). For the next well-controlled study following Liggins and 
Howie (1972), see Papageorgiou et al. (1979).
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to everybody else. You heard on the tape that Mont gives all the credit for 
surfactant work to Mary Ellen Avery, and for the clinical trials to Ross Howie. 
Ross, on the other hand, assures me that it was all Mont’s idea. In fact, it’s my 
view that it was a quite remarkable partnership. At the time, Ross was a New 
Zealand MRC research fellow, the only paediatrician at the National Women’s 
Hospital in Auckland and indeed in New Zealand, who was able to ventilate 
newborn babies. I would like to quote now from Ross Howie’s words describing 
these events, although I have abbreviated them somewhat: 
At the outset, it might be worth reminding others that the project was 
only a sideline of the main work of both Mont Liggins on the one 
hand and myself on the other. Mont has his much more widely ranging 
research into reproductive endocrinology for which he is justly renowned. 
My own main interest was in health rather than science, especially in 
helping develop newborn services in New Zealand, and I just happened 
to be around at the time. But I helped to design the trial, supervised 
the collection of data and did all the work in analysing them….I still 
remember the excitement I felt at my ﬁrst evidence of it, when he handed 
me the lungs of twin lambs for pressure–volume studies. The lambs had 
been delivered very early…one had been infused with glucocorticoids 
and the other not. Lungs of the infused lamb were perfectly stable after 
Figure 2: Diagram of Liggins’ work in sheep from which the serendipitous discovery of the 
effect of cortisol in accelerating fetal lung maturation was made. 
Originally published in Liggins et al. (1973), 141.
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inﬂation: pink, ﬂuffy and ﬂoated in water. In total contrast, the lungs of 
the other remained solid and liver-like, and sank.20
There are a couple of things that interest me about these descriptions. One is 
the unique pairing of an experimental scientist who was also an obstetrician, 
with the only paediatrician in the country who was capable of looking after 
the premature babies. Another is that whatever the later perceptions became, 
it’s clear that both the authors of the study were involved together from the 
beginning, in the animal laboratory, as well as in the clinical aspects.21 Finally, I 
am entranced with Ross’s comments that this lamb trial was simply a sideline for 
both of them. It’s an interesting warning against the narrow and predetermined 
endpoints of some research programmes, and highlights the importance of 
serendipity in progress. 
Ross describes presenting the results of the completed study – not the initial 
part of the study that was published in 1972, but the completed study – at a 
symposium hosted by the Royal College of Obstetricians and Gynaecologists 
(RCOG) of the UK in 1977.22 He said to me, ‘They didn’t really want to hear’. 
He also reported that when he was asked for a recommendation as to what 
people should be doing, he said that the treatment looked very promising, but 
that it would be unsafe to initiate a new treatment on the basis of a single 
trial. He said that he knew what he should do, but that others should wait for 
ongoing trials. Other people here can talk about the progress of the treatment 
after that time. My own involvement began perhaps when I entered medical 
school in 1973. Both of the principal actors were my tutors. The use of antenatal 
steroids was routine at that time in our hospital and has remained so ever since. 
20 See Appendix 2, pages 89–95, quotes on page 89, 91.
21 Dr Ross Howie wrote: ‘Jane Harding is too kind in saying that I was involved in Mont’s animal work 
from the beginning. Our contacts were occasional. I do remember what may have been the start of his work, 
a visit to the Ruakura Agricultural Research Station, the leading institution of its kind in the country, about 
120km south of Auckland, probably between 1962 and 1965. I have an idea this visit was facilitated by Sir 
William (Bill) Liley of fetal transfusion fame. Contacts in Ruakura would have helped Mont with his work, 
notably Bob Welch. But animal work was not my thing; in any case I had too much else to do.’ E-mail to 
Mrs Lois Reynolds, 12 June 2005. For details of the Liley chart to measure amniotic ﬂuid bilirubin levels 
plotted against gestational age, see Zallen et al. (eds) (2004): 11–12. See also Appendix 1, page 85–8.
22 Dr Clive Dash wrote: ‘At the time when Ross Howie presented the results to the RCOG in 1977 [Howie 
and Liggins (1978)], the UK study was in its recruitment phase. Whether knowledge of the status of the 
UK study played any part in the cool response of the delegates at the meeting that Ross sensed, would 
be speculative.’ E-mail to Dr Daphne Christie, 10 January 2005. For the protocol for the UK Study, see 
Appendix 5, pages 103–8.
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By this time Mont had moved on to other studies. Ross was completing the 
four- and six-year follow-up of the original cohort, funded by the World Health 
Organization.23 He always believed very strongly that long-term follow-up was 
essential for anything in neonatal care and set about this with his usual thorough 
approach. The follow-up studies were published in the early 1980s and the 
ongoing follow-up studies we will talk about later.24 
Hey: Would you like to explain why they chose the steroids they did, because a 
lot of people never seemed to have noticed. Most people think that if they are 
using betamethasone they must be using the product that Ross and Mont did. 
They think it was betamethasone, full stop. 
Harding: I can tell you that story because I speciﬁcally asked both of them in 
recent weeks. To paraphrase a long story: Mont had been doing work in human 
pregnancy on the effects of steroids on the fetus. He had a reasonable idea of 
what dose of steroid was required to suppress oestrogen production and he 
presumed that that would be an adequate dose to do something to the fetus. He 
knew that he wanted something that would be reasonably long-lasting, so that 
it didn’t have to be given too frequently to pregnant women and decided that 
something that would last for 24 hours – and therefore two doses would give you 
about a 48-hour effect – would be adequate, based on the animal studies. He 
therefore set about looking for a drug that would be clinically easy to manage, 
long-lasting, and which had an identical appearing placebo. This is not easy, 
because all the long-lasting preparations of glucocorticoids are opaque, they are 
milky substances, and a placebo wasn’t easy to ﬁnd. He wrote to a number of 
drug companies asking for help, and in the end Glaxo – originally the name of a 
dried milk powder sold by a New Zealand company, and it so happened that the 
medical director was a mate of Mont’s – provided an opaque placebo.25 Their 
long-acting preparation was the one he used, because that was the one that was 
23 MacArthur et al. (1981, 1982).
24 See notes 105 and 197.
25 Dr Clive Dash wrote: ‘Because of the Glaxo link, it was well known in the UK which product had been 
used in New Zealand [Gamsu et al. (1989)]. The NZ product was an ester of betamethasone (acetate), the 
properties of which caused a slower absorption from the intramuscular site than the very soluble product 
(phosphate salt) available in the UK. It was estimated that more frequent injections of the soluble product 
would give a similar bioavailability. The placebo used in the UK was specially prepared for the study by 
Glaxo and consisted of the vehicle in which the phosphate salt was formulated. Both were opaque solutions 
in identical vials and labelled similarly except for patient numbers assigned randomly. Thus, the blind was 
preserved.’ E-mail to Dr Daphne Christie, 10 January 2005.
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available and they were provided with the placebo. So the placebo was cortisone 
acetate, which had much lower potency but looked the same, and the drug that 
he selected was the Glaxo drug because that was what was available and because 
the director was a mate who provided it for free. I might say that the study was 
unfunded. Mont said to me, ‘We didn’t need funding to do this trial’. And of 
course they didn’t, because the drug was provided free, and both Mont and Ross 
were fully salaried and were able to put in all of their time. 
Hey: Just remind us how many babies were eventually recruited. 
Harding: Twelve hundred. The actual number was 1218. 
Hey: Still the biggest trial. 
Harding: Still the biggest trial. The original publication that everybody cites 
from 1972 was only the ﬁrst 282.26 But they continued to recruit long after 
that trial. 
If I could just comment: the other thing that most people aren’t aware of is that 
after the ﬁrst 717 women were enrolled, when they did the ﬁrst analysis and 
thought ‘The stuff really does work’: they doubled the dose. In the rest of the 
trial, the other 500-odd actually received twice the dose, to see whether more 
was better. They concluded that it was not, and published all of the data as a 
combined single trial.27 
Hey: May I just ask one other question? I get the impression that the gap 
between their having the recognition that it worked and starting the trial was 
pretty short. The trial started in December 1969, and it’s there in print in 
July 1972. 
Harding: That’s correct. 
Hey: Were the ﬁrst patients actually randomized? Did they start right from the 
beginning? 
Harding: They truly did start randomizing at the end of 1969 and it really 
was the beginning of the trial. In his usual way, Mont decided that the animal 
studies were conclusive and that they should move on to human trials. When 
26 Liggins and Howie (1972).
27 Liggins (1976); Howie and Liggins (1978, 1982).
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I asked him why it was so short a period, because it was only a few months 
between concluding the animal studies and starting the trial he was already 
convinced that it needed to be a randomized trial. Ross was also very much of 
the same mind and they devised the protocol together. It didn’t take them long 
to get the drug. There were no ethics committees in 1969, but the hospital’s 
Senior Medical Staff Committee approved all trials. It functioned as an ethics 
committee at that time, and this committee approved it without further 
discussion. Mont was very keen to get started, because the head of department 
was actually planning a different trial which would have precluded this one and 
Mont was going to get in ﬁrst, which he did. 
Professor Richard Lilford: It sounds, from the way you speak, as though Mont 
regarded this as a sideline and that there wasn’t a need to pursue it himself. 
Harding: In the end he did pursue it, but I think you are right. I think the interest 
elsewhere, particularly from Mel Avery’s group and the San Francisco group 
[Roberta and Phil Ballard, Jo Kitterman, John Clements and Bill Tooley] on the 
effects of steroids on lung maturation, not so much rekindled as accelerated his 
interest in the topic. He recognized the importance of pursuing this and what a 
clinical impact it might have.28 He took Ross along with him, because it was a 
sideline for Ross as well. 
Professor Miranda Mugford: I am a health economist. I just wanted to ask 
what the clinical situation was with neonatal intensive care at that time in New 
Zealand? Was it at different states of development in different countries? Just 
the background to what was normally done with babies at an early stage of 
gestation when they were born. What was the funding situation for their care?
Harding: The funding situation was easy. We had a public health system so 
there was no direct charge to patients and that has always been the case for 
newborn intensive care in New Zealand. It’s fair to say that the state of intensive 
care varied around the country. The National Women’s Hospital was opened 
in 1964, I think, but I would need to check that, speciﬁcally to enhance both 
the care of women and their babies and to encourage research in this ﬁeld.29 It 
28 See, for example, Platzker et al. (1975).
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had the only intensive care unit in the country where babies were ventilated. 
Ross started ventilating babies in the mid-1960s with a primitive Bird ventilator 
and started using continuous positive airway pressure (CPAP) in the 1970s.30 
That was before Gregory’s publication on CPAP, again because of the link to 
San Francisco, both he and Ross knew the San Francisco group well and had 
seen the data before it was published and were convinced that this was a useful 
thing to do.31 So the CPAP was just beginning to be used at the time of the trial. 
Ventilation was initiated, but outcomes were still poor and in the paper from 
Ross, which I think everybody has a copy of, he describes the change in perinatal 
mortality over that time.32 I think he also describes in that paper, but certainly 
has described to me in person, that at the end of the trials he went to Geneva in 
1975 to talk to the World Health Organization about the funding of the follow-
up, and while he was away two large preterm babies died of uncomplicated 
RDS, because nobody else could care for them. He was extremely upset about 
that. So it was a unique position in a sense that this was the only place that 
it could have been done, in New Zealand certainly, and the only people who 
could do it. 
Professor Ann Oakley: I am a sociologist. One of the lessons that one could 
take from this story is that the progress of scientiﬁc research and the testing 
of ideas in clinical trials is helped if there aren’t any obstacles such as ethics 
29 Dr Ross Howie wrote: ‘Both the hospital and the academic unit actually started before 1964. What those 
of my generation called the “new” National Women’s Hospital indeed opened in that year (incidentally, it 
closed in 2004), but the relevant date is probably 1951 when the Postgraduate School of Obstetrics and 
Gynaecology (O&G) was set up. It all started in the rather dilapidated remnants of what had been built 
as the 39th US Army General Hospital during the Second World War in a city park. After the war the 
buildings were taken over by the then Auckland Hospital Board, which moved both its O&G Unit and 
geriatric wards there in 1946. This was possibly a unique pairing of services for both the beginning and 
end of life. The O&G Unit became the National Women’s Hospital in about 1954.’ E-mail to Mrs Lois 
Reynolds, 29 August 2005.
30 Dr Ross Howie wrote: ‘I started using CPAP in 1970 (Gregory et al.’s paper appeared in 1971). The idea 
was brought back to Auckland by Mont Liggins; I did not myself meet the San Francisco group until 1972. 
It [CPAP] was, incidentally, brilliant and possibly the greatest single advance ever made in the management 
of RDS, therapeutic surfactants notwithstanding. In retrospect the development was simple and logical, 
and I am sure I was not the only one in the ﬁeld who kicked himself for not having thought of it.’ E-mail 
to Mrs Lois Reynolds, 26 August 2005.
31 Gregory et al. (1971). See also Dunn et al. (1971); Dunn (1974). For one source of Gregory’s inspiration, 
see Christie and Tansey (eds) (2001): 25. The new Cochrane Review will appear in Issue 2, 2006. 
32 See Appendix 2, pages 89–95.
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committees, and that is a point of view that is held in some circles. I thought 
of this because I know a little bit about the history of the National Women’s 
Hospital in Auckland and it doesn’t have a very good history itself in terms of 
ethics of trials.33 So I just wondered what the original protocol for this trial said 
about seeking consent and giving information to the parents of these babies. 
Harding: I have to tell you that I have never seen a detailed trial protocol. I have 
seen the paper that went to the Senior Medical Staff Committee and it does say 
that the women would be asked to consent to randomization. It would have 
been verbal consent.34 And, like you and a number of other people, I wondered 
how real and how effective that process was at the time. We will talk further 
later, I am sure, but we have just completed the 30-year follow-up of these 
babies, and one of the things that we had some concerns about is how people 
would react to being approached 30 years later about a trial in which we weren’t 
sure how informed the consent was.35 We have been overwhelmingly impressed 
with how positive people were about the trial.36 In the end, we traced 72 per 
cent of the original participants and a number of the children, now 30-year-olds, 
who obviously did not know they were part of this trial, and who went back to 
their mothers, and sometimes we traced the mothers rather than the children. 
There were a few women who did not recall being part of the trial. I think that’s 
not surprising, given the circumstances. Remember that the tocolytic [a labour 
inhibitor] used during the ﬁrst three years of the trial was intravenous ethanol, 
which was in use until about 1971.37 However, the vast majority of women did 
33 Professor Ann Oakley wrote: ‘From the late 1950s for some 20 years staff at the National Women’s 
Hospital carried out an uncontrolled experiment examining the natural history of untreated cervical cancer. 
Some women with abnormal smears [vaginal vault] were left untreated, and outcomes in this group were 
compared with those in treated women. Smears were also taken from newborn babies. The experiment 
lacked a scientiﬁc research design since there was no proper control group, and there was no provision for 
informed consent. The scandal of the experiment was exposed by two journalists [Coney (1988)] and there 
was a public inquiry [Cartwright Report (1988)].’ E-mail to Mrs Lois Reynolds, 22 August 2005. See www.
nzma.org.nz/journal/117-1202/1084/ (visited 1 September 2005); see also Young (2005).
34 See Appendix 1, page 87.
35 Dalziel et al. (2005). Mrs Brenda Mullinger, who worked with Professor Harold Gamsu (died 31 August 
2004) during the 1975 UK trial, wrote: ‘Professor Gamsu was disappointed that we did not learn more from 
Professor Jane Harding of the data from the original Liggins and Howie trial in New Zealand, as promised 
in this part of the Witness Seminar.’ Letter to Dr Daphne Christie, 6 January 2005.
36 Dr Ross Howie wrote: ‘This would have been greatly helped by the way Barton MacArthur and Anne 
Dezoete carried out the four- and six-year follow-up studies. They were superb not only in their testing but 
in the way they related to their subjects and the parents.’ E-mail to Mrs Lois Reynolds, 26 August 2005.
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recall that they were in the trial and recalled it very positively. A number of the 
subjects, the offspring, the children – now adults, I don’t know whay to call 
them because of that difﬁculty – came along because they said their mothers 
told them they had to come. The mothers were so grateful that they had been 
part of the trial, that their preterm baby had survived as a result of this trial, as 
they perceived it, and were very positive about it. That’s a slightly long answer 
to your question. I think consent really did happen, it was verbal consent, and 
the reaction of the majority of people involved was very positive 30 years later. 
[Figure 3.]
Mrs Gill Gyte: I am interested also in the women who were in the control arm. 
Did you get a similar sort of response, 30 years later?
Harding: The vast majority of participants still do not know which group they 
were in. So in terms of the 30-year follow-up, most of the people that came 
along were convinced they had had steroids because their babies survived, and 
we have done our best not to unblind them, because we think a further follow-
up is going to be fairly critical for reasons that we might talk about later.38 So 
women simply know they were in a trial and have a surviving baby, because 
obviously we didn’t trace the mothers of the babies who did not survive.39 
Professor Dafydd Walters: Could you remind us of the gestation, the shortest 
gestation period of this group of babies?
Harding: Given a moment, I could look it up, but from memory the youngest 
37 Dr Clive Dash wrote: ‘The UK study was being planned at the time of the move from ethanol as a 
tocolytic to various newly introduced β-agonists. We decided to use salbutamol, if a tocolytic was clinically 
necessary, so as to standardize one of the management modalities – and also because salbutamol had been 
developed by Glaxo.’ E-mail to Dr Daphne Christie, 10 January 2005. For the protocol used in the UK 
study, see Appendix 5, pages 101–8. For a later meta-analysis of β-agonists as tocolytics, see Tsatsaris et al. 
(2001). For the background to the discovery of salbutamol as an asthma treatment, see Reynolds and Tansey 
(eds) (2001): 37–42. 
38 Professor Jane Harding wrote: ‘Some of the ﬁndings of the 30-year follow-up suggest that there may be 
subtle changes in insulin responses in those exposed to antenatal glucocorticoids. These are of no clinical 
signiﬁcance in 30-year-olds, but we think that it would be of great interest to see whether those changes 
persist, and whether they develop into changes of any clinical signiﬁcance, as these people age.’ E-mail to 
Mrs Lois Reynolds, 21 October 2005.
39 Professor Jane Harding wrote: ‘Many babies died in both groups, most in the neonatal period but also 
a few after this period. We did not make any attempt to trace these mothers; indeed we tried to avoid 
contacting any whose babies had died, to avoid any distress that might be caused by reminding the parents 
of their loss.’ E-mail to Mrs Lois Reynolds, 21 October 2005.
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gestation was about 28 or 29 weeks, and the average gestation at delivery was 
around 35 weeks.40
Walters: Time moves on, and obviously steroids are now used for much shorter 
gestation babies.
Hey: But most of the trial evidence was still based on the old data from the pre-
ventilator days, and now we might say that all the data that showed that steroids 
saved lives antedates the arrival of surfactant. There hasn’t been a trial done, as 
far as I know, looking at the additional beneﬁt of steroids as well as surfactant. 
Harding: There have been at least four trials in the 1990s and I am sure Dr 
Crowley will talk about this. But the new Cochrane Review, which is in the 
process of being produced, will show clearly that the beneﬁt is still there in the 
surfactant era, in the ventilator era and in the four randomized placebo control 
trials done in the 1990s.41 
Sir Iain Chalmers: Jane, I don’t know whether you have tried to do this already, 
but it would be wonderful if these mothers and children that you are in touch 
with came to know just how important a contribution they have made to the 
40 Professor Jane Harding wrote: ‘The youngest was 20 weeks and the mean gestation at delivery was 34 
weeks.’ Note on draft transcript, 4 September 2005.
41 See, for example: Carlan et al. (1991); Garite et al. (1992); Kari et al. (1994); Botet et al. (1994); Lewis 
et al. (1996); Amorim et al. (1999); Pattinson et al. (1999); Qublan et al. (2001) Fekih et al. (2002). The 
new Cochrane Review will not be available until 2006.
Figure 3: Investigators in the original Auckland trial [Liggins and Howie (1972)] and its 30-year 
follow-up [Dalziel et al. (2005a and b)]. L to R: Stuart Dalziel (Research Fellow), Mont Liggins, 
Ross Howie and Jane Harding, July 2005.
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history of perinatal care. If you haven’t planned to do so already, could you 
think about letting them know that? 
Harding: We tried very hard to emphasize how important they are; this is part of 
our recruitment process, as you can imagine. Getting 30-year-olds, who are busy 
with family and life and career and everything else, to come along and have fairly 
extensive testing is not easy. We did spend a great deal of time and energy trying 
to explain to the participants and their mothers how important this trial was and 
how important it was to know what effect it might have in the long term. But 
as I think I have already said, people were very, very positive about the whole 
experience of being involved in the trial, which really reassured me immensely 
about the consent process and the whole management of the trial.
Chalmers: You can tell them now they are formally part of history.
Harding: When we write to them, telling them the results of the follow-up, we 
will do that.
Professor John Gabbay: We have been left with a slight impression that there 
was a wonderful element of serendipity with Mary Ellen [Avery]’s coffee room 
discussion, happening to bump into these people. I would like to test that by 
asking Mary Ellen if you could say why you chose to go to New Zealand, and 
why that conversation happened and how it came about that you were discussing 
that, because I suspect that it’s not pure chance. I would like to explore what led 
to that particular common interest being discussed there. 
Avery: At the meeting in Christchurch, with Liggins in attendance, I had given 
the most boring paper ever, describing the time of onset of a whole bunch of 
things that we could measure to map out the terrain of the maturation of different 
organs in the lamb, knowing that we were particularly interested in lambs. Why 
did we tumble to that? It was partly that Mont wanted information from sheep, 
some of which were different from what he expected. And the difference turned 
out to have been that some of the animals got steroids and some didn’t, and the 
ones that were advanced had received the steroids. There was a concern that there 
would be a permanent effect if they were treated in utero, but injured in some way 
by the steroid; that they would grow up with small lungs or the lung would fail 
to perform in some way, and so Liggins needed all the information he could get 
about safety. I think we published our ﬁrst paper on six sets of twins.42 That wasn’t 
a very big series, but six out of six showed the same result. It meant that the data 
42 Rokos et al. (1968). 
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were pretty secure, but the next question was: what happens when they are ten 
years old? 
Some of the follow-up has been done and it turns out that the lungs play ‘catch 
up’, just as children do on steroid therapy for a month for whatever disease, and 
when you withdraw it, you see their growth curves are ﬂat while they are on 
steroids, and then they catch up and hit the very level that was predicted before. 
Catch-up growth takes place in these babies. And that is quite remarkable: 
maturation at the expense of cell division. Take away the stimulus from the 
cells, they do more than they would have done otherwise and catch up. I think 
others in this room might be better students of this phenomenon than I am.
Gabbay: If I could just pursue that for one second. You have taken us into the 
science of it. I was interested, if you like, in the community of scientists who 
were interacting, and how it was you came to be discussing these topics. It seems 
to me that what you have said – and I just wondered if this was an accurate 
impression – is that he [Liggins] actively sought out your data. He came to 
hear your talk, came to talk to you because it was of particular interest to him, 
and that we have not so much the coincidence that Richard [Lilford] intimated 
earlier with his question, but a deliberate conversation between people with a 
common interest.
Avery: We didn’t know we had a common interest until we were drinking tea 
that afternoon. 
Professor Sir Christopher Booth: How did it happen that you were in 
Christchurch at that crucial moment?
Avery: They had invited me over as a visiting speaker. They had heard that I was 
fooling around with surfactants.
Mr Ian Jones: You mentioned that Mont had Wellcome Trust funding. Could 
you tell us anything about the type of funding he had, and how signiﬁcant that 
was to his work?
Harding: The short answer is no, I cannot, but I could go back and ask him. 
He commented about who gave him the money and I think probably he simply 
asked for research funding to look at preterm labour.43 I cannot tell you more 
details about how much it was, not his personal salary, it must have been working 
43 See Appendix 3, pages 97–9, for details of the eight years of funding for research assistance from the 
Wellcome Trust, 1968–76.
Prenatal Corticosteroids
21
expenses. It was for some considerable period of time, because he worked on 
this for several years. 
Dr Stephen Hanney: We have been looking at the ‘payback’ or beneﬁts from this 
whole stream of work, and I will be talking about that later.44 On this speciﬁc 
question, at one stage we did have a ﬁgure of £20 000 from the Wellcome Trust 
for one of these pieces of work, I think it was for the original animal trial. I am 
not quite sure how that ﬁtted in, how long a period that was, but that is a ﬁgure 
that was quoted. It was obviously a very small grant even in those days. 
Harding: I think at that time it would have been a very large grant in New 
Zealand, and it was probably the only one, because I am pretty sure Mont only 
had the one block of funding to work on the initiation of parturition in sheep. 
I have already commented that the clinical trial itself was never funded, because 
they just did it.
Hey: That included his going to America and learning how to hypophysectomize 
fetal sheep.45
Harding: He did all that before he left New Zealand for California, and when he 
came back he had the Wellcome Trust funding to start his own lab.46
Hey: Hypophysectomizing a fetal sheep, popping it back in and discovering 
that the ewe never goes into labour, because as we now understand the pituitary 
drives labour in the lamb, but not in the human. 
Harding: That’s correct. He [Liggins] had presumed that that would be the case. 
When he was on sabbatical at the University of California at Davies he devised 
a way of doing the hypophysectomy and did the initial experiments there, and 
then came back to set up a sheep lab in New Zealand with Wellcome Trust 
funding. So I think that was probably the one and only grant and a very large 
one at that time for working expenses.
Hey: One of the things that we learn is that sometimes, as Maureen Young 
will tell us, you cannot jump from species to species. Sometimes you try, but 
hypophysectomy [in sheep] doesn’t work and steroids do. 
44 See page 69.
45 Surgical removal or ablation of the hypophysis, or pituitary gland, of the fetal sheep. See Liggins 
et al. (1967).
46 See Appendix 1, page 86.
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Harding: I think they were different questions. Mont knew before he started 
with the sheep that hypophysectomy made no difference to gestational length 
in humans.
Hey: We will move on and listen to what happened when people started to do 
the many other trials. Ross sounded as though he actually encouraged other 
people to go ahead and do more trials, most of which seemed to have been done 
in the US. 
Harding: That’s true. Ross was very much, and still is, of the view that even if 
a treatment did work – and he was convinced that this treatment did work in 
his hands – that it was unlikely to work all of the time in all groups of patients, 
under all circumstances, and he was very concerned about the potential long-
term risks as were most other people at that time. He remained unapologetic 
for that, in the sense that you know medicine is not simple, biology is not 
simple, and there’s no point in pretending that it is. He was convinced that 
even if this treatment worked, it might not work in some groups, and it might 
have adverse effects in some groups. He felt it was important that other people 
test this in other places, under other circumstances, in other groups, and he 
also thought it was critical that the long-term follow-up should happen, and he 
himself therefore never recommended – right through, I think, into the early 
1980s – that anybody else should act on the basis of their trial alone, and was 
very encouraging of other trials. 
I was asked about the follow-up and the NIH trial, which we will no doubt 
come to, and the follow-up was still going on at the time that the Auckland 
trial follow-up was completed.47 I asked Ross if he knew about this and he 
said he couldn’t remember if he had known about it, but if he had he certainly 
would have encouraged them to proceed, because again he thought it important 
that other groups replicate the trial under other circumstances, and check what 
speciﬁcally was and wasn’t helpful about this treatment.
Hey: It is time that we move on to ask Patricia Crowley to tell us something of 
how the various trials that did get done in the 1970s and early 1980s got put 
together for the ﬁrst time. But I suspect after that we need to go back over some 
of these individual trials and explore, with Mel’s help, some of the thinking that 
47 Professor Jane Harding wrote: ‘The “follow-up was still going on” refers to the follow-up of the NIH 
trial, which was published as Collaborative Group on Antenatal Steroid Therapy [(1984)]. The next line 
“at the time that the Auckland trial follow-up was completed” refers to the two papers by MacArthur et al. 
[(1981, 1982)].’ Note on draft transcript, 4 September 2005.
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went into the US NIH Collaborative Group trial and how it got interpreted and 
how it got analysed. Let’s have the overview ﬁrst.
Dr Patricia Crowley: I ﬁrst heard about antenatal corticosteroids in an 
undergraduate lecture in 1974. The possibility of preventing RDS made an 
immense impact on me because the ﬁrst baby I delivered as an undergraduate 
died in the neonatal period from RDS, despite weighing seven pounds and being 
born at 36 weeks. So the scene was set for a life-long interest in this topic. Later, 
in 1977, as a senior house ofﬁcer in neonatal paediatrics, I attended a lecture on 
fetal lung maturation given by Professor Mel Avery, who was an invited lecturer 
at the Irish Perinatal Society. At a time when young female medical graduates 
had few role models, an innovative paper delivered by an attractive woman [see 
Figure 5] made an enormous impression, especially as I was continuing to see 
premature babies die on a regular basis from RDS. 
At that time I was working in the National Maternity Hospital, Dublin, which 
fostered a culture of nihilism towards most medical interventions, with the 
exception of those ordained by institutional policy. I encountered a woman 
whose previous baby had died from RDS, and together with a paediatric 
colleague, approached the Master (Clinical Director) of the hospital to obtain 
permission to prescribe antenatal corticosteroids for this patient. That was the 
ﬁrst and only time in a two-year spell in obstetrics and paediatrics between 
1976 and 1978 that I was allowed to prescribe antenatal steroids. 
I then went to work in the Hammersmith Hospital in London and in 1978 attended 
a meeting at the Royal College of Obstetricians and Gynaecologists (RCOG) 
marking the publication of the proceedings of the 1977 RCOG Preterm Labour 
Study Group. Ross Howie had attended this meeting in 1977, and presented a 
paper jointly authored with Mont Liggins on the outcome of 1068 women and 
their babies who had been enrolled in randomized trials of antenatal corticosteroid 
therapy. This showed a massive reduction in neonatal mortality in those babies 
who were exposed in utero to antenatal steroids.48 The Proceedings of that Preterm 
Labour Study Group contained 14 papers on tocolysis and only two papers about 
fetal lung maturation – a clear indication of where the emphasis of British obstetrics 
lay at that time when it came to preterm labour. Obstetricians were obsessed with 
trying to stop preterm labour rather than with trying to improve the outcome for 
the premature baby by accelerating lung maturation. Despite a dearth of objective 
48 Howie and Liggins (1978). 
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evidence of efﬁcacy, a variety of betasympathomimetic drugs were being actively 
promoted by the pharmaceutical industry at this time, whereas no pharmaceutical 
company was promoting the use of antenatal steroids.
In 1980 at the Hammersmith Hospital, London, Professor Denis Hawkins 
founded the Journal of Obstetrics and Gynaecology. He received a paper from 
Ben Sachs, a British obstetrician working in the US, which reviewed the adverse 
effects of antenatal steroids and the lack of evidence to support their efﬁcacy.49 
He challenged me to write an opposing view to this manuscript. This led to 
a paper written in 1980 and published in 1981, entitled ‘Corticosteroids in 
pregnancy: the beneﬁts outweigh the costs’.50 I was either lucky or lazy, because I 
decided to ignore observational evidence. Although I had never been taught that 
the randomized controlled trial was the best form of evidence, instinct led me in 
that direction. My literature search yielded four randomized controlled trials of 
antenatal steroids. I based the paper on two tables derived from amalgamating 
the results of the four trials, showing substantial reductions in neonatal mortality 
and morbidity in babies whose mothers were randomized to receive antenatal 
steroids. [See Tables 1 and 2.]
49 Sachs (1981). 
50 Crowley (1981).
Maturity 
(weeks)
Betamethasone- 
treated group 
(%)
Control 
group (%)
Difference
Liggins and Howie (1972) 24–37 4 24 P < 0.002
Block et al. (1977) <37 10 27 P < 0.05
Papageorgiou et al. (1979) 25–34 18 58 P < 0.005
Tauesch et al. (1979) <36 13 30 P = 0.085
Table 1: Incidence of respiratory distress syndrome as percentages of live preterm births.  
Crowley (1981): 148.
Betamethasone- 
treated group (%)
Control group (%) Difference
Liggins and Howie (1972) 4 24 P < 0.002
Block et al. (1977) 10 27 P < 0.05
Papageorgiou et al. (1979) 18 58 P < 0.005
Table 2: Perinatal mortality rates as percentages of preterm births.  
Crowley (1981): 148.
Prenatal Corticosteroids
25
By the time this paper was published in 1981 I had started a nine-month 
attachment at the National Perinatal Epidemiology Unit (NPEU), which was 
one of the most rewarding periods of my professional life. Anne Anderson and 
Iain Chalmers read the paper and invited me to contribute a chapter on antenatal 
steroids to a book that they were planning on ‘Effective Care in Labour and 
Delivery’. This was intended to follow Effectiveness and Satisfaction in Antenatal 
Care.51 I started work on a chapter on fetal lung maturation, examining the 
evidence in relation to antenatal corticosteroids and any other agents that aimed 
to accelerate pulmonary maturation. 
Progress on this proposed book was delayed by the illness and eventual death of 
Anne Anderson. It was eventually subsumed into a much more ambitious venture, 
Effective Care in Pregnancy and Childbirth.52 Meanwhile, led by Iain Chalmers, 
a group of individuals based at or associated with the NPEU, became involved 
with the development of the Oxford Database of Perinatal Trials, which aimed 
to identify, assemble and analyse all published and unpublished randomized 
controlled trials available in the world literature in perinatal medicine. 
I left Oxford in 1981 and returned to Dublin to continue to train as an obstetrician 
but maintained my contact with the NPEU. My associates working with the 
Oxford Database regularly alerted me to new trials that had been uncovered by 
enthusiasts who had searched the literature to ﬁnd randomized trials. The next 
three years saw the publication of follow-up data from the Auckland trials and 
of the results of the US NIH Collaborative Group on Antenatal Steroid Therapy 
study.53 With hindsight, we could ask whether the Collaborative Group trial 
should ever have taken place, because at the time when recruitment was taking 
place for that trial there was already substantial evidence in the literature that 
antenatal steroids were effective and safe. If we look at the 1000 or so babies 
who received antenatal steroids in the randomized trials prior to 1980, and the 
1000 babies who received placebo in these trials, 130 of the babies who received 
placebo died, compared with 70 of the babies who received antenatal steroids. 
Were those who were recruiting participants for the NIH Collaborative Group 
trials unaware of these results? Had clinicians or parents been aware of these 
results, it would have been difﬁcult to persuade anyone to be randomized to 
placebo in the late 1970s or early 1980s.
51 Enkin and Chalmers (eds) (1982).
52 Chalmers et al. (eds) (1989).
53 Collaborative Group on Antenatal Steroid Therapy (1984).
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As the 1980s progressed, I regularly updated my collection of randomized 
trials. Because of a series of subgroup analyses emerging from the US NIH 
Collaborative Group trials, I became interested in subgroup analysis of the 
outcomes of the accumulated trials. Commentators on the NIH trial reported 
that antenatal steroids were effective mainly in babies of between 32 and 34 
weeks, and ‘worked’ in black females but not in white males.54 I went back to 
the collection of trials that I had accumulated and looked at what happened to 
white males in Auckland and found they beneﬁted from antenatal steroids. This 
was how many of the subgroup analyses produced in the original systematic 
review of randomized trials came into being. It was driven by a need to refute a 
number of reviews questioning the efﬁcacy of antenatal steroids based on these 
subgroup analyses, principally from the NIH Collaborative Group study. 
Some form of systematic review of antenatal steroids was part of my life in 
various ways throughout the early 1980s. The proceedings from a conference 
I attended in Italy in 1984 show that by then I was looking at the outcome 
of seven trials, loosely synthesizing the outcomes.55 In 1987/8 the technology 
became available at the NPEU to produce a meta-analysis with electronically 
entered data, and to generate results in the form of odds ratios with conﬁdence 
intervals. The review of antenatal steroids became the ﬁrst to be entered on to 
the Oxford Database of Perinatal Trials. This was a very exciting time, when, 
after years of collecting data, I saw graphic evidence of the efﬁcacy of antenatal 
steroids in preterm babies in general and in all relevant subgroups. 
By 1989, when the results of the antenatal corticosteroid review were available 
in an attractive, accessible electronic format on the Oxford Database of Perinatal 
Trials and on paper in the book Effective Care in Pregnancy and Childbirth, I 
thought that this information was accessible to obstetricians around the world, 
and believed that no further publications were necessary to promote the use of 
antenatal corticosteroids. However, I was eventually persuaded by Iain Chalmers 
to publish a paper version of this systematic review in the British Journal of 
Obstetrics and Gynaecology.56 
Looking at practice throughout the world with respect to antenatal steroid use, 
it is only after 1990 that we can see any more than 20 per cent of preterm 
54 Roberton (1982).
55 Crowley (1986). 
56 Crowley et al. (1990).
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babies being exposed to antenatal steroids in any country, with the exception of 
Australia and New Zealand. Work from Melbourne in the 1970s, showed 45 per 
cent of Melbourne babies in the 1970s were delivered to mothers who had been 
treated with antenatal steroids prior to delivery.57 Elsewhere around the world, it 
fell often under 10 per cent and never higher than 20 per cent, up to 1990. So 
the publication of this paper in the British Journal of Obstetrics and Gynaecology 
was a landmark in terms of improving the use of antenatal steroids. 
In 1994 the NIH Consensus Conference on antenatal steroids took place.58 At 
that meeting I contributed an updated version of the systematic view of antenatal 
steroids,59 derived mainly from the electronic review published on what was by 
then the Cochrane Pregnancy and Childbirth Database of Perinatal Trials.60 The 
rest of that three-day meeting was taken up with many observational studies, 
and laboratory-based papers on antenatal steroids and following the three-day 
meeting a strong recommendation was released, urging obstetricians in the US 
to use antenatal steroids. 
In 1996 I was invited by the Royal College of Obstetricians and Gynaecologists 
to update a guideline on the use of antenatal steroids issued in 1992.61 The 
revised guideline, based on the systematic review published in the Cochrane 
Library, strengthened the recommendation from the RCOG on antenatal 
steroids use. By the late 1990s, 70 per cent of preterm babies delivered in the 
UK were being treated with antenatal steroids prior to delivery. 
57 Doyle et al. (1986). For a discussion on the evolution of paediatrics at the University of Melbourne 
Department of Paediatrics at the Royal Children’s Hospital 1959–2003, see www.cshs.unimelb.edu.au/
programs/jnmhu/witness/001.html (visited 2 August 2005).
58 National Institutes of Health (NIH) (1994). Their recommendation was to give a single course of 
corticosteroids – two doses of 12mg of betamethasone given intramuscularly 24 hours apart or four doses of 
6mg of dexamethasone given intramuscularly 12 hours apart – to all pregnant women between 24 and 34 
weeks’ gestation considered to be at risk, clinically, of preterm delivery within seven days. Freely available at 
http://consensus.nih.gov/1994/1994AntenatalSteroidPerinatal095html.htm (visited 28 September 2005). 
See also NIH Consensus Development Panel (1995).
59 Crowley (1995). Fifteen trials were listed in descending order of quality presented at the NIH Consensus 
Development Conference in Bethesda, MD, on 28 February 1994.
60 The ﬁrst systematic review by Crowley appeared on the Oxford Database of Perinatal Trials in 1987. 
The 1996 version appears as an example of a Cochrane Review at www.cochrane.org/reviews/exreview/htm 
(visited 2 August 2005). See also Figure 6.
61 RCOG, Scientiﬁc Advisory Commitee (1992).
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Figure 4: Meta-analyses of corticosteroids in pregnancy, 1992–2004.
1. 7 trials from Crowley (1981) as used for the Cochrane logo, see Figure 6;  
2. 12 trials, Crowley (1989); 3. 15 trials, Sinclair (1995); 4. cumulative meta-analysis of 
ﬁrst 15 trials, Sinclair (1995); 5. 18 trials, Cochrane Library (2004).
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Within a year or two of ﬁnally adopting the evidence-based practice of prescribing 
a single course of antenatal steroids to women at risk of delivering a preterm 
infant, obstetricians started to prescribe repeated courses of antenatal steroids. 
The practice of repeated courses of antenatal steroids in women who remain 
undelivered a week or more following the original treatment crept in rapidly, 
without any evidence to support its safety or efﬁcacy. All the evidence from 
randomized trials related to a single course of antenatal corticosteroid therapy. 
This widespread practice, unsupported by any evidence, generated the need 
for a new round of randomized trials to evaluate the immediate and long-term 
beneﬁts and hazards of single versus repeated courses of antenatal steroids. 
These trials are currently recruiting. Had the publication of the Auckland trial 
in 1972 been followed rapidly by a large multicentre trial and by the subsequent 
use of a single course of antenatal steroids as the standard of care, trials of single 
versus repeat courses of antenatal steroids would have taken place in the 1980s. 
So, largely due to a collective professional failure to disseminate and implement 
evidence concerning an effective intervention, progress in the area remains 
about 20 years behind where it should be. 
Hey: I think it might be sensible to explore something of the debate that went 
on between 1976, when Liggins presented an update of his ﬁndings at the 70th 
Ross Conference on Pediatric Research – a meeting devoted to the topic of lung 
maturation and the prevention of hyaline membrane disease, and 1994 – when 
we end up with the NIH-sponsored Consensus Conference.62 It is a long period 
of time. Mel, you were a witness to much of this. 
Avery: It was frustrating. 
Hey: Well, you banged the drums quite hard. 
Avery: I cannot begin to organize my thoughts for this period. I was not centrally 
engaged: I am not an obstetrician; I didn’t want to tell obstetricians what to do 
and what not to do. In fact, I didn’t have that kind of self-conﬁdence. I wanted a 
long-term follow-up. I spent hours with Ross Howie, urging him to ‘please keep 
track’ because the Swiss were talking about this treatment seriously inhibiting 
lungs, and even brains weren’t growing well if little animals got big steroid doses 
62 Liggins (1976), where he was able to report on the outcome of 884 spontaneous preterm births rather 
than the 226 births described in Liggins and Howie (1972); National Institutes of Health (NIH) (1994).
Prenatal Corticosteroids
30
during pregnancy.63 You probably know that. It’s kind of scary. It was done by 
the group in Berne, I think it is Burri at the Université de Paris, the fellow who 
is still publishing on ‘beware, beware,’ and I cannot counter that.64 I’m glad he’s 
looking at it, and I just think we have to be vigilant and that those of us who 
spend more time with this have to keep track of the babies. 
Lilford: Since this is a history meeting, and while you have been talking about 
the early 1970s, I have been thinking back into the recesses of my own mind. 
I was a young doctor in Cape Town and news about this crossed the Indian 
Ocean and people were interested there. As I can recall it, there seemed to be 
a notion that many babies would, in retrospect, be found not to have needed 
antenatal steroids because their lungs were very mature. And so the idea that 
was being put around then was that one should test ﬁrst to see if the lungs were 
already mature. And the person who did that testing was me. So if somebody 
needed early delivery, then I would do an amniocentesis. We had a thing called 
a bubble test and I would take the ﬂuid off to a side room and I would mix 
it with alcohol.65 I would shake it and then there was this chart on the wall 
where the bubble density could be related to maturity. If there were more than 
a certain number of bubbles, then we could safely proceed with the delivery the 
next day. If there weren’t, then we gave steroids. We would re-test two days later 
and if there were now bubbles we knew we could go ahead with delivery. So 
there must have been another scientiﬁc climate running at that time which said 
that [we should] discriminate more before we shove these steroids in. But as far 
63 Dr Ross Howie wrote: ‘About the possible hazards of steroids to the fetus: I am surprised that in all the 
discussions I have heard and read, little mention has been made of the work of the Ballards [Ballard et al. 
(1975)]. They measured glucocorticoid levels in maternal and cord serum after prenatal betamethasone 
therapy, and concluded that glucocorticoid concentrations in cord serum were in the physiologic stress 
range and not at potentially harmful pharmacologic levels. Many people (I know not Mel Avery) in talking 
about hazards confuse therapy before birth with therapy after: in the course of ordinary treatment, steroid 
levels are many times higher in the latter case. The dose Mont Liggins gave to the mother resulted in levels 
in the newborn comparable to those the baby would have in the course of an illness like RDS. Has anyone 
ever thought of doing a 30-year follow-up of babies with RDS with this in mind? Of course, as Mont has 
suggested, there may be hazards of synthetic steroids as opposed to naturally occurring compounds, but I 
know of no evidence for this.’ E-mail to Mrs Lois Reynolds, 26 August 2005.
64 Tschanz et al. (2003).
65 The Clements’ shake test or bubble test measures the physical properties of surfactant, the ability of 
pulmonary surfactant to form a foam or bubble on shaking that remains stable for at least 15 minutes. Pattle 
(1958); Clements et al. (1972); Strang (1977a and b). For Richard Pattle’s contribution to lung surface 
tension and surfactant, see Clements (1996): 218–24. See also Hughes (2001); and Figure 5.
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as I know, that line of thought ran into the sands, it didn’t progress in any way. 
I just mention that for your ediﬁcation.
Mrs Brenda Mullinger: At the time of the UK multicentre trial, I was working 
for Glaxo and I coordinated the trial in the UK.66 What I wanted to say relates 
to what Dr Crowley said about uptake. Although we originally coordinated the 
study after different clinicians had approached Glaxo, we found that we needed 
more centres to join the study, and so we did actually approach other centres 
in the UK. Looking at the paper, I see we got underway in mid-1975, but I 
was told by Dr Clive Dash, the medic at Glaxo, who unfortunately cannot be 
here, that many of the UK centres who were approached wouldn’t join the study 
because they were already using betamethasone and they felt that it wasn’t ethical 
to have control groups. So that although your uptake maybe was only 10 per 
Figure 5: Mary Ellen Avery and Richard Pattle at a CIBA Symposium in 1965. 
Clements (1996): 222. 
66 Mrs Brenda Mullinger wrote: ‘The UK multicentre trial was conducted from mid-1975 to February 
1978; 251 women were randomized to double-blind treatment with either betamethasone phosphate (4mg 
every eight hours for a maximum of six doses) or matching placebo, each given by intramuscular injection. 
Betamethasone treatment reduced the incidence of RDS relative to placebo – the greatest beneﬁt was 
seen in those infants born before 34 weeks’ gestation. See Gamsu et al. (1989).’ Note on draft transcript, 
6 January 2005.
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cent, certainly the research centres, the sort of centres that might have joined the 
study, were starting to think about using it by the mid-1970s in the UK.67
Avery: We have to think in terms of the 1970s versus the 1990s and up to 2000, 
because up until the 1970s the controlled trials were very supportive of the 
efﬁcacy of prenatal glucocorticoids, but that was an era when we didn’t have lots 
of babies under 800g. Now the story is different. We have babies weighing 600g, 
700g and 800g, who are getting glucocorticoids, and we assumed that they 
wouldn’t have any serious toxicity. But along came Petra Huppi from Geneva, 
who worked with us at Harvard and had developed a great experience with 
imaging studies of the brains of these babies. There is no question that there 
can be white matter problems which she has documented and published.68 I’m 
not prepared to take a stand, I’m only saying this is one group where there could 
be toxicity, and where we really don’t know the cost–beneﬁt of accelerating the 
lung versus some white matter problems in the baby. This is a new frontier, and 
I just wanted to put this on the table. I don’t know any more about it than I 
have just said. 
Crowley: Through all the systematic reviews of the trials we have kept an eye on 
intraventricular haemorrhage (IVH) and periventricular leukomalacia (PVL). 
There is good evidence that these adverse outcomes are reduced by antenatal 
steroids across the gestational ages. The use of early postnatal steroids is associated 
with an increased risk of adverse outcome. Antenatal steroids are protective in 
67 Dr Clive Dash wrote: ‘The UK multicentre study [Gamsu et al. (1989)] was designed in 1974, largely 
stimulated by the publication of Liggins and Howie (1972) and their prior animal studies. The idea for a 
UK study was an amalgam of interest from some obstetricians and neonatal paediatricians and from within 
the Medical Department of Glaxo in the UK because of the organizational link with the Antipodes. A 
taxing question in the design and analysis of the UK study was the imprecision in estimating gestational 
age at the time of recruitment. Maternal dates and obstetrical palpation were the only antenatal assessments 
available then – so different from the current techniques! The clinicians documented both estimates for the 
analysis. These were augmented (or confounded) by neonatal assessment [Farr et al. (1966); Dubowitz et 
al. (1970)], which were also recorded. Clinicians’ views can change during the planning and conduct of 
long-term studies (about four years to plan and complete recruitment and follow-up for the UK study). 
All the clinicians involved in the early planning recognized that more clinical work was needed to conﬁrm 
the results from New Zealand. Everyone involved in the study’s planning recognized that it was important 
to have commitment from an obstetrician and paediatrician at each participating hospital. By the time the 
study recruitment started (about one year later), some of the clinicians did not wish to recruit patients to the 
study for various reasons, even after Ethics Committee approval.’ E-mail to Dr Daphne Christie, 10 January 
2005. See Appendix 5, pages 103–8, for the protocol used in the study.
68 Murphy et al. (2001).
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terms of neonatal neurology, whether you look at the brain at autopsy or with 
imaging techniques for PVL. Would you agree with that, Jane? 
Harding: If I could come back brieﬂy to address Richard Lilford’s point and 
then go back to some of the reasons, perhaps, why steroids weren’t used. I have 
just dragged out the report of the 70th Ross Conference on Pediatric Research, 
which was I think about 1979, but I don’t have a date on the paper. [From 
the ﬂoor: 1976]. It was one of the places where Mont Liggins reported the 
outcomes of the Auckland trial. He also reports the outcomes of ratios in 
amniotic ﬂuid before and after steroid treatment, and points out that they don’t 
change consistently, so that amniotic testing for fetal lung maturation did not 
reﬂect clinical lung maturation. I was reminded of his concluding paragraph, 
which is why I dragged it out: 
We have not attempted to select patients on the basis of assessment 
of pulmonary maturation from amniotic ﬂuid analyses. In pregnancies 
beyond 34 weeks in which the risk of RDS is low, a strong case can be 
made for giving glucocorticoids only when the results of amniocentesis 
indicates pulmonary immaturity. Before 32 weeks, the likelihood of 
RDS is so high, and ﬁnding a mature pattern in amniotic ﬂuid is so low, 
that treatment without prior amniocentesis is probably justiﬁed.69 
So back then, they had considered the phenomenon, had picked the subjects to 
include, and concluded that it wasn’t worth doing, except perhaps in pregnancies 
more than 34 weeks. 
If I could go back to the question of why, perhaps, uptake wasn’t as widespread as 
it might have been in the 1980s. I have asked both Ross and Mont quite carefully 
about why they thought that it took so long for this treatment to come into 
widespread use, and they have both given me the same two general answers. The 
ﬁrst is that, particularly in the UK, they felt, ‘Nothing good could come from the 
colonies,’ and the fact of where the trial was done was very relevant. The other 
thing that they both said to me was they felt that in many places the paediatricians 
were the people who were discouraging use, since they felt that they could manage 
lung disease, that there was not really a problem, and that the obstetricians were 
treading on their territories, or at least on their toes. It was actually paediatric 
versus obstetric issues in many centres that discouraged its use. 
69 Liggins (1976): 103.
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Mr John Williams: I am a humble obstetrician, who is a recipient of the 
literature rather than a contributor, but I was developing during the era of 
these publications, and here are some of the things that struck me. The ﬁrst 
was an oration by Sir Stanley Clayton [President of the Royal College of 
Obstetricians and Gynaecologists, 1972–75] in 1975 at the American Congress 
of Obstetricians and Gynecologists, where he said that in his experience as the 
editor of the grey journal, the Commonwealth Journal as it was then, how much 
rubbish was submitted for publication.70 He wished that registrars didn’t have to 
do research to get jobs, and it was time it was all stopped. That was the ﬁrst thing 
that hit me. And I was then at a meeting in Cardiff where Cliff Roberton spoke, 
and he seemed to be of the opinion that obstetricians shouldn’t be treading on 
the toes of paediatricians, and that they were very good at looking after babies 
and we didn’t need to interfere. He went on to pour scorn on quite a lot of the 
uncontrolled and poor publications, and again this struck me. I said, ‘Why were 
these published if they were such bad studies?’ He replied, ‘You know, people 
having a glass of whisky and refereeing a paper, if it’s somebody they know they 
will put it in, if it’s not they won’t’. He was fairly scornful of the poor quality 
publications, and it gave the impression, certainly in Cardiff, that we shouldn’t 
be using steroids. And that set me back a little way. 
The poor publications continued to come out and were very confusing. In fact 
I wrote to Iain [Chalmers] asking what was going on: ‘I want to carry out best 
practice’. Paediatricians where I was then working in Chester were very keen 
that we should be using steroids based on the original work, and I said that 
everyone else says it’s rubbish. And it wasn’t until the systematic reviews and 
the guidelines came out that we actually introduced it as an overall practice; we 
had been giving it to certain selected patients, but not overall. I think that was a 
common view among obstetricians in this country in the non-academic world. 
Dr Roger Verrier Jones: There are two maternity hospitals in Cardiff: I 
worked in St David’s and John [Williams] was at the University Hospital of 
Wales maternity unit. The reason I am here is that Iain Chalmers kindly asked 
me when he reminded me of a letter I had written to him in 1980, about a 
retrospective study using steroids that we had done at St David’s, and that the 
results seemed to be quite startling. [See Tables 3 and 4.] 
70 The grey journal is the British Journal of Obstetrics and Gynaecology, known as such from its cover. 
Originally the Journal of Obstetrics and Gynaecology of the British Empire from 1902 to 1961 when the name 
was changed to British Commonwealth and in 1975 to its present title. 
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71 Exclusions: severe pre-eclamptic toxaemia (PET); congenital anomalies; uncertain gestational age; and 
delivery within 24 hours of steroid administration. In his letter sent in response to Dr Verrier Jones’ request 
for advice on whether the observational data from St David’s Hospital should be submitted for publication, 
Iain Chalmers stated that he found the data difﬁcult to interpret because of uncertainty about whether 
the way in which the comparison groups had been assembled had been sufﬁciently unbiased. He listed 
references to ten reports of RCTs, noting that these seemed to suggest that steroids were useful in preventing 
RDS, and advised Dr Verrier Jones against submitting for possible publication. Letters circulated at the 
Witness Seminar by Dr Verrier Jones. The correspondence and complete observations will be deposited with 
all the records of the meeting in GC/253, Archives and Manuscripts, Wellcome Library, London.
Steroid Non-steroid
Sex (M:F)   8:3 22:14
Mean gestational age (weeks) 32.1 32.3
Mean birth weight (kg) 1.63 1.59
Mean Apgar score 
at 1 minute
at 5 minutes
5.8
8.2
5.5
7.9
Twin pregnancies 1 2
Mortality   0 (0 %) 10 (28%) 
(p<0.001)
Incidence of RDS 
RDS 
No RDS
  2 (18%)
  9 (82%)
21 (59%)
15 (41%)
(p<0.001)
 
Table 3: Retrospective analysis of steroid and non-steroid use in preterm births, St David’s 
Hospital, Cardiff, 1979–80.71 Unpublished letter to Sir Iain Chalmers from Dr Roger Verrier 
Jones, 24 November 1980. 
PROM No PROM 
1. Steroid group (n=11) 
RDS 
No RDS
(n=4) 
1 (25%) 
3
(n=7) 
1 (14%) 
6
2. Control group (n=36) 
RDS 
No RDS
(n=10) 
6 (60%) 
4 
(n=26) 
16 (62%) 
10
TOTAL 
RDS 
No RDS
(n=14)  
7 (50%)  
7
(n=33)  
17 (51%)  
16
Table 4: Effect of prolonged rupture of membranes (PROM) on steroid- and non-steroid-treated 
preterm births, St David’s Hospital, Cardiff, 1979–80. Unpublished letter to Sir Iain Chalmers 
from Dr Roger Verrier Jones, 24 November 1980. 
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We had started using steroids in the late 1970s, I think, based on the work that 
Liggins and Avery and others had done. Our obstetricians were fairly conservative, 
so not all premature pregnancies were given them. However, we were able to 
look retrospectively at 47 babies, of which 11 had steroids and 36 did not. The 
mortality rate was zero in the steroid group and 28 per cent in the non-steroid 
group. The incidence of RDS in the steroid group was 18 per cent and 59 per cent 
in the non-steroid group. On the basis of that, certainly in St David’s Hospital, 
we continued to use steroids in premature births, but my memory is that as time 
went on and ventilation techniques got better, that the controversy about steroids 
seemed to be reduced, and then surfactants came along, so that there wasn’t a 
controversy about whether one should use steroids or not. 
Hanney: The point was raised by Jane about Ross Howie’s perception of the 
attitude in the UK. I don’t know whether people here were at the earlier Witness 
Seminar on ‘neonatal intensive care’ that was undertaken a few years ago, but 
exactly that point was made by somebody at the time who felt that in the UK 
there was this attitude and that was one of the reasons why there had been a 
slower prenatal/antenatal steroid uptake.72 I am very interested, Patricia, when 
you raise the issue of the role of the NIH Collaborative Group trial, because 
we were trying to trace through uptake levels and it did seem to us that in the 
1970s there had been some increase in uptake: there was a supportive review, 
in the Lancet, for example, in 1979,73 and there had been the survey of use by 
Members and Fellows of the Royal College [RCOG] which showed that quite 
a lot of them were using it in 1980.74 It then seemed that things happened in 
the 1980s, as I think you were saying, that did seem if anything to increase the 
opposition. There was, for example, the editorial in the British Medical Journal 
(BMJ) written by Cliff Roberton, based on the NIH Collaborative Group 
subgroup analysis that’s been criticized.75 So I would just like to ask you how far 
you think that subgroup analysis perhaps did reduce usage? 
Crowley: I think ﬁrst the results of the US Collaborative Group trial set things 
back, because this was the ﬁrst of the randomized trials published that didn’t 
show any difference in neonatal mortality, even though it showed a difference 
in respiratory distress and in particular the duration and the cost of neonatal 
72 Christie and Tansey (eds) (2001): 55–60.
73 Ritchie and McClure (1979).
74 Lewis et al. (1980).
75 Roberton (1982).
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care. This was the ﬁrst trial that looked at economic outcomes. But nonetheless, 
the lack of difference in neonatal mortality seemed to get a lot of press and then 
the excessive performance of subgroup analyses was given undue emphasis, even 
though these subgroups had not been speciﬁed at the start of the trial. They 
were produced following data-dredging after the trial had concluded, and these 
were emphasized, for instance, in that editorial by Cliff Roberton.76 You referred 
to the survey of Members and Fellows of the Royal College of Obstetricians and 
Gynaecologists, which asked obstetricians about their practice and what they 
said they did, which is not the same as what we actually do.77 While 44 per cent 
of obstetricians surveyed in 1979 said that they used antenatal corticosteroids 
‘often’, only 12 per cent of preterm babies recruited to the UK Ten Centre 
Study of artiﬁcial surfactant had been exposed to steroids antenatally.78
Hey: That was a huge trial in 40 or 50 hospitals, wasn’t it?79 It was the ﬁrst time 
any paediatrician in the UK had been able to get their hands on surfactant. And 
it was free, so everybody joined the trial. The analysis of that study when it came 
out showed that nationally in 1990/1 – which was when that trial ran – fewer 
than 12 per cent of British babies who were potentially eligible for treatment 
were being treated. 
Dr Sam Richmond: That’s absolutely true. We did a subanalysis of the regional 
data. The whole of the northern region entered this study and we published 
results looking back at steroid usage and found very similar results.80 Some 
hospitals approached 25 to 30 per cent usage, and others, by far the majority, 
scarcely reaching 10 per cent. 
I wanted to ask two other things. From my perspective at that stage as a paediatric 
registrar interested in neonates and the business of steroids, I think that there 
76 Roberton (1982).
77 Lewis et al. (1980).
78 Lewis et al. (1980); Ten Centre Study Group (1987).
79 Open Study of Infants at High Risk of or with Respiratory Insufﬁciency – the Role of Surfactant (OSIRIS) 
Collaborative Group (1992). In 1990/1, 6774 babies were recruited to an international multicentre trial 
to assess when administration of Exosurf, a synthetic surfactant, should be started and how often it should 
be given.
80 Dr Sam Richmond wrote: ‘I would point out that the price difference between steroids and surfactant 
mentioned in the last paragraph of the letter [Khanna and Richmond (1993)] contains a basic arithmetical 
error – the price of surfactant being nearly 100 times that of steroids rather than ten times.’ Letter to Mrs 
Lois Reynolds, 26 June 2005.
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were a number of the subanalyses in the US Collaborative Group study which 
were useful, such as the long-term outcome worries which were one of the major 
concerns.81 What I found interesting were two aspects of that study. One was 
the vast number of mothers who were eligible but excluded, 88 per cent of those 
thought eligible to be considered but not actually entered, they were excused for 
various reasons, the vast majority being excluded because they weren’t thought 
to be delivering within the time frame. I wondered what actually happened, 
whether they did or they didn’t deliver within the time frame, I can ﬁnd no 
evidence to show what happened. But the other issue is whether there ever was 
any biological plausibility to the reasons for the subgroup analyses? Why would 
we expect betamethasone to work differently according to sex of the fetus?82 I 
wondered if anyone had any clues as to that. I am not a laboratory person, but 
I cannot see any particular reason why one should divide on the basis of the sex 
of the fetus in relation to likely outcome. I could be completely wrong. But that 
seemed to be one of the major issues that it was a waste of time, unless you were 
expecting a black female baby, and that’s clearly incorrect.83 But why did anyone 
think to look in the ﬁrst place? 
81 Dr Sam Richmond wrote: ‘I was particularly interested in the subanalyses of the collaborative study 
because of concern over long-term adverse effects in babies exposed to antenatal steroids, and thus the wish 
to be more discriminating in its administration. What I thought signiﬁcantly undermined the conclusions 
drawn were: ﬁrstly, the number of eligible mothers excluded from the study (7197/7893 = 91 per cent), 
which must raise some questions, and secondly the illogical interpretation of some of them. One might 
expect a medication to have a greater effect among a subgroup at greater risk – such as among Caucasians 
rather than African Americans of equivalent gestation, or among males rather than females of equivalent 
gestation – that does mean that steroids don’t work in the lower risk group, one merely requires a larger 
sample to show an effect.’ Note on draft transcript, 26 June 2005. See Collaborative Group on Antenatal 
Steroid Therapy (1981). 
82 Dr Ross Howie wrote: ‘Outcome according to sex of baby: this is something I had not analysed in the 
Auckland study, and when I heard of the NIH ﬁndings I went back to check. This showed that in our hands, 
in contrast to the NIH study, betamethasone appeared to be more effective in boys than in girls. I concluded 
that the difference may have been due to the fact that we are in the southern hemisphere.’ E-mail to Mrs 
Lois Reynolds, 26 August 2005.
83 Dr Sam Richmond wrote: ‘I know of no biologically plausible reason to expect any such difference (other 
than the well-known fact that girls of an equivalent gestation are at less risk of death than boys) and thus 
I could not understand why the subanalyses by sex were made in the ﬁrst place – nor why this aspect was 
so vigorously pursued. If one undertakes a large number of subanalyses of any dataset one will ﬁnd some 
statistically signiﬁcant differences purely by chance.’ Note on draft transcript, 25 June 2005. See Roberton 
(1982); Collaborative Group on Antenatal Steroid Therapy (1981); see also Lucas and Roberton (1982). 
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Avery: First, there is deﬁnitely a difference between male and female, and white 
and non-white. The Asian population is more advanced, yet when you look at 
these differences they are real, even into 20 weeks. I don’t think they are big 
enough to swamp all the other things that are going on. It’s a very interesting 
issue, I think, taking into consideration the chance that you might have all girls 
and look at the output in terms of scoring.
Richmond: I fully accept that there is a difference in survival based on race and 
sex, but I didn’t think there would necessarily be a difference in response to 
steroids based on that. It just means that you get more informative clients if 
you choose the ones with the higher risk, but is there a differential response to 
steroids based on sex or race? 
Avery: I cannot give you chapter and verse, but I think there is a difference.84 
Maybe somebody else has a reference. 
Chalmers: I want to comment on extrapolation from data in animals, 
pathophysiological data in humans, and observational data in humans. One 
of the most remarkable things about the Auckland story is that Mont and Ross 
went directly from hypotheses they had tested in animals to assess the relevance 
of the hypotheses to women and their babies. People working with animals who 
generate hypotheses – whether it’s about brain damage in the long term or some 
other matter – too often fail to exercise the scientiﬁc self-discipline shown by 
Mont Liggins and Ross Howie. I’ll give you an example. Geoffrey Dawes was one 
of the hubs of perinatal physiological research in this country.85 He and I often 
had arguments about the behaviour that I have just been complaining about. I 
had the impression that he was very annoyed that he hadn’t made the discovery 
that Mont and Ross had made. I remember how in the 1990s he telephoned 
me in some glee to say that he had discovered – in an observational study – that 
prenatal steroid administration was associated with a pattern of fetal breathing 
movements that he regarded as worrying. I said to him, ‘So what? You have now 
a mass of data from women and babies. If you have a hypothesis that is worth 
testing in terms of the relevance of your observations to human health, then test 
84 Professor Mel Avery wrote: ‘A male infant has 1.5 to 2.0 times the risk of fatal hyaline membrane disease 
[also known as respiratory distress syndrome (RDS)]. See Wood and Farrell (1974).’ Fax to Dr Daphne 
Christie, 21 June 2005. See also Farrell and Wood (1976); Avery (2000). 
85 See biographical note on page 130–1. Sir Iain Chalmers wrote: ‘Liggins notes that Joseph Barcroft’s 
work on fetal physiology was largely ignored by obstetricians until the mid-1960s, when Geoffrey Dawes’ 
Nufﬁeld Institute became the “hub of the universe” in terms of fetal physiology.’ E-mail to Dr Edmund 
Hey, copy to Dr Tilli Tansey and Dr Daphne Christie, 17 April 2004.
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it, using the mass of data that’s now available from human experiments’. There 
is this bizarre lack of scientiﬁc self-discipline among people who know how to 
design experiments in animals, but actually don’t know how to design, or even 
exploit, experiments in human beings. 
Walters: Having done a lot of work in the lab and also done some clinical trials, 
I would do lab work every time. It is very hard to do clinical trials because of the 
obstacles that are currently in our way, particularly in this country. I mean ethics 
committees, 60-page ethics forms, trying to get support from the institutions 
and even more European hurdles to get through even now, with having to record 
our clinical trials centrally. Also on a scientiﬁc basis, the variables in clinical 
trials are much more difﬁcult to control than they are in the lab. So as a humble 
physiologist trying to get into clinical work, give me the lab every time.
Avery: Just a note, Mont Liggins spent a sabbatical in Geoffrey Dawes’ lab 
and speciﬁcally was told by Dawes that he [Dawes] would not allow anyone 
to do any work on, even discuss, surfactants for the whole time that Mont 
was there.86
Hey: Well, that’s straight from the horse’s mouth. 
Avery: One petty observation, but I couldn’t resist. 
Hey: I will just interject that in the Ross conference report that you mentioned in 
1976, there are ﬁve papers from the US saying that they tried to do a trial and it 
was too difﬁcult.87 We moan now about trials being difﬁcult. You go back and ﬁnd 
86 There was some discussion between Avery, Liggins and the editors on this point. This correspondence, 
along with tapes and other records of the meeting, will be deposited in CG/253, Archives and Manuscripts, 
Wellcome Library, London. 
87 Dr Edmund Hey wrote: ‘In introducing the contribution by Professor Liggins, the Chairman, Professor 
T D Moore, said: “The information which is most likely to reduce the uncertainty associated with decisions 
dealing with the safety and effectiveness of drugs is obtained from tightly controlled, double-blind clinical 
studies. As you will learn from subsequent discussion sessions, such studies are extremely difﬁcult to execute. 
Not only must the clinical investigator have the blessing of the Human Research Committee, he must also 
have complete cooperation from his medical colleagues and their patients. You say impossible? Most of the 
time, yes. However, on rare occasions someone is able to pull it off. When that happens, we have a classic 
piece of research on which many others can build. Such is the case with Dr Liggins’ studies of the effect 
of prenatal treatment with betamethasone on the prevalence of RDS.” Clinicians from centres in Quebec, 
Canada, San Francisco, Texas and from two medical schools in Boston, all indicated during the subsequent 
discussion that they had found it impossible to undertake such a study. Liggins (1976): 97, 119.’ Note on 
draft transcript, 27 August 2005. 
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that they have always been saying that they are difﬁcult. I think they are getting 
more difﬁcult, but it’s always been difﬁcult. Yet sometimes it goes very well. 
Gyte: I am moving away and back to a theme that was mentioned before. As a 
consumer representative, I have always been very interested in the implementation 
of research ﬁndings, and my experience in this area came when I was a consumer 
representative on the ORACLE trial, which was a trial looking at antibiotics 
in preterm labour.88 In the development of that protocol, the researchers 
wanted to do a second randomization of steroids within the main trial, and 
as it was actually not our organization, the National Childbirth Trust (NCT), 
but another consumer organization, the Association for the Improvement in 
Maternity Services (AIMS), who put their foot down and said it was unethical 
to randomize women to steroids, and that actually all women should be given 
them within this multicentre trial, so that second randomization was removed. 
Hey: Just remind us of the date of the ORACLE trial. 
Gyte: We are doing a seven-year follow-up now, so it was 1995.
Hey: It was 1995, the results came out three years ago in the Lancet.89 The 
relevance is that one of the uncertainties that remains about steroid use is whether 
it is a wise thing to do for the mother’s sake, when there is premature rupture of 
membranes, because you may, in doing something good for the baby, increase 
the risk of the mother developing a generalized septicaemia. So presumably the 
consumers couldn’t see the unanswered question there. 
Gyte: I went to Effective Care in Pregnancy and Childbirth90 to read Patricia 
[Crowley]’s chapter to ﬁnd an NCT perspective, and I remember thinking 
that there were some areas of uncertainty, but certainly that randomization was 
removed from the study.
Dr Peter Brocklehurst: I suppose I was just thinking about how we now 
approach the use of antenatal steroids, how we have heard today that it was 
very difﬁcult to get antenatal steroids used in clinical practice, particularly in 
the UK, and then, within a very short space of time, we were throwing them 
around like Smarties. I suppose what nobody has mentioned yet is that in order 
to get 90 per cent coverage of babies admitted to the neonatal unit exposed to 
88 Kenyon et al. (ORACLE Collaborative Group) (2001a and b).
89 See Kenyon et al. (2001a and b).
90 See note 52.
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antenatal steroids, you have to give them to an awful lot of pregnant women. 
I have heard it said that in some hospitals a pregnant woman under 34 weeks 
only has to burp to be given antenatal steroids. And then there was the use of 
multiple courses of steroids that is becoming very frequent. Now, of course, what 
are being considered more and more in the literature are the potential adverse 
effects, not just of multiple courses of steroids, but the potential long-term 
hazardous effect of a single course of antenatal steroids on brain development, 
which John Newnham’s group at Perth is coming up with evidence about.91
I think a lot of what is difﬁcult about this issue is that we are not very good at 
predicting preterm birth, and if we were better at predicting who was going to 
deliver preterm we would probably feel much more comfortable about using 
steroids in a more targeted way. The concern is that currently at least 50 per 
cent of women who get antenatal steroids do not deliver preterm and therefore 
if there is long-term harm, it will be in these babies that it will manifest itself. If 
we could target our use of steroids better, we would all probably feel a bit more 
comfortable. So I think we are beginning to go the other way, where people are 
actually being more cautious now with steroids than they were maybe even ﬁve 
years ago. 
Crowley: Could I remind you that in the Auckland trial a lot more babies 
died in the placebo group, and therefore one might have expected an increased 
incidence of adverse neurological outcome in the survivors from the steroid-
treated group compared with the control group. These survivors have now been 
assessed at 30 years of age, and if there’s no difference between the two groups 
at age 30, it’s unlikely that there is any hazard associated with a single dose of 
antenatal steroids. 
Harding: There are a number of comments I could make. I think you are quite 
right about the issue that you had to treat a lot of women. In fact, if you look 
at the studies that we were able to put together in a systematic review overall, 
40 per cent of women who were entered into the trial did not deliver after one 
week.92 So when you get into the issue of, well, how long did the effect last, and 
what do you do with the women who’ve been treated and haven’t delivered after 
a week – you have a lot of women to consider.
To come back to the issue of ruptured membranes, and I think it is fair to say 
in the mid-1990s there was still confusion about the issue, but the solution 
91 Their earlier work includes Newnham and Moss (2001); Newnham et al. (2002).
92 McLaughlin et al. (2003).
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was not to do a new trial. The solution was to go back to the old trials. At that 
time there had been over 4000 women randomized, and the data were present 
from the original trials, they had just never been analysed. In about 1994/5 
– I cannot remember the exact date – we had a debate around a clinical case 
at a clinical conference at my hospital, after which David Knight, who was the 
Director of the nursery at the time, said to me, ‘Isn’t that question answered? 
Surely the data must be there?’ Now just parenthetically, David Knight was at 
the Barcroft Symposium in 1973 at which Mont presented the data.93 That was 
one of the reasons that David came to New Zealand and ended up as Director 
of the nursery. He got all excited about antenatal steroids and thought that he 
would come to Auckland. That’s a slight aside. But it was David’s question to 
me that prompted me for the ﬁrst time to go back to Mont and Ross to ask, 
‘You know all those ﬁles in the locked cupboard in the corridor where my ofﬁce 
was, how would you feel about our getting them out and doing a new analysis, 
because I think the data might be there and we need to know the answer to a 
question that you hadn’t asked at the time’. 
With enormous generosity they agreed that I could do that. I would hate 
somebody to come along 30 years later and ask for my data from any of my 
studies and re-analyse it, it’s a very scary thought, and I think they were very 
brave. But they said, ‘Yes, that would be ﬁne’, and the original trial data sheets, 
beautifully handwritten by Ross, were still in the locked cupboard in the 
corridor.94 They have lived in my ofﬁce, under lock and key, ever since. We were 
able to retrieve the data from those data sheets, there was a code on the coding 
sheet that said ‘ruptured membranes at trial entry, yes/no’, so we were able to 
retrieve about 400 women who had ruptured membranes at trial, and even 
more remarkably we were able to go back to the hospital clinical records section 
and get out 80 per cent of the clinical records, which I think is phenomenal 
30 years later, but they were still there. They have also lived in my ofﬁce under 
93 Liggins and Howie (1973). 
94 Dr Ross Howie wrote: ‘On retention of records: the records were kept for just this purpose, for possible 
future use. There was hardly enormous generosity on my part, and I was delighted that Jane and others were 
able to make use of them. One possible reservation: I was once told early in my career never to let anyone 
else look at my raw data. The reason given was that there are many ways of analysing them, and some people 
would be only too willing to do so in such a way as to make you look a fool, or a fraud, or both. The person 
who told me this was one of the ﬁnest scientists I have known and no more paranoid than the rest of us. I 
had no hesitation about Jane’s use of the material. I imagine there would be no problem of this kind in these 
days of grand multiplicity of authorship, but we did not have that luxury in the early 1970s.’ E-mail to Mrs 
Lois Reynolds, 26 August 2005.
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lock and key ever since, and we were able to go back, retrieve the original data, 
redo the systematic review, and show, I think, very clearly that there was still 
considerable beneﬁt in the presence of ruptured membranes, and that there was 
no evidence of adverse effects.95
Hey: The answer for Gill Gyte was that the data were there but, 20 years later, 
it had still not even been analysed. Who can put their hands up and say that, 
of a trial completed and published more than ﬁve years ago, that they can still 
ﬁnd the original raw paperwork? One of the most amazing things that I found 
in reading around before today’s meeting, was to come across this paper by 
Jane Harding in the American Journal of Obstetrics and Gynecology on just this 
subject, published in 2001, and this is control trial data, and it has sat there all 
that time.96 
Harding: I think there are a number of messages. One is that the data were still 
there and still in a form that we could use, which I think is very impressive. The 
second is that new questions have come up that the trials weren’t necessarily 
designed to answer at the time, but it’s terribly important that the data are still 
there.97 Thirdly, someone might like to comment on the length of time it took 
us to get that paper published. The study was done in 1996/7, we wrote it up 
in 1998, it was rejected by two journals, submitted to the American Journal of 
Obstetrics and Gynecology in 1999, and it was eventually published in 2001. 
I do think the people who publish have something to contribute to this very 
prolonged process. 
If I could just go on to the other issue that was raised: what about the women 
who get steroids and don’t deliver within the next week? We have been concerned 
about this with respect to the repeat steroid issue. There has been a multicentre 
randomized trial run by Caroline Crowther out of Adelaide for the past seven 
years.98 We hope to ﬁnish recruiting this month. It includes 980 women, and 
we have been doing huge detailed studies of the babies in Auckland, the second 
largest centre recruiting to this trial. It occurred to us early on in that trial that 
we still didn’t have good data about risks and beneﬁts for the group who receive 
95 Harding et al. (2001).
96 Harding et al. (2001).
97 See Peter Elwood’s description of planning the Caerphilly study in Reynolds and Tansey (eds) 
(2005): 81.
98 See also Crowther and Harding (2003).
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steroids but then don’t deliver within the next week; the group who don’t stand 
to achieve the greatest beneﬁt for the infant and are potentially at the greatest 
risk. Once again, we thought the data weren’t out there, but I bet it was in the 
original trial. We were able to go back to the original data, look speciﬁcally at 
that group, write a new meta-analysis which has also been published after many 
rejections, after a very long time, which showed, in fact, that there may be 
adverse effects in that group.99 Therefore people need to randomize them to the 
new trials. We were in fact trying to help recruitment of the randomized trials. 
It took so long to publish that I think it’s had very little effect on recruitment to 
the trial, but the data are nevertheless there. Yet another outcome that was not 
relevant at the time, the question has come up subsequently. 
Hey: Would Glaxo still be able to ﬁnd the data? 
Professor Harold Gamsu: Oh yes, I have all the data in my ofﬁce.100 It’s still 
there, all the data sheets, because I was hoping to do a long-term follow-up on 
the adults, and in fact things haven’t turned out that way, but that’s still available 
for people to do if they would like to. 
Hey: Because people are still asking the questions: ‘Does it work in twins?’ or 
‘Should you give it in mothers with hypertension?’ 
Gamsu: Our numbers, of course, are very small. 
99 McLaughlin et al. (2003).
100 Gamsu et al. (1989). See Appendix 5 for the Protocol, provided by Dr Clive Dash. The sample case record 
used in the 1975 UK study will be deposited along with other records from this meeting in GC/253, Archives 
and Manuscripts, Wellcome Library, London. Dr Clive Dash wrote: ‘The retention of clinical trial data in the 
1970s–80s was poor. This has changed in recent years. When Harold Gamsu persuaded us to do a detailed 
analysis of the UK study, the computer software had changed and so had most personnel acquainted with 
the prior system. Luckily, Alex Paton at Glaxo was able to interrogate the database and through her efforts 
we were able to meet Harold’s expectations and answer his critical questions. Also, Harold volunteered to 
keep safe the original case record forms and other study documentation when Brenda Mullinger and I left 
Glaxo to pursue other career opportunities. I believe Harold always hoped to trace the babies in adult life to 
address the question of the long-term safety. It is due to his diligence and enthusiasm that he persuaded us 
(again, pleasantly) in 2001 to begin the process towards a 30+ years follow-up. His untimely death occurred 
in August 2004, soon after this witness meeting. We hope to continue this project with the support of NPEU 
in Oxford provided external support can be mobilized and plan to dedicate any outcomes to his memory.’ 
E-mail to Dr Daphne Christie, 10 January 2005. Mrs Brenda Mullinger wrote: ‘The idea of undertaking a 
follow-up of babies born in the UK study was mentioned at the seminar – this is a real possibility because 
Professor Gamsu was diligent in retaining all the trial record forms (and randomization codes) long after 
others’ interest in the study had ceased.’ Letter to Dr Daphne Christie, 6 January 2005.
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Hey: So are everybody’s, but if people have kept their data, there are more that 
can be analysed. Could anybody ﬁnd the NIH data? Would the NIH people 
share their data? 
Avery: I have no idea. 
Gamsu: May I ask a question about this study by Newnham et al.? My feeling 
is that it is in animals, but could you tell us a little bit more, because it sounds 
very signiﬁcant if it’s not in animals.
Brocklehurst: I cannot tell you very much more, because I heard it presented 
in Glasgow about six weeks ago, but I have seen nothing in press yet.101 My 
recollection is that it was in animals, but we’ll be able to explore this further 
when the study is published.102 Having tried to do one of the large trials of 
multiple courses of steroids, I think one of the issues for clinicians about the 
use of multiple courses of steroids is that their [clinicians] threshold for starting 
antenatal steroids is lower, because if they are wrong, and the woman doesn’t 
deliver soon, they have felt that they can always give a second course. If people 
are restricted to giving a single course of steroids they may delay starting until 
there is stronger evidence, if you like, of impending preterm birth. So the 
groups of women selected into these trials are likely to be quite different from 
the multiple steroids group and that will make the interpretation of the results 
interesting. 
Lilford: I recently had a debate with my 14-year-old daughter Philippa about 
whether history is just an interesting thing to read, or whether it helps us to 
design our own futures. Listening to Jane speak makes me think that there really 
are occasions when history has a lesson for the future. Hearing you speak about 
ﬁnding these records has been very interesting, but I suspect that many people 
101 Professor John Newnham from the King Edward Memorial Hospital, University of Western Australia, 
Perth, Australia, delivered the British Maternal and Fetal Medicine Society (BMFMS)’s Lecture, ‘Antenatal 
Steroids and Outcome’, at their Ninth Annual Conference, 1–2 April 2004, Glasgow. He presented results 
from human and animal studies where infants had been exposed to steroids before birth. See the full report 
by Dr Margaret M Ramsay, Honorary Secretary, BMFMS at www.bmfms.org.uk/presssummaryofglagow04.
doc (visited 18 July 2005). Professor Jane Harding wrote: ‘A large amount of Professor Newnham’s animal 
work has been published, but obviously the speakers here are not familiar with this. Some of the relevant 
articles include: Quinlivan et al. (1998); Sloboda et al. (2000, 2002a and b); Huang et al. (2001); Moss 
et al. (2002, 2003).’ Note on draft transcript, 4 September 2005.
102 The lecture will be published as Newnham (2006). 
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in this room were amazed that you really could ﬁnd those source materials after 
30 years, that you could ﬁnd the trial documents and so on. When Harold 
Gamsu moves the documents from his ofﬁce, goodness knows where they might 
go. So the lesson that we might want to learn from this is the importance of 
some sort of systematic paid-for archive for trial information, and I don’t know 
if you might want to comment. I know that the Economic and Social Research 
Council (ESRC) archive their most precious data and build the cost of so doing 
into the grant.103 The more I hear, the more I think this might be something we 
ought to try to take forward as a matter of some urgency. 
Chalmers: The MRC has a working party under the chairmanship of Peter 
Dukes, which is creating circumstances through which it would be possible 
for anyone receiving an MRC grant to archive their data.104 So biomedicine is 
catching up with the social scientists.
Dr Dino Giussani: I wanted to draw together some of the many comments, in 
particular one made by Iain Chalmers, as to how we translate evidence that we 
ﬁnd in animal studies to the human situation. We haven’t talked about many 
of the more subtle effects of antenatal glucocorticoid therapy that may prove 
detrimental in the long term to the adult. In the animal, there is overwhelming 
evidence now accumulated that antenatal steroid therapy, in doses and dose 
intervals used in human clinical practice today, has detrimental effects on 
the development of the adrenal gland. For example, fetuses that have been 
treated by steroids have an overreactive adrenal function, which may lead to 
detrimental long-term consequences in adult life. We have not talked about 
maturational effects on other systems, such as the cardiovascular system. We 
103 The Economic and Social Data Service (ESDS) Qualidata is a specialist service of the ESDS led by the 
UK Data Archive (UKDA) at the University of Essex. The service provides access and support for a range 
of social science qualitative datasets. Established in 1967 the UKDA holds the largest collection of digital 
data in the social sciences and humanities in the UK, funded by the ESRC, the Joint Information Systems 
Committee (JISC) of the Higher Education Funding Councils, and the University of Essex.
104 Dr Peter Dukes wrote: ‘The MRC’s policy is that population and trials datasets should be managed such 
that they sustainably accessible (through preservation) and shareable [see www.mrc.ac.uk/index/strategy-
data_sharing_policy.htm (visited 30 September 2005)]. From 1 January 2006, investigators are required 
to submit brief data sharing and preservation plans with their grant applications. To create awareness 
and support preservation, the MRC has commissioned guidelines for both investigators and peer-review 
committees. Following a jointly commissioned study by MRC, BBSRC, DTI, JISC, NERC and the 
Wellcome Trust, these funders expect to assess during 2006 the requirement(s) for coordinated support for 
data preservation, curation and sharing.’ E-mail to Mrs Lois Reynolds, 30 September 2005.
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know that glucocorticoids in fetal life increase blood pressure in a sustained 
manner at a time that mechanisms that are going to control the blood pressure 
of the individual in adult life are being programmed, such as the baroreceptors. 
We have evidence that antenatal glucocorticoid therapy resets the arterial 
baroreceptors to run or to maintain blood pressure at a higher level. And of 
course we don’t know whether that would lead eventually to detrimental effects. 
We all agree that glucocorticoids are life-savers, but we have to begin to think 
as to whether some of these more subtle side-effects may become detrimental 
in later life. 
I was also wondering whether we will talk later about reﬁning some of the 
dosing regimens of glucocorticoid therapy today, in an effort to maintain the 
beneﬁcial effects, but to ‘weed out’ the unwanted, adverse side-effects.
Harding: If I can make a very brief comment about that? This is another 
example of a new question for which the old data already had the answers. The 
blood pressure of the six-year-old children was recorded, but never analysed 
and published, and it will be published very shortly in Pediatrics.105 We found 
the archives in the roof of the hospital, dragged them down, and said, ‘Would 
you mind if we analysed these and published them?’ There is no difference in 
blood pressure at six years or, incidentally, at 30 years, but I think the issue for 
this conference again is one of new questions to which old data actually has the 
answer. 
Dr John Hayward: I wonder whether this is an opportunity to look at getting 
research into practice, one of the future topics after the tea break, just to hold in 
our mind some of the questions that have been raised. 
What strikes me is that during my own career as a GP – becoming interested in 
systematic reviews, training in public health, and then returning to public health 
– the same issues keep cropping up. There is always a concern whether we have 
looked at the subjects correctly? What will the long-term detrimental effects be? 
Everybody is actually inﬂuenced by some horror that they have come across. 
That’s perhaps not so much the case for steroids, but it’s certainly true if you 
look at external cephalic version (ECV) of breech presentation, for example. My 
statement later will be about how we looked at getting research evidence into 
practice. I think the danger is that everyone worries about some rare outcomes 
30 years hence as justiﬁcation for sitting on your hands and not doing anything. 
105 Dalziel et al. (2004, 2005a and b). 
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The outcome of interest here was death, compared with survival, and I think 
that’s the critical thing to hold in our minds and presumably there are children, 
now adults, who would not be here at all if their mothers hadn’t consented to 
take part in the original trials and been fortunate enough to have the coin fall 
on their side, who got the intervention rather than the control. I would have 
thought that those adults who are alive now would accept a certain amount of 
hypertension or some other problem as an alternative to not being here at all.
Hey: I think we had better draw this to a close for tea. We haven’t got as far as we 
should have. Death isn’t the only outcome, there are cost–beneﬁts apart from 
that and we must move on.
Mugford: My background is a degree in economics. I graduated from the 
University of Stirling in 1972: health economics as a discipline didn’t exist then. 
I think the ﬁrst Penguin book of readings for students of health economics 
was published in 1973.106 I looked at it and wished that I had studied health 
economics. There wasn’t at that stage even postgraduate training in it. I ﬁnished 
my economics degree quite disillusioned with the subject, because it was very 
much centred on the formal economy – that is how people trade goods and 
services using the money mechanism and adjustments of it through the public 
services as a method. So I ﬁnished a Master’s in monetary economics and then 
dabbled in bits of health of economics research. I joined the NPEU in Oxford, 
as a researcher in statistics with Alison Macfarlane, but also to work in the 
unit on other topics, including incorporating economics alongside randomized 
trials with Adrian Grant. This was a very new notion of building economic 
evaluations using evidence from syntheses of evidence of effectiveness, building 
on the work that Iain Chalmers and others were pioneering in the Oxford 
Database of Perinatal Trials (as it later became but wasn’t when I ﬁrst joined the 
unit in 1981). 
In the early 1980s when I was still working on the book of statistics of pregnancy 
and childbirth with Alison Macfarlane, Iain Chalmers asked me to keep a ﬁle 
in my ﬁling cabinet on neonatal intensive care, because it was an issue that was 
of increasing interest in the health services and it was going to be of economic 
importance.107 And so I did. 
106 Cooper and Culyer (1973).
107 Macfarlane and Mugford (eds) (1984).
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At that time, health economics was emerging and that’s another whole historical 
story which has been documented elsewhere.108 My connection with it was really 
through Professor Alan Williams at York, who was probably the founding father 
of health economics in the UK, and his visit to the unit. I think he was examining 
a dissertation in Oxford with Iain and I asked him how I could qualify as a health 
economist. He replied, ‘What you have to be able to do if you are a graduate 
economist is to stand up and say that you are a health economist in front of a bunch 
of doctors.’ So I girded my loins and worked on subjects, including the systematic 
review of steroids, that seemed to be relevant to our brief in the NPEU and to the 
enthusiasm of people within the unit. I remember the day when the results were 
being worked through by Patricia and Iain before it was published. The coffee room 
was buzzing and this was very exciting. At the same time I was host and supervisor 
to a series of students from York, where they had a new health economics Master’s 
degree and they looked for placements for their students during the summer to do 
dissertations. One of them, James Piercy, came to me to work on the economics 
of antenatal corticosteroids. He did some observational work in the neonatal unit 
in Oxford to try to assess the costs of treating babies at risk of preterm delivery 
and eligible for steroids. In fact, the surfactant question was also – I was going 
to say ‘bubbling’ – around at that time. He and I with Iain wrote a paper which 
was a modelling exercise, a very, very simple decision-modelling exercise, based 
on different assumptions about initial birth weight and mortality risk, based on 
the cost data, which James had gathered for his dissertation, and the evidence of 
effectiveness from the systematic review. That was published by Archives of Disease 
in Childhood, having been rejected by the British Medical Journal, in 1991, after 
the systematic review.109 So as far as I am concerned, that wasn’t quite the end 
of the story because the Oxford Regional Health Authority had introduced the 
Getting Research Into Practice and Purchasing (GRIPP) programme.110 We are 
going to hear more about that later, I think. 
One of the things I was asked to do by the public health doctors was to model 
the impact in the Oxford region of this particular policy, GRIPP, on increased 
uptake beyond current uptake, which I think we assumed conservatively to be 
about 10 per cent, I can’t remember.111 We worked out that implementing the 
108 Croxson (1998).
109 Mugford et al. (1991).
110 Dopson and Gabbay (1995).
111 Mugford (1993).
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policy in the Oxford region might reduce not only mortality but also the costs 
of neonatal intensive care after paying for the drugs, which were not a great cost 
to the health service, and that reduction would probably be in the region of 10 
per cent of the cost of neonatal intensive care for those babies. Although when 
I talked to the ﬁnance director in the health authority, as it then was, he was a 
bit dismissive and said, ‘If you cannot tell us how many cots we can close, it’s 
not really very interesting to us, because those paediatricians will just ﬁll the cots 
anyway, they will put someone else into them’. I replied that this was not the 
point of the economics. The point of the economics is that it is better if you can 
do more with what you have got.
Hey: Your study came in just at the time when if you didn’t give steroids you 
might have had to end up giving surfactant at £250 per ampoule, wasn’t it? 
Mugford: I think it was more than that. Up to £600. 
Hey: And it has still not gone down. So you did it at exactly the right time, I 
think. 
Mugford: There’s just one other thing which I think Mary Ellen Avery referred 
to, and Patricia [Crowley] too, and that was that the analysis we did was quite 
unsophisticated, but we did make some effort to model the impact in the smaller 
babies and the more preterm babies, and in those cases there wasn’t a predicted 
cost saving. One of the problems we had with people was the assumption that 
that is not then cost-effective, which isn’t true, because society has shown that it 
is willing to pay for neonatal care, to pay for the beneﬁts of having survivors. So 
it’s not just that they need to save money, it’s that there’s a willingness to pay for 
the beneﬁts beyond the straight, evident cost savings. Among economists, it is 
not very fashionable to look at areas where in fact there is a win–win situation. 
The exciting academic work goes on at the fringes, where beneﬁts perhaps might 
not be worth the costs. 
Hey: I have been doing a little bit of economic work myself recently, and you 
realize, of course, that the cost of neonatal intensive care is nearly all the cost of 
the doctors’ salaries, and what isn’t the doctors’ salaries is the cost of the nurses’ 
salaries, and that’s what your treasurer means when he wants to close a bed. He 
wants to be able actually to use fewer nurses, and those are the driving costs 
which put most of the other costs into second place. Last time I looked at a 
hospital budget for a neonatal intensive care unit, and that is a unit with a lot 
of expensive drugs in it, they still only account for 10 per cent of the annual 
budget of the unit. 
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Gamsu: I agree with you. The cost of anything is almost always invested in the 
cost of salaries, particularly nurses, of course, because they have to be there all 
the time. 
Hey: And at night as well. They are now expected to have only one baby in their 
care. 
Mugford: We can say that over the past 20 years the resources devoted to neonatal 
intensive care have expanded incredibly – you [the History of Twentieth Century 
Medicine Group] held a different Witness Seminar on this subject, but I haven’t 
looked at that transcript.112 There are very many more nurses, doctors, ventilators 
and techniques for the care of preterm babies than there were 20 years ago.113 
Hey: I think we shall move straight on, because we examine next how to get 
research into practice. I am going to ask Iain to explain how it came about that 
he chose to use a very early version of Patricia’s meta-analysis as late as 1992, 
at a time when there were twice as many trials involved in her analysis for his 
Cochrane Centre Logo.
Chalmers: It’s good that Patricia Crowley has already described some of the 
history. Given that I am going to be talking about the Cochrane Logo, I might as 
well start with Archie Cochrane, whose famous book – Effectiveness and Efﬁciency: 
Random reﬂections on health services – was published in 1972.114 I read it in 1973 
and it changed my life!115 In spite of the fact that I had been ‘licensed to kill’ six 
years earlier after studying at the Middlesex Hospital Medical School, London, 
to qualify as a doctor, I had not previously been aware of the term ‘randomized 
controlled trial (RCT)’. Cochrane showed me how I might adjudicate among 
incompatible clinical opinions about treatments – a common situation faced 
by me and other junior doctors – and it was after reading Cochrane’s book that 
I started to collect reports of RCTs. A librarian at the University of Cardiff, 
Steve Pritchard, designed a Medline® [online version of Index Medicus] search 
to identify these studies for me, and I started noting those in my special area of 
interest (perinatal care) during my reading of journals and books. 
112 The Witness Seminar, ‘Origins of Neonatal Intensive Care in the UK’, was held on 27 April 1999. See 
Christie and Tansey (eds) (2001), also freely available online at www.ucl.ac.uk/histmed following the link 
to Publications/Wellcome Witnesses.
113 Macfarlane et al. (1999).
114 Cochrane (1972).
115 Chalmers (1999).
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In 1976, because it was clear that this was an insufﬁciently systematic method of 
ﬁnding reports of RCTs, I outlined a plan for using a more systematic approach 
both for ﬁnding published reports, and for identifying unpublished studies, 
because biased under-reporting of RCTs means that unpublished studies tend to 
have less dramatic results than those that get into print. This plan, which was set 
out in a letter to Martin Richards, a psychologist in Cambridge, also stated an 
intention to use statistical synthesis of the results of similar but separate studies 
(meta-analysis) to reduce type 2 errors (false negatives) in estimating treatment 
effects. My letter to Martin Richards happened to be sent to him during the 
same year as the term ‘meta-analysis’ was introduced by the American social 
scientist Gene Glass.116 
The ﬁrst opportunity that I took to do a systematic review using meta-analysis 
related to different ways of monitoring babies during labour.117 Electronic fetal 
heart-rate monitoring had been introduced in obstetrics not long previously, 
sometimes accompanied by fetal scalp blood sampling to assess fetal acid–base 
status, particularly if the heart rate had raised concerns. It was being suggested by 
some people that these more intensive methods of intrapartum fetal monitoring 
should replace intermittent auscultation using fetal stethoscopes. I set about 
analysing three published reports of RCTs comparing different methods of 
intrapartum fetal monitoring, and the ﬁndings from one unpublished RCT, 
which were kindly made available to me by the investigators. About 2000 
babies had been born to the women who had been entered into these four 
trials: 13 of their babies had had neonatal convulsions. With the help of a 
medical statistician – Klim McPherson – I analysed the distribution of these 
babies among the comparison groups in the RCTs.118 This revealed that the 
pattern was very unlikely to have occurred by chance (less than 1 in 100): the 
analysis suggested that continuous electronic fetal heart rate monitoring with 
scalp sampling might reduce the risk of neonatal convulsions.
I was very impressed by this observation which had not been picked up in any 
of the individual RCTs, and it inﬂuenced the design of a very large RCT (in 
which over 13 000 women and their babies participated), done at the National 
Maternity Hospital, Dublin, while Patricia Crowley was working there.119 
116 Glass (1976).
117 Chalmers (1979).
118 See, for example, McPherson (1990).
119 MacDonald et al. (1985).
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The results of the Dublin trial of fetal monitoring conﬁrmed the hypothesis 
generated by my systematic review and meta-analysis. That seemed to me to 
provide encouraging evidence that systematic reviews and meta-analyses could 
be useful for generating and testing hypotheses about the effects of healthcare 
interventions. Furthermore, it was becoming clear that this approach was 
regarded as promising in other ﬁelds, particularly in cancer and cardiovascular 
disease.120 
As has already been noted by Patricia Crowley, hundreds of people volunteered 
during the following decade to collaborate in helping to prepare systematic reviews 
of RCTs assessing the effects of interventions during pregnancy, childbirth and 
early infancy. For example, to identify relevant studies for a register of RCTs,121 
some of these people searched over 70 obstetric and paediatric journals back to 
their 1950 issues,122 while others developed an agreed methodology for analysing 
the data from these studies.123 Some of the resulting systematic reviews were 
published in journals (we were encouraged particularly by Frank Hytten, David 
Paintin and Sheila Duncan at the British Journal of Obstetrics and Gynaecology), 
and all of them were published in books124 as well as electronically, so that the 
analyses could be kept up to date.125 It was very important that an institutional 
base for this work existed – the National Perinatal Epidemiology Unit (NPEU). 
The Unit was funded by the Department of Health, which recognized that 
systematic reviews of existing evidence were a relevant way of identifying 
priorities for new research. 
So what about the logo of the Cochrane Collaboration? The publications 
that had come from this ‘pilot study’ in the perinatal ﬁeld were quite widely 
well received. Importantly, an oncologist, Michael Peckham, who had 
been appointed in 1991 to establish a new NHS research and development 
programme, commented favourably on our work in a Lancet article about his 
120 Stjernsward et al. (1976); Chalmers et al. (1977); Anonymous (1980).
121 National Perinatal Epidemiology Unit (1985).
122 Chalmers et al. (1986).
123 Chalmers et al. (1989).
124 Chalmers et al. (eds) (1989); Enkin et al. (1989); Sinclair and Bracken (1992).
125 Chalmers (1989–92). The contents were subsequently transferred to and maintained in The Cochrane 
Database of Systematic Reviews, accessible through the Cochrane Library at www3.interscience.wiley.com/
cgi-bin/mrwhome/106568753/HOME (visited 2 June 2005).
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Figure 6: The story of the Cochrane Logo, 1992.
In 1992 Iain Chalmers asked David Mostyn to design a logo to illustrate the objectives of 
the Cochrane Centre, which was being established in Oxford later that year. On leaving the 
Cochrane Collaboration ten years later, Iain commissioned David to produce a painting to 
illustrate how the Cochrane Logo had been conceptualized and created.
The circle in the upper left panel reﬂects global objectives and international collaboration. The 
addition of the mirror image Cs in the upper right panel initially stood for Cochrane Centre 
and subsequently for Cochrane Collaboration. The horizontal and vertical lines added in the 
lower left panel show the results of several RCTs of prenatal corticosteroids, a simple and 
inexpensive treatment to reduce problems experienced by premature babies. The reason there 
are eight horizontal lines in the painting compared with only seven in the ofﬁcial Cochrane 
Logo is because Iain had inadvertently overlooked one of the 1991 studies. The diamond added 
in the remaining panel is a statistical summary of the information derived from the individual 
studies above it. This summary statistic shows that prenatal corticosteroids, which were not 
then in widespread use, reduced mortality in premature babies. 
The Cochrane Logo thus illustrates the human costs that can result from failure to perform 
systematic, up-to-date reviews of controlled trials of healthcare. The Cochrane Collaboration 
was established to do something about this unsatisfactory state of affairs.  
See www.cochrane.org (visited 22 November 2005). 
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plans for the new programme.126 He also responded encouragingly in that year 
when I suggested that a centre might be established to facilitate extension of the 
methods we had used to other areas of healthcare. His advisers subsequently 
agreed that it was worth giving the proposal three years to see whether we 
could make anything of it. As I have never had a contract for longer than a few 
years, I accepted this challenge, and the (UK) Cochrane Centre was opened 
in 1992.127 
Part of the Centre’s logo shows the results of the ﬁrst seven trials of prenatal 
corticosteroids. I overlooked, inadvertently, an eighth trial that had been 
published during this time period. It happened to have exactly the same 
conﬁdence interval as one of the others, and I had thought that we might have 
been double counting. The reason that we used the steroid trials was that we 
wanted to show that within ten years of the Liggins and Howie trial,128 there 
had been crystal-clear evidence that this was a very important way of reducing 
neonatal deaths. In launching the Cochrane Centre, we wanted to make the 
point that this very important information had been available more than a 
decade earlier, yet it was still not being acted upon sufﬁciently in practice. In 
the brochures we produced and the talks we gave to introduce the objectives of 
the Centre to others, we made the point that tens of thousands of babies had 
suffered and died unnecessarily (and cost health services more than they need 
have done) because information had not been assembled in a systematic review 
and meta-analysis to show the strength of the evidence. In 1993, a year after the 
Cochrane Centre had opened for business, we convened the meeting at which 
the international Cochrane Collaboration was founded, and the Centre’s logo 
was adopted by the new organization.129 [See Figure 6.]
I want to end with a statement that may sound rather carping, but I am keen 
that it should be on the record, given that this seminar is supported by the 
Wellcome Trust. Although the Trust supports clinical trials in some other parts 
of the world, it has always discouraged applications for support of clinical trials 
in the UK. In addition, I have it on good authority that some of the governors 
of the Trust have not only been unsupportive, but actually dismissive of the 
126 Peckham (1991).
127 Chalmers (2003). See www.cochrane.org/docs/orderformarchiecochrane backtothefront.doc (visited 
1 June 2005).
128 Liggins and Howie (1972).
129 Chalmers (1993a); Chalmers et al. (1997).
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kind of research I have described here – RCT registration, systematic reviews 
and meta-analysis. Indeed, the Trust’s website declares unambiguously that it 
will not support systematic reviews of clinical trials.130 Given that those assessing 
payback from research and others recognize the crucial importance of systematic 
reviews of clinical trials for patient beneﬁt, I and others continue to resent the 
Trust’s unwillingness to engage in discussion with outsiders about the scientiﬁc 
rationale for its attitudes to clinical trials and systematic reviews.131 It is time that 
the Trust and other funders of biomedical research assessed more rigorously and 
transparently the cost-effectiveness of their research funding decisions. 132
Hey: The problem with your logo, of course, as my maths teachers would have 
said, is that it doesn’t have a scale on it.
Chalmers: Is there no artist in you?
Hey: And the little blobs on the bottom. This is all very well, but it doesn’t 
actually tell you that you halve the chance of the baby getting respiratory 
distress. Getting research into practice: we have already started down the path, 
haven’t we?
Lilford: It’s a great honour to be here today to say a few words about moving 
knowledge into clinical practice. I was plucked from obscurity in 1991, I 
think it was, by the then President of the Royal College of Obstetricians and 
Gynaecologists, Stan Simmons. He called me into his ofﬁce and said that he 
wanted me to take over the audit committee. I had not been on the committee 
before, so I went down to the ﬁrst meeting as their Chair. It was a very boring 
meeting; it didn’t seem to go anywhere. The idea of guidelines was coming into 
people’s consciousness at around this time, and on the train back home the idea 
came into my head that what I should do with the committee was promulgate 
guidelines. So I told the council how I was going to do this, and they must have 
had something else on their minds that day, because they nodded it through, 
and moved on to the next item. I then had a mandate to produce guidelines for 
dissemination. The next thing to decide on was the context of the guidelines. Iain 
Chalmers along with his colleagues had recently published his book, Effective 
Care in Pregnancy and Childbirth, and so I thought, ‘That’s what we will do: we 
130 See the Wellcome Trust Funding for Clinical Trials at www.wellcome.ac.uk/doc%5Fwtx022708.html 
(visited 5 August 2005). Chalmers (2005). 
131 Hanney et al. (2005).
132 Chalmers (2000).
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will go through all these trials, and come out with lots of guidelines.’ So I called 
a small group together – Marc Keirse, who was an obstetrician and an associate 
of Iain’s, now working in Australia, and a chap called Jim Thornton, my clinical 
partner – and we went through this whole dataset in a day. [From the ﬂoor: In 
a day?] Yes, in a day, a long day, I can tell you, but it was a day. I remember that 
it went on into the evening and Marc came round to our house for supper after. 
I thought we would have, say, 100 guidelines, as the book was very thick, but 
when we went through it, we could make only 21 ‘yes’ or ‘no’ statements. That 
really surprised me, as I had no idea it would be as few as that. 
How many trials were there in those days? There would have been about 20 000 
trials? [Chalmers: Three-and-a-half thousand.] From these 3500 trials, what 
do you get? Twenty-one guidelines that say categorically ‘do this’ or ‘do not do 
that’. Even some of these were not completely uncontentious. The one that 
worried me most was the ventouse.133 In any account, most of the guidelines 
were based on very convincing evidence and these included the injunction to 
prescribe steroids in the case of premature labour. Anyway this was our yield, 
21, and we showed them to a bemused council who approved dissemination. So 
it was that the guidelines were distributed to all the people practising obstetrics 
and gynaecology in the country, under the President’s signature.134 Of course, 
as so often happens in life in our modern complex society, a number of other 
dissemination activities occurred at around this time. Liam Donaldson, who 
was then a regional director of public health, published a commentary in 
the British Medical Journal on the use of steroids, although, as we shall see, 
his was an eulological study.135 Then there was a publication from the British 
Association of Perinatal Medicine (BAPM), and in 1993 there were letters in 
the Lancet.136 An NHS Management Executive letter, EL(93)115, was [also] 
dispatched in 1993.137 There was an NIH consensus development conference 
133 An alternative to forceps delivery, where a traction cup is attached to the head of the fetus when delivery 
has not progressed sufﬁciently or the fetus is distressed. Negative pressure is applied through the suction tube 
ﬁxed to the cup. When the baby’s head emerges, the cup is removed and the rest of the baby is delivered.
134 Simmons (1992).
135 Donaldson (1992). 
136 Joint Working Group of the BAPM and the Royal College of Physicians of London. (1992). See letters 
in the Lancet (1993) 341: 172–4; Chalmers (1993b).
137 NHS Executive Letter (1993). Appendix B, Development of audit measures and guidelines for good 
practice in the management of neonatal respiratory distress syndrome, cites BAPM and RCP (1992); BAPM 
and Neonatal Nurses Association (1992). 
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in 1994.138 So there was quite a lot of buzz going on, and I didn’t realize that 
my idea was so unoriginal until Edmund Hey made me aware of these other 
activities, but there again, that’s life. We did disseminate our guidelines, and I 
rested myself content.139 In fact we went on to produce further guidelines about 
communication in maternity services and organizational standards, but those 
were studiously ignored. With Lesley Page, Professor of Midwifery Practice at 
Queen Charlotte’s Hospital, I then applied for a prize from BUPA, who give an 
annual prize to he or she who communicated best during the year.140 We didn’t 
get it, and the reason we didn’t, again quite properly, was that all we had done 
was propagate these guidelines; we hadn’t investigated what effect they had. So 
then I applied for a grant to do a study on the uptake of guidance with Jenny 
Hewison, Jim Thornton, Ian Watt, David Braunholtz and Michael Robinson. 
Edmund Hey also sent me a paper by a very nice man called Jack Sinclair, and 
in it he says, 
Despite the evidence of efﬁcacy and effectiveness of steroids in reducing 
RDS and death rates, the use by obstetricians of antenatal corticosteroids 
has remained low by many accounts.141 
For example, in the Canadian multicentre trial of neonatal surfactant, it was 
found that many of the mothers had not had steroids. This was in the early 
1990s.142 So the question was what happened after that – did the practice move 
on following dissemination of the guidelines and the other activities in the early 
1990s? After all, if it wasn’t necessary to have systematic reviews, if it wasn’t 
necessary to put them into databases, and if it wasn’t necessary to show that they 
138 National Institutes of Health (NIH) Consensus Statement (1994); NIH Consensus Development 
Panel (1995).
139 The Royal College of Obstetricians and Gynaecologists (RCOG) President’s Newsletter of December 
1992 noted a single page of advice from the RCOG Scientiﬁc Advisory Committee that ‘antenatal 
corticosteroid administration reduces the incidence of neonatal respiratory distress syndrome’. See Simmons 
(1992): 4–5. See also note 158. A series of national evidence-based guidelines funded by the Department 
of Health followed in 1996. For the current antenatal corticosteroid advice, see www.rcog.org.uk/index.
asp?PageID=73 &BookCategoryID=2&BookTypeID=5 (visited 30 June 2005). See also Mann (1999); 
Scottish Intercollegiate Guidelines Network (1999).
140 For further discussion of maternal care, see Christie and Tansey (eds) (2001).
141 Sinclair (1995).
142 Long et al. (1991); Canadian Paediatric Society, Fetus and Newborn Committee (1992); Smyth et al. 
(1995); McMillan et al. (1995).
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had societal endorsement, then why embark on all these activities? That was 
what our study was designed to ﬁnd out. We took four guidelines: the ventouse, 
stitching up of the perineum using the correct materials, antenatal steroids, and 
antibiotics in preterm labour. Then we added one on the hoof, because during 
the course of the study, Lelia Duley and her colleagues published a spectacular 
trial – it must be the trial of the 1990s – which showed that magnesium was 
the optimum treatment for eclampsia.143 So we quickly took the opportunity of 
observing the effect of this seminal publication. The results of the study have 
been published.144 There is one thing to say about these results with particular 
reference to corticosteroids and that is this. Right from the start, we realized that 
simply looking at all mothers who had given preterm birth to see whether or not 
they had had corticosteroids, was not going to give the right information. This 
would produce a logical fallacy, because not all women who give birth prematurely 
would have had indicators for steroids. What we really needed to know was the 
proportion of women receiving or not receiving steroids (a) who were recognized 
to be in preterm labour; (b) in whom birth was not so imminent as to negate any 
possible beneﬁt; and (c) in whom there were no contraindications. 
The same situation arises in the audit of treatment of people with a heart attack. 
We know that one of the tenets of good care if you are having a heart attack 
is that you should be given aspirin and a clot-busting drug like streptokinase. 
Some studies have shown that only 50 per cent of people who had a heart attack 
received the clot-busting drug. But this gives a considerable underestimate of 
proper care, because the clot-busting drug can only be given for a short period 
of time after the onset of pain (a day or so). Furthermore, some people do not 
have clear evidence of heart attack on admission, such as raised ST segments 
on the ECG. The clot-busting drug can have some nasty side-effects (brain 
haemorrhage) and it is properly withheld in these cases. So you need to look at 
people who have presented with clear features of heart attack, not those coded 
as having had a heart attack.145 
We took a lot of trouble and your money to really make sure that the people 
who were judged not to have received antenatal steroids should have had them. 
What we showed in respect of all four guidelines was a massive change in the 
143 Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) Collaborative Group (1994); 
Duley (1998).
144 Wilson et al. (2002).
145 For details of the streptokinase trials see Reynolds and Tansey (eds) (2005): 93–112.
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uptake and if you have got a copy of the paper you can see it in the graphs:146 
a massive change in practice in line with the evidence over the period of study 
[1988–96]. So the notion that the doctors do not use the evidence is no longer 
true, there is massive change. 
Now, is it perfect? No. With reference to steroids, for example, only 80 per cent 
of eligible women received the correct treatment, so there was a 20 per cent 
shortfall. On some of the other standards, it’s more like 70 per cent compliance, 
so there is still work to be done. I am not saying everything is perfect. And 
indeed, when this result was published it was called in a newspaper, the Observer 
I think, ‘a shameful result’. The result can be ‘spun’ either way. But one thing 
that it did show was the amount of change in line with the evidence.
Since I have titivated you, I will mention magnesium as well. Within a year of 
the publication of Lelia Duley’s study, magnesium use improved from zero to 
80 per cent of women in this country. That was without any guidelines. But it 
was a particularly powerful study.147 
I have one last thought to leave with you. The whole notion of diffusion of 
information into a community of experts is one that has been studied for a 
long time. I understand that it started with two sociologists, Ryan and Gross, 
who were looking at the uptake of effective agriculture practice among farmers 
back in the 1930s.148 Later a man called Everett Rogers analysed the original 
‘diffusion curve’ in terms of communications theory, showing that some people 
are very avant-garde and adopt a new method right away, some are in the 
middle ground, and then a few laggards, who are very slow to take it up.149 Now, 
you can think of that in two ways: one is in terms of a particular technology. 
Are the farmers using the latest and best fertilizer? Are the obstetricians using 
the latest treatment for a particular condition? That’s one way to track the 
diffusion of a speciﬁc technology. But, of course, underneath all that lies an 
epistemological issue: what is perceived by the society of experts, the society of 
farmers, or the society of obstetricians, as constituting authoritative knowledge? 
What I believe, and we can discuss this later if you wish, is that not only have 
146 Wilson et al. (2002). See Figures 1–4 on page 178, which were distributed at the meeting.
147 Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) Collaborative Group (1994); Duley 
(1998).
148 Ryan and Gross (1943).
149 Rogers (1962).
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obstetricians adopted these particular technologies, but they have also adopted 
the very idea of evidence-based practice. Not only have specialists taken on the 
idea of particular treatments – clot-busting drugs in cardiology or antenatal 
steroids in obstetrics – but they also have taken on the idea that practice should 
change in line with the evidence. So the notion of evidence-based practice has 
also been ‘sold’. Throughout my professional career there has been a sea change 
in that respect, so I don’t think we need to be quite so pessimistic in the future 
as we have been in the past about the uptake of new practice. That is the ﬁrst 
part of my last point. 
The second part is that not only has there been a change in the hearts and minds 
of practitioners, but there has also been a change, in a societal sense, in how 
we organize ourselves to receive new evidence. Back in the 1970s and 1980s 
many trials were done, and the whole idea of doing trials had to be sold. Those 
ideas were coming, but what we didn’t have was a method, a societal method, to 
assimilate the results of the trials. Trials would be done and that would be that. 
No one knew what to do with the results. How do you react to these trials? When 
is trial evidence sufﬁcient for a guideline to be developed? So what I did back in 
those early days of 1992 was to start to provide some kind of societal mechanism 
to pick up the results of research. It’s not surprising that it took us a while to 
learn how to do this, and, of course, that’s now been formalized much more, 
some would say too much, with organizations such as the National Institute for 
Clinical Excellence (NICE) and its equivalents in other parts of the world.150 
Williams: For practising clinicians a new accelerating factor is the Clinical 
Negligence Scheme for Trusts (CNST), which gives a discount in your 
insurance for a hospital if you are following evidence-based guidelines and can 
show that you have these in place. To actually achieve CNST grade-1 status, 
you have to jump through a lot of hoops and it’s all about practising evidence-
based guidelines.151 I think that’s a new accelerating factor in the application of 
research into practice.152
150 NICE was established in 1999 to give guidance on the use of new and existing medicines and treatments; 
the appropriate treatment and care of people with speciﬁc diseases and conditions; whether interventional 
procedures used for diagnosis or treatment are safe enough and work well enough for routine use. From 
April 2005 it joined with the Health Development Agency to become the National Institute for Health and 
Clinical Excellence, still known as NICE. See www.nice.org.uk/ (visited 29 June 2005).
151 For further details of the scheme, see www.nhsla.com/Claims/Schemes/CNST/ (visited 5 August 
2005).
152 For a review of this ﬁeld, see Hicks and Mant (1997). See also Mant et al. (1999).
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Gabbay: I like Richard’s analysis at the end, but when you talked about the 
epistemological change I thought you were going to say something slightly 
different, which I would think is the case and that is that what people count as 
evidence and what we as researchers and members of the Cochrane Collaboration 
might wish to count as evidence may not be the same thing. I was very struck by 
the wonderful vignette earlier on from our colleagues in Wales, John [Williams] 
and Roger [Verrier Jones], when they were faced with the dilemma of whether 
to move to using steroids or not. What seemed to sway things in the ﬁrst case 
that Roger described was a very unscientiﬁc retrospective analysis of a case series, 
which was done locally and which was quite persuasive, and John was saying 
that it was probably as persuasive as the trials and systematic reviews that we 
as researchers would wish people to use.153 So I just wanted to add to Richard’s 
analysis that it’s also a shift in what people count as legitimate evidence and the 
kind of mechanism that John has just described, where it has to be scientiﬁcally 
based evidence in order to get your points and get more money or whatever it 
is you are after. 
Maybe part of the mechanism we need is to shift people’s views of what evidence 
is, because in the work I have been doing, watching clinicians using evidence, 
stories, anecdotes, personal experience, and of course what the great and the 
good around you are saying – local opinion leaders – counts at least as much 
as what we, as rational scientists, would like them to use as evidence.154 I would 
like to hear more about that interaction between different forms of evidence in 
people’s minds as they develop their policies.
Mugford: I have an anecdote to add to John’s point, to strengthen it. When 
James Piercy and I went to the Department of Obstetrics in Oxford, at the end 
of his dissertation period, to present our economic modelling, Professor Alec 
Turnbull was in the audience. He was very gracious and kind and very gentle 
with us as young researchers, but at the end of all the questions from midwives 
and neonatal nurses and house ofﬁcers, he stood up and said but of course this is 
all – I cannot remember his exact words, and I won’t even try – but he very gently 
poured a lot of cold water on it, because we hadn’t taken account of the effect 
on women, and the increase in risk of infection in women. And so I bowed to 
his authority, I couldn’t deny it, but I said as far as I knew the systematic review 
had not shown any effect in that respect, but I wasn’t conﬁdent enough. So my 
153 See page 64 for a comment on the use of steroids at St David’s Hospital.
154 Gabbay and le May (2004).
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feeling was that the general mood of the audience at the end was that what we 
had done had been a bit of a waste of time. 
Chalmers: Alec Turnbull was Professor of Obstetrics and Gynaecology in Oxford 
at the time. He was also one of the people looking at the maternal mortality 
experiences for the reports on Conﬁdential Enquiries into Maternal Deaths.155 I 
know that he was very inﬂuenced by a particular case, a woman who had died 
of septicaemia, who had received corticosteroids, and I think that was the basis 
for his opposition. If you have seen someone have a haemorrhagic stroke after 
you have given streptokinase,156 it makes it far more difﬁcult to say that this is 
a policy that we should adopt, because you actually don’t know which of your 
patients would have died if you hadn’t given it to them. 
Just to clarify the experience in St David’s Hospital in Cardiff, because John 
Gabbay misunderstood what had happened: they had adopted steroids on the 
basis of the trials. The unpublished analysis that Roger Verrier Jones did was 
a retrospective assessment.157 The staff at St David’s had taken up steroids to a 
greater extent than the University Hospital of Wales, based on the Liggins and 
Howie trial.
Hayward: I wonder whether it might be useful to describe brieﬂy an intervention 
that I led over a two-year period, which was partly triggered by Richard’s list of 
suggested effective interventions that should be used for prospective audit by 
obstetricians under the banner of the RCOG.158 I am Director of Public Health 
in Newham, but I am here because in 1994 I was a public health specialist in 
training at Camden and Islington Health Authority. I have also known Iain 
[Chalmers] for years, because I married his sister. 
It took me ten years to get a grip on what Iain had been going on about 
evidence-based treatment. But there’s nothing like a convert late in life to 
become a passionate advocate, and this made me very interested to know why 
other people were having equivalent problems. A number of things happened 
to coincide, as is usually the way when you start an initiative, and someone 
who had seen the draft of those clinical audit suggestions was on the Maternity 
155 See, for example, Department of Health and Social Security (DHSS) (1986).
156 For a discussion of the streptokinase trials, see Reynolds and Tansey (eds) (2005): Appendix 3, 
93–112.
157 See Tables 3–4 on page 35.  
158 Royal College of Obstetricians and Gynaecologists, Scientiﬁc Advisory Committee (1992).
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Services Liaison Committee (MSLC) for Camden and Islington that covered 
three maternity units – the Whittington, the Royal Free and University College 
Hospital (UCH), just round the corner here. We hatched an idea over a beer 
in one of the local pubs that it would be interesting to look at four of those 
interventions,159 and to take them around three units, using the Camden and 
Islington MSLC. What made it uniquely different was that there would be 
women, the users of services, involved and at the centre of the work. Out of 
that a two-year project emerged called the Effective Care Project, subsequently 
published in Quality of Health Care in 1997.160 My guess is that nobody will 
have read it, and it certainly isn’t on Richard’s reference list. Like most of these 
things, it didn’t get into the British Medical Journal either. It was advocated as 
an example of good practice for MSLCs nationally, but my guess is that very 
few of them have been able to do what we did, because we had an unusually 
committed bunch of users who were really passionate to get into it, and we also 
had three units to deal with. Most MSLCs only deal with one. It’s much easier 
to deal with three, because you can compare your information automatically. 
What we did was to visit each of the units, asking them to share with us their 
policies on these four interventions, giving them an advance section of what 
was later going to be the Cochrane Library, but in those days was the Cochrane 
Pregnancy and Childbirth Database, and we still referred to ECPC – Effective 
Care in Pregnancy and Childbirth.161 All our users had already received the users’ 
copies, I may say. 
We took the evidence that was in the actual trials, and made certain that every 
unit had them so they knew what information we were using. We used the 
blobograms, and it’s nice to see four different varieties of those blobograms 
from Patricia Crowley’s original work.162 I remember ringing Patricia in Dublin 
at the beginning of this project and she was extremely helpful. We reserved the 
right that we might ask a statistician to help us resolve complex issues about 
odds ratios or whatever, but we never needed one. The women understood it 
instinctively, because blobograms graphically are so striking. You immediately 
159 The four interventions were: use of steroids prior to likely preterm delivery; prophylactic antibiotics 
for caesarean section; management of perineal repair; and external cephalic version (ECV) for breech 
presentation at term. See description on page 60.
160 Berrow et al. (1997).
161 See note 52.
162 See Figure 4 on page 28.
Prenatal Corticosteroids
66
see the effect size, and the size of the wings on the aircraft, as it were, give you an 
idea of the conﬁdence level, about the precision of the results. They understood 
that instantly. [See Figure 4.]
So we went round with the four interventions – steroids, suture materials, 
antibiotics for caesarean section and the fourth one – one you didn’t mention, 
Richard [Lilford], the difﬁcult one – ECV for breech presentation near term.163 
We did steroids ﬁrst, because we knew that they were all supposed to be using 
them, and ECV last, because we knew they certainly weren’t and the other two 
interventions were in between. The main thing that emerged from the study 
in relation to steroids is that everybody was ‘signed up’ to using them – the 
guidelines in the three units were not quite the same but they had never shared 
them before, so we shared them. What was not transparent was the eligibility 
and exclusion criteria, the crunch to determining how many actually got 
steroids and when. What they had not done was a prospective audit, and they 
had not shared it with the MSLC, and they undertook to do that. Eventually 
a prospective audit was reported to the MSLC from three different maternity 
units on their use of steroids. It was, again, between 80 and 90 per cent, broadly. 
That had never been done before. I suspect it’s not been done since, but my 
goodness it didn’t half concentrate the minds of the clinicians in the room. The 
women asked laser-like questions, such as, ‘Why aren’t your ﬁgures as good as 
“St Elsewhere’s?”’ – not very easy to answer, but really important questions. 
We ran into less trouble with steroids than we did with the others and I want 
to say that we did persuade one hospital to introduce vicryl for the midwives 
to repair the perineum, whereas otherwise only the doctors had been given 
these expensive sutures.164 That was a dramatic change. One hospital that used 
antibiotics for caesarean section had realized, of course, that it’s the anaesthetist 
who tended to give it, but when the anaesthetists had audited it, actually only 
60 or 70 per cent of women who should have been getting antibiotics actually 
were. That was changed. And, the most difﬁcult thing was ECV, where the 
baby is breech presented, and there’s an opportunity to turn the baby round in 
utero before labour, provided it is done close to term, with an operating theatre 
163 See discussion on page 48.
164 A polyglactic-acid suture. Christine Kettle, a midwife at North Staffordshire NHS Trust, Stoke-on-
Trent, conducted a randomized trial comparing suture materials by following up the treatment of 1500 
women over 12 months. Vicryl Rapide, a quickly absorbed synthetic thread, was the most effective. Kettle 
et al. (2002). See also Kettle and Johanson (2000).
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available and consent for an emergency section obtained. You can, if necessary, 
bail out by doing an emergency section if anything goes wrong. 
What we discovered were the main barriers for these interventions. Steroids 
had few major barriers, just bits of detail. Suture was a misunderstanding 
about cost and appropriateness. Antibiotics were restricted by lack of an audit 
done by the right people. But ECV was different. The main barrier here was 
fear of death of baby or mother. I remember as a medical student having seen 
an ECV done in the antenatal clinic and every so often there would be cord 
entanglements, or placenta abruptions, haemorrhages and disasters. When 
we got into the meetings, one Camden and Islington unit was using ECV 
regularly and felt that everybody should do so. One used it intermittently 
and the third, somewhere near Hampstead, was not using it at all, except a 
few junior doctors who had tried to introduce it and had been told that they 
were not to use it because it was dangerous. We had the following sorts of 
discussions: the clinicians would say, ‘It’s a dangerous procedure, there’s no 
evidence to support its effectiveness, except the trials that have been published 
in South Africa’. We would answer that there were trials from Zimbabwe 
and California, Denmark, and Holland, and plonk the evidence on the table. 
‘Oh, it doesn’t apply to us’, they said, ‘and anyway our women’s pelvises are 
different. ECV is easier in South Africa and doesn’t apply to our case mix.’ 
Excuse me, we are in London. But what emerged after this hostility was 
actually that they had all experienced a death or near miss, and that was the 
barrier to implementation.
Apart from power, I think that vested interests, empire-building and struggles 
and political competition between trusts were barriers – this was the time of the 
purchaser–provider split and market competition was a really important issue 
around 1995/6. The main barrier was fear of something going horrendously 
wrong. People would then distort their perception of the evidence and 
vigorously resist being told to do something that they didn’t think was safe to 
do, regardless of the evidence. After about six months the staff went through a 
series of educational events at this particular hospital and eventually decided to 
start to introduce ECV and as far as I know it is now common policy. But we 
couldn’t make them do it, they had to decide to do it themselves, and they had 
to take their clinicians with them. I think it was a painful and difﬁcult process 
for them. 
May I just mention the main conclusions from this particular piece of work? 
Don’t expect to get this sort of study into the British Medical Journal. It won’t be 
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accepted.165 Secondly, advocates are really important when it comes to getting 
guidelines adopted and I think opinion leaders are really important within 
institutions, but the important thing is that the guidelines have got to be written 
in such a way as to be usable, understandable and accessible to those who are 
going to implement them. That means clear inclusion and exclusion criteria. 
Another important agent for change is the users, and if you have women asking 
these sorts of questions, after a while people do get a bit embarrassed coming 
up with the same answers that clearly won’t be supported by evidence or by 
colleagues. I would like to see women users being far more involved in ways 
in which we can encourage the implementation of best practice. I am not 
surprised that there was no sign of managers actually implementing any change 
in Richard [Lilford]’s study. It’s a scary business. There was blood all over the 
carpet when we were dealing with the ECV meetings, and it required somebody 
– like the users who were tough, or somebody like me who’s a public health 
specialist and who has been a GP and is not afraid of consultants – to hold the 
line if necessary. Managers cannot do that, and I don’t think we should expect 
them to. I think it’s exceedingly difﬁcult. The most important barrier, the most 
important inﬂuence to achieve change, is the personal experience of the person 
making the clinical decision. When new interventions are being rolled out we 
must encourage people to be at the centre of it, so they get feedback of the 
positive results. Then it is much easier to get change implemented. 
Hey: That rings true for a lot of us, I think, you said something very important. 
Harold [Gamsu], while you were out of the room we did hear that quite a lot 
of units said that they couldn’t join your trial, because they were already using 
it so widely, at a time when we know that in most maternity units in the UK 
less than 10 per cent of the mothers meriting steroid treatment were getting 
it.166 Did being involved in the trials themselves inﬂuence the centres? Did the 
centres that had been involved in the research take up the outcome of that 
research more than those who only read about it?
Gamsu: I don’t know the answer to that, I am afraid. We didn’t follow that point 
up, but Brenda Mullinger might know something about it. All I can say is that 
there were local reasons that indicated against the use of steroids. There was 
quite a lot of gossip about this and we have heard some examples of this today: 
165 Dr John Hayward wrote: ‘It was rejected by BMJ (submitted as a short report) and not submitted to 
the Lancet. A longer version was published by Quality in Health Care [Berrow et al. (1997)].’ E-mail to Mrs 
Lois Reynolds, 21 October 2005.
166 Khanna and Richmond (1993).
Prenatal Corticosteroids
69
the risk of infection, especially in ruptured membranes, and the unexplained 
deaths in hypertensive women from Liggins’ original report, which turned out 
to be spurious. 
The other thing that I found that was inﬂuencing obstetricians was the increased 
risk of pulmonary oedema, which people widely accepted as a complication of 
steroid therapy. In fact, it was a complication of tocolytic agents that were used, 
especially when those agents were given in large volumes of ﬂuid. As far as I know, 
steroids given alone were not tocolytic agents and did not result in pulmonary 
oedema. So I think we had quite a lot of persuading to do, even in those places 
that accepted that they would be in the trial. I know that Brenda Mullinger 
and Clive Dash from Glaxo had a lot of difﬁculty keeping the momentum up, 
trying to persuade centres to recruit women, even though investigators had 
agreed to participate in the trial and had obtained ethics committee approval. 
As you possibly remember from the paper, 60 per cent of the cases came from 
patients who were recruited from three hospitals, the rest of the centres just put 
it [the request] away.167
Hanney: We at Brunel have been looking at the beneﬁts from health research 
for about ten years now, and this particular stream of work seems to us to have 
been one of the most interesting that I have worked on with Miranda, Martin 
Buxton and Jonathan Grant. I apologize for checking my notes from time to 
time, because I am trying to pick up what various people have said today in 
what I think is an interesting session. 
For instance, John [Hayward], we at least read your work. There is a paper that 
sets out most of this in detail in press and will be published in Social Science 
and Medicine.168 I will just highlight all the key points for now. Perhaps it’s just 
worth spending a minute going over our payback framework so you can see 
how we tried to drop this stream of work into a framework that we had already 
developed. Apologies to those who have already heard this many times before. 
Basically, there are two aspects to our payback framework: a multidimensional 
categorization of beneﬁts, and a model to examine how they arrive. The 
categories that we suggest are ﬁve: knowledge production; the targeting of future 
research and building research capacity; better informing policies, with the term 
‘policies’ being widely interpreted; health gain and beneﬁts to the health sector; 
167 Gamsu et al. (1989).
168 Hanney et al. (2005).
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and the broad economic beneﬁts. There’s a series of stages in the model in which 
we think these various beneﬁts can be identiﬁed. A key feature of our model is 
to attempt to identify actual levels of uptake so that we can then say what the 
beneﬁt has been, and this, of course, links with previous discussions. 
There’s always a problem when doing this type of analysis as to where you 
start. Various initial presentations today showed clearly that research builds on 
previous research etc., and so whenever one chooses a starting point, it is always 
artiﬁcial. On the other hand, I do think the nature of the discussions today, 
and what Mary Ellen [Avery] says, has provided a realistic basis for saying we 
will start by looking at the work of Liggins and Howie. In terms of knowledge 
production, clearly the 1969 paper from Liggins, and the 1972 paper from 
Liggins and Howie, were very important.169 There are lots of weaknesses in 
citation analysis, but it does indicate whether people have taken notice, and 
these are two very highly cited papers, especially the 1972 paper which has been 
cited over 1200 times.170 
There has been some bibliometric analysis in this ﬁeld undertaken by the Policy 
Unit here at the Wellcome Trust.171 Various generations of papers were traced 
backwards and showed again that this was the most important work in this ﬁeld 
in several generations. Clearly knowledge production is very high. In terms of 
affecting future research, again citations indicate that it has inﬂuenced much 
subsequent work. It’s also interesting that many of the other pieces of work, trials 
etc., actually start with a reference to the work of Liggins and Howie, which 
again I think emphasizes their importance for further work. And it’s also been 
mentioned that Ross Howie felt that further trials should be undertaken rather 
than necessarily saying that people should act on the ﬁndings. Nevertheless, 
there was quite an uptake in some places, on the basis of this very important 
trial and the ensuing publications from it. In the UK the ﬁgures in the 1980s are 
somewhat unclear, but it was deﬁnitely higher in Australia and New Zealand. 
169 Liggins (1969); Liggins and Howie (1972).
170 Dr Stephen Hanney wrote: ‘The article pre-dated the start of the electronic record of citations, therefore 
I calculated this ﬁgure from the post-1981 electronic data plus hard copies of ISI data from earlier years 
[Hanney et al. (2005)]. Mont Liggins had an article in the Citation Classics series in March 1982 and by 
then the number of citations for the 1972 paper was already 565.’ Note on draft transcript, 12 July 2005. 
See Mont Liggins’ article of 29 March 1982 freely available at www.garﬁeld.library.upenn.edu/classics1982/ 
A1982NF37800001.pdf (visited 14 June 2005). 
171 Grant et al. (2003).
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By the early 1990s there seemed to be this consensus that the take-up rate 
in the UK was between perhaps 10 and 20 per cent, and Miranda’s analysis 
shows that at a 20 per cent take-up level it could be said to lead to at least 150 
deaths annually being averted in England and Wales. So it is clear that even in 
the 1970s and 1980s there were substantial health gains, primarily from the 
Liggins and Howie work with the other trials providing a bit more evidence. 
Not only were deaths avoided and less morbidity due to the reduced incidence 
of RDS, but also there were the cost savings, even if these were in terms of more 
resources being available to treat other babies.
Richard [Lilford] raised the interesting analysis from Rogers’ work on the diffusion 
of innovations.172 From the analysis that I have, I agree with you that, on the 
whole, the profession is much more receptive now. One of the things that Everett 
Rogers did say was that often when an innovation gets to between 10 and 20 
per cent uptake, in fact diffusion becomes almost impossible to stop, it tends to 
escalate.173 What I ﬁnd interesting in this case is that it is clear that the bottom 
level of where take-off should be impossible to stop, was achieved and then it just 
didn’t take off for quite a long time. There was stalling at exactly the point when 
Rogers suggested that usually there would be this take-off. So what was it that gave 
it the nudge to start going again? This is where the systematic review comes in as 
being very important. It was published in 1989/90, we have heard, and perhaps 
particular attention was focused on this systematic review for several reasons.174 
The link, as explained earlier with the logo of the Cochrane Collaboration and 
Miranda’s subsequent cost-effectiveness studies, showed that this was one of the 
few areas where there had been economic cost savings as well as health gains. 
A few years later there were several policy statements advocating the use, in the 
form of clinical guidelines from professional bodies and, as is said in the paper,175 
these did cite the systematic review, again emphasizing the importance of this 
particular review.176 I hadn’t realized until he spoke quite how explicitly Richard 
172 Rogers (1962, 1995). 
173 Hanney et al. (2005): 938. For details of the S-shaped curve of diffusion of innovation, see Rogers 
(1995): 259.
174 Crowley et al. (1990).
175 Hanney et al. (2005).
176 Joint Working Group of the British Association of Perinatal Medicine and the Research Unit of the 
Royal College of Physicians (1992); Royal College of Obstetricians and Gynaecologists, Scientiﬁc Advisory 
Committee (1992).
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[Lilford] looked through systematic reviews to produce the clinical guideline on 
that, and clearly the systematic review there inﬂuenced the policy guidelines. 
There were also these important implementation initiatives. There’s one that’s 
been mentioned. All these factors seem to have resulted in quite a dramatic 
increase in uptake during the 1990s. There’s the ﬁgures from your study, 
Richard, and ﬁgures in 1997, from your survey, Peter [Brocklehurst],177 which 
show a very large uptake by the end of the 1990s. Miranda’s analysis suggested 
that with 75 per cent uptake there would be more than 400 deaths averted 
annually in England and Wales. So clearly, there has been quite a big health 
gain. The problem though, as has already been mentioned, without putting a 
precise ﬁgure on this, is that with the use of surfactant and the improvement 
of the neonatal care, it is not clear of course that all these deaths would have 
actually happened if there hadn’t been the use of steroids. But nevertheless, 
as has been said, there is also evidence that even if some of them would never 
have happened, surfactant wouldn’t have stopped all of them. What I think is 
unclear, is whether there is an actual measure of how many. So, deﬁnitely, this 
has had substantial health gain as well as impact on policy, knowledge gain, 
impact on further research. 
Mention has been made of the US NIH consensus conference.178 This was 
broadly endorsed by the American College of Obstetricians and Gynecologists 
and it is claimed that this consensus statement had more impact than most 
of them.179 An implementation project found that after a year of passive 
dissemination, implementation of the guidelines went up to 58 per cent, which 
is quite substantial.180 But following active dissemination it went up from 33 to 
68 per cent. So it does seem that there are many elements of this whole stream 
of research that have produced beneﬁts. Perhaps the key thing from our work 
on this stream of research that is different from some other perspectives in the 
debate about research utilization, is that our work has been concentrated on 
showing that beneﬁts have been achieved even when the uptake level has been 
less than optimum. 
177 Brocklehurst et al. (1999).
178 National Institutes of Health (NIH) (1994).
179 American College of Obstetricians and Gynecologists, Committee on Obstetric Practice (1995, 1999). 
180 Leviton et al. (1999).
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Hey: It was nice to hear from somebody totally outside the ﬁeld, an outsider 
looking in on us. We hear many of the same themes coming up, so perhaps 
it might be true. Perhaps we ought to say that there are more beneﬁts than 
just preventing death and respiratory distress. Shall we remind the rest of the 
audience of the other outcomes that you get from giving steroids that you don’t 
from giving surfactants?
Crowley: Probably a very important one is the reduction in the risk of 
intraventricular haemorrhage (IVH) and that’s a particular beneﬁt for the most 
premature babies. Also a reduced number of days on mechanical ventilation for 
babies who do get RDS. 
Harding: The new systematic review will also suggest beneﬁts in terms of 
childhood developmental outcome.
Chalmers: We keep on talking about beneﬁts in terms of the baby, but what 
about the parents? The reduced exposure to the terrible courses that babies 
would go through before death, and indeed before surviving – and the 
accompanying anxiety – those things haven’t been made explicit. We had hoped 
that there would be a woman here who had received prenatal corticosteroids. I 
was impressed by Barbara Stocking, now Director of Oxfam GB, saying that in 
her ﬁrst pregnancy she had delivered prematurely and her son went through a 
really rough time.181 After she read Patricia’s systematic review before her second 
pregnancy, she insisted that she should have steroids if she went into preterm 
labour again. She became a big advocate of prenatal steroids when she was a 
senior manager in the NHS. I have come across more than one mother – maybe 
Gill Gyte can enlighten us here – who has lobbied to have this. Obviously, 
as parents, they think this is important, because they are worried about their 
children. But possibly also so that they have less to worry about themselves.
Gyte: I don’t have any personal experience of antenatal classes, but I do know 
that the National Childbirth Trust (NCT) does lobby to implement evidence-
based care. 
181 Ms Barbara Stocking wrote: ‘Iain nicely cites my story in the seminar but it isn’t quite right. I still 
consider it a real blessing (a) that I knew the evidence at the time of my ﬁrst pregnancy and (b) I had an 
obstetrician who knew it too and was committed to being at the forefront of best practice. The neonatal 
intensive care/special care period was hard, but inﬁnitely better that Andrew, my son, never had to be 
artiﬁcially ventilated, plus, I guess, had fewer IVHs [intraventricular haemorrhages], hence [his] ending 
up healthy and bright (now at Cambridge doing economics). It’s true I’d have asked for it second time 
around too. Fortunately, I didn’t have to due to three months enforced lying down. Very good for me (in 
retrospect!).’ E-mail to Mrs Lois Reynolds, 7 September 2005.
Prenatal Corticosteroids
74
Oakley: This is slightly beside the point, or perhaps not, because I think this 
issue of the role of the users of health services and the extent to which they are 
demanding evidence is a very important one and it’s something that we need 
to know more about. But, of course, one of the problems with that, or one of 
the issues in that area, is that ﬁrst of all the user needs to be dissuaded from the 
belief that experts know what they are doing. 
I remember one of the early projects that I worked on in 1974 involved an 
observational study of an antenatal clinic at a hospital in London that, of course, 
has got to be nameless, and I hung around this clinic for about a year observing 
what the doctors were doing. I was absolutely astonished. In my second week, 
there was a changeover in junior doctors, and two of them came to me and they 
asked me what Consultant X would recommend in a particular case, because 
they didn’t know what they were supposed to be doing because they hadn’t met 
their consultant yet. I didn’t realize that the eight different consultants who ran 
this clinic all had different policies. I was learning what those policies were and 
then I was passing on this information to the junior members of their team, 
so that they could also practise non-evidence-based medicine. That was a long 
time ago, but I think it is still the case that many people believe that doctors and 
other experts know what they are doing. 
Another issue in all of this is about the epistemological shift in society’s 
understanding that experts, including those in other ﬁelds, often don’t engage in 
evidence-based practice. I spend a lot of my time at the moment with professors 
of education who don’t believe in systematic reviews of the evidence. This is 
about the role of the expert, and the relationship between research, evidence 
and policy across a lot of different sectors. 
Crowley: As an obstetric senior registrar in 1985, I took over the care of a 
woman who was having an antepartum haemorrhage at 37 weeks’ gestation. 
We thought she was 37 weeks because of an error in estimating the dates made 
earlier in the pregnancy. Because of continuing antepartum haemorrhage I 
induced labour following consultation with a supervising consultant. She had 
not had antenatal steroids. She was, in fact, only 33 weeks’ gestation and the 
baby went on to develop severe RDS and after prolonged ventilation survived 
with severe cerebral palsy. His mother sued the hospital, my consultant colleague 
and myself. The patient was awarded €4 million compensation in an out-of-
court settlement in 2003 because I had failed to give her antenatal steroids. The 
decision by the protection society and the legal team was that whereas other 
obstetricians might be able to defend themselves against not giving antenatal 
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steroids in 1985, the papers I had published demonstrating the evidence in favour 
of antenatal steroids prior to 1985 rendered my failure to prescribe antenatal 
steroids indefensible. So a very disabled 20-year-old man and his parents have 
suffered a lot as a result. This medico–legal event contributed a further chapter 
to my 30-year personal involvement with the antenatal steroid story.
Hey: One of the good things that came out of the book, Effective Care in 
Pregnancy and Childbirth, was a version which has been widely read by parents, 
wasn’t it?182 Not many other branches of medicine have pursued it through to 
that point yet, have they? 
Mugford: Following on from Patricia’s story and also what I said earlier, that the 
impacts on the economic side that we measured were purely the health services 
facts. Many economic studies are just cost-effectiveness analyses from the point 
of view of the health service for the efﬁcient running of the health services. But 
the impact on family is terriﬁc and there’s a long-term impact of children with 
disabling chronic lung disease.183 We did a study in the NPEU with another 
York MSc student, Birgitta Rudbecke, who looked at the cost of babies going 
home on oxygen. And it was terriﬁc. Parents gave up their whole careers to look 
after their children. If we redid the steroid analysis taking account of family and 
household impact it would just emphasize the same answer, it’s even more of a 
‘win-win’. We don’t really need to do the study, but sometimes you have to do 
the study to have the impact.
Hey: I think I am going to move on, because we are almost ﬁnished. We have 
started preening ourselves, we have done something good, and we have now 
rolled it out, and it’s happening, so perhaps Peter Brocklehurst might remind us 
that some of the questions posed 30 years ago are still not answered. 
Brocklehurst: I am conscious that I have been asked to speak about current 
research and where the research gaps are in a session about twentieth-century 
medicine. So we are already a bit beyond the twentieth century in terms of what 
I intend to discuss, although hopefully in a few years time this will be history 
and you can tell me that I was completely wrong in guessing where we were 
182 Dr Edmund Hey wrote: ‘The ﬁrst edition of A Guide to Effective Care in Pregnancy and Childbirth was 
published in 1989 [Enkin et al. (1989)]. There have been two further editions, each with varying editorial 
panels, the most recent having appeared in 2000. The book provides a synoptic summary in non-technical 
language of the many systematic reviews that ﬁrst appeared in the two-volume book also published in 1989 
[Chalmers et al. (1989)].’ Note on draft transcript, 27 August 2005. 
183 Hallam et al. (1996).
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going to go. I want to talk about some of the issues that have come up today 
in terms of how we are now looking at the evidence that we have and what is 
beginning to come out. I am going to discuss the issue of the use of multiple 
courses of steroids, but there are a couple of other issues that I wanted to touch 
on which have been brought up this afternoon, one of which is the choice of 
agent that we use for antenatal corticosteroids. 
A very interesting paper has been published in the American Journal of Obstetrics 
and Gynecology by Alan Jobe and Roger Soll,184 which looked at the available 
trials and separated them into those that have used dexamethasone and those 
that have used betamethasone. The interesting thing is there have been no head-
to-head comparisons of dexamethasone versus betamethasone, which have 
looked at substantive neonatal outcomes.185 There have been trials that looked 
at antenatal fetal heart rate, which seem to be irrelevant if they are not related 
to the outcome for the baby.186 Jobe and Soll suggest that betamethasone is 
preferable to dexamethasone, because the betamethasone trials, compared with 
placebo, have a marked reduction in the incidence of death, and RDS, while 
dexamethasone has no statistically signiﬁcant effects on neonatal death. Although 
one of the things they report is that the number of trials using betamethasone 
is substantially larger than the number of trials using dexamethasone, and the 
numbers of participants in each trial of betamethasone are larger. However, they 
have suggested some biological plausibility for this, and I am sure we are going to 
see a lot more about what agent we should be using. One of the issues that they 
184 Jobe and Soll (2004). Dr Ross Howie wrote: ‘I wonder how much of the apparent difference between 
the two drugs in effect on mortality may have been due to differing standards of newborn intensive care at 
the times and places the trials were carried out.’ E-mail to Mrs Lois Reynolds, 25 September 2005. See also 
Appendix 2, page 89, paragraphs 3–4.
185 Dr Clive Dash wrote: ‘Various preparations of betamethasone are available in different countries. The 
preparations are all designed to release the active sterol, betamethasone, but at different rates. The soluble 
phosphate preparation is suitable for intravenous administration, like hydrocortisone, as well as intramuscular 
injection. The acetate preparation is not suitable for intravenous (IV) use. Some products are a mixture of 
the acetate and phosphate derivatives (e.g. Celestone®, Schering). In some countries dexamethasone is more 
readily available than betamethasone and this is why it has featured in some studies. These two steroids 
are isomers in which the methyl group differs in its orientation (dexamethasone is 9-α-ﬂuoro 16-α methyl 
prednisolone; betamethasone is 9-α-ﬂuoro 16-β methyl prednisolone)[Sweetman (2002): 1063 and 1067]. 
In the usual pharmacological tests of corticosteroid potency, they are equivalent. In general, the mode 
of action (pharmacodynamics) seems similar, so they should be therapeutically equivalent.’ E-mail to Dr 
Daphne Christie, 10 January 2005 
186 See for example, Senat et al. (1998); Subtil et al. (2003).
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raised is the availability of the drug, because no drug companies hold a licence 
for steroids for antenatal indications. The ability to get hold of dexamethasone 
and betamethasone in the US is becoming more and more difﬁcult, because 
no company is producing it, because it doesn’t have a licence. So people are 
using all sorts of other steroids, some of which clearly do not cross the placental 
barrier and may not be effective at all. They also raise issues about whether oral 
steroids may be as good as intramuscular steroids and also discuss different ways 
of giving steroids to the baby, whether you can give it into the intra-amniotic 
ﬂuid, or give it directly intramuscularly into the fetal thigh, which seems a 
little bit more invasive than a quick intramuscular injection into the mother’s 
thigh. I suspect we are going to see a lot more about the choice of the agent 
in the future. 
We have heard a lot about long-term follow-up after a single dose of antenatal 
steroids and the 30-year follow-up of the original Liggins and Howie trial will be 
extremely useful. I think we probably need to do more follow-up, much longer-
term follow-up of the other trials that have been done to try to strengthen the 
evidence base on the long-term effects, if only to be reassured that there are 
no adverse effects, even though the death rate has decreased and therefore one 
might expect a worse outcome in the steroid arm. 
Another issue is the one of twins and there is an ongoing debate about what you 
should do with twins and higher-order births. I was very interested when I saw 
the title of a paper in the American Journal of Obstetrics and Gynecology in 2002, 
looking at twins.187 Unfortunately it was comparing prophylactic multiple doses 
of steroids with a single course of ‘rescue’ steroids when the women presented 
in preterm labour and which showed no difference. But it certainly didn’t 
elucidate whether the dose that they were using was appropriate or whether 
it was beneﬁting twins. Studies of individual patient data meta-analysis of the 
existing trials may well take us forward on that issue, if we can ever get the data 
or the money to do it. 
Finally, I want to touch brieﬂy on the issue of repeated doses of antenatal 
steroids that has been brought up time and time again today. I think here there 
are lessons to be learnt. As Patricia [Crowley] said, within a very short space of 
time of our beginning to use steroids, we were liberally splashing them around 
and giving them to everybody we possibly could, often on a weekly basis, to 
187 Murphy et al. (2002). 
Prenatal Corticosteroids
78
the point where we were giving prophylactic steroids weekly to twins from 20 
weeks. Certainly, lots of clinicians were giving it to their triplets weekly from 
20 weeks, until they got to 34 weeks or when the risk of preterm delivery was 
no longer thought to be present. Because of this a great deal of effort went into 
designing a number of trials around the world to compare a single course of 
steroids and multiple courses of steroids to look at the outcome for the baby. 
When we originally thought about this, following our survey of practice in 
1997, there were ﬁve trials designed that would have added up to a total of 
10 000 women randomized.188 Five trials around the world, one of which we 
have already heard about in Australia, two in the US, one in Canada and one in 
the UK, and in Europe, which I was going to be leading from the NPEU.189
I want to update you brieﬂy on where those trials are, because I think it is 
crucial in telling us whether we will ever get an answer to the single course or 
multiple course of steroids debate. Ours was the largest of those trials, the Trial 
of the Effects of Antenatal Multiple courses of Steroids (TEAMS) trial, which 
was going to include 4000 women and would have measured the primary 
outcome at age two.190 We did undertake a pilot trial, but unfortunately we went 
to the MRC at the time when the MRC had no money – you may remember 
that event – so despite achieving the highest grade that we could possibly get 
for the quality of our trial, there was no money to fund it. That trial would 
almost have been ﬁnished now if we had got the funding. The Canadian trial, 
which aimed to recruit over 1900, is still recruiting. It was due to ﬁnish several 
years ago, but has currently enrolled 900 women. I don’t know whether it will 
ever get to 1900 because it might take as long again to reach the target. The 
Australian trial is getting close to the 980 it wanted to recruit, although 980 is 
188 Brocklehurst et al. (1999).
189 Dr Peter Brocklehurst wrote: ‘Unfortunately I can ﬁnd no reference to these trials in any of the literature. 
They are not included in our website and the transcript of this meeting may be the only place where they are 
explicitly referred to in such detail.’ Letter to Mrs Lois Reynolds, 23 August 2005.
190 The Trial of the Effects of Antenatal Multiple courses of Steroids versus a single course (TEAMS) 
study was designed to test whether the administration of more than one course of steroids to those at risk 
of preterm labour (PTL) does or does not reduce perinatal death, respiratory distress syndrome (RDS) or 
intraventricular haemorrhage (IVH) and have a long-term adverse effect on later health and development, 
when compared with a single course. Originally planned to recruit 4000 women at risk of premature 
delivery, randomized, after one course of antenatal corticosteroids if gestational age was less than 32 weeks, 
the study was stopped in March 2003 due to lack of funds, having recruited 154 women. See www.npeu.
ox.ac.uk/teams/ (visited 26 July 2005).
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too small to look at long-term outcomes. The US trial aimed to recruit 1000, 
but was stopped early by the Data Monitoring Committee (DMC) at 500, 
because they decided it was futile to continue as they wouldn’t be able to detect 
the short-term beneﬁt.191 The other large trial of 2500, run by the Maternal 
Fetal Medicine Unit Network, was also stopped by the DMC at 500, because 
they found a slightly lower birthweight in the group receiving multiple courses 
of steroids. So it looks likely that we may end up with about 3000 women 
recruited around the world in trials on multiple courses of steroids versus a 
single course, instead of the 10 000 women. I am very sceptical whether in ﬁve 
years time we will actually have enough information to answer the question of 
the long-term outcomes. The short-term respiratory outcomes look as if they 
may be favourable for multiple courses of steroids, but clearly that is only part 
of the question. So the fact that we didn’t get the original trials into practice very 
quickly has not necessarily taught us to improve on past performance when it 
comes to evaluating antenatal corticosteroids. 
The other thing to mention, I suppose, is that in the absence of trial evidence 
about long-term outcome, people will rely on observational studies of long-
term outcome. The one observational study with repeated courses of steroids 
which has been published is from the Western Australian group. It suggested 
a statistically signiﬁcantly decreased incidence of cerebral palsy with multiple 
courses of steroids versus a single course, but a statistically signiﬁcant increase 
in signiﬁcant behavioural problems among the children who survived to the 
age of six years.192 I was discussing this with Jane [Harding] during the break 
this afternoon and the fact that in Australia and New Zealand the amount of 
steroids used is going down. I think it is going down in the UK when I talk to 
clinicians, because of these uncertainties and concerns about the harm associated 
with multiple courses of steroids. How we ever get people to interpret what we 
say correctly, I am not sure. Clearly the messages that are coming out at the 
moment are not that steroids are bad, but that we need to be more sophisticated 
in how we use them and how that information is interpreted appears to be to 
stop using them. 
The issues for the future in terms of our current gaps are: the biggest one is 
that we cannot currently identify women who are going to deliver preterm very 
effectively. We can agree we are going to deliver them preterm electively, but for 
191 Guinn et al. (2001).
192 French et al. (2004).
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the vast majority of women who deliver spontaneously, we are not very good 
at recognizing them. And things like fetal ﬁbronectin and cervical length on 
ultrasound screening may help us to identify a group of women who are at a 
much higher risk of preterm delivery, and we can target our intervention more 
effectively. I am sure that we will see much more of this in the future. 
As to the gestational age at which to use steroids, what formulation, what dose, 
and what route of administration, I think these are questions that we will have to 
tackle in the future. What gestational age to give steroids? Nobody has mentioned 
yet the trial that has only been published in abstract that Peter Stutchﬁeld did 
in Wales, where they recruited women who were going for elective caesarean 
section at greater than 37 weeks.193 They randomized nearly 1000 women to 
receive steroids or not and showed a signiﬁcant decrease in admissions to the 
neonatal unit with respiratory symptoms in the group receiving steroids. So even 
beyond 37 weeks, if you deliver electively by caesarean section, steroids seem 
to offer some advantages. The issue about whether there is a cut-off when you 
don’t give them is going to be re-opened. The multiple course of steroids debate 
is, as I said, still wide open, although we will see more evidence about this over 
the coming years, and it may hopefully answer some of our questions. 
A big lesson that has come out of the steroids trials – not only antenatal steroids, 
but postnatal steroids – is that with perinatal interventions we really, really have 
to look at the children, if not the mothers as well, in the longer term, because 
these babies don’t stop developing the minute they are born, they go on and 
on and on.194 I was reading in Time magazine recently about a study where 
they had done serial MRI scans in teenagers and they are suggesting that the 
193 Dr Edmund Hey wrote: ‘The abstract to which Dr Peter Brocklehurst was referring appeared in Archives 
of Disease in Childhood 2004 89 (Suppl. 1): A5. However the full paper reporting the trial was published 
online ahead of publication (22 August 2005) in the British Medical Journal on 24 September [(Stutchﬁeld 
et al. 2005) along with an editorial by Philip Steer (2005)]. I think it is worth recording that the whole 
ASTECS (Antenatal Steroids for Term Elective Caesarean Section) trial involving the randomization of 998 
women from ten different maternity units over a seven-year period, 1995 to 2002, was undertaken with the 
support of a single £10 000 grant from the Welsh R&D Ofﬁce. The original trial by Liggins and Howie 
was also managed on a shoestring of external funding, but the regulatory requirements that have come into 
operation in the past few years mean that any trial of this nature could now almost certainly cost at least ten 
times as much as this.’ Note on draft transcript, 27 August 2005.
194 Dr Clive Dash wrote: ‘The response by the delegates at the RCOG meeting in 1977 may also have 
been tempered by the anxiety, certainly among many clinicians with whom I spoke at that time, that the 
long-term effects might prove to be signiﬁcant.’ E-mail to Dr Daphne Christie, 10 January 2005. See also 
note 22.
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195 Wallis (2004).
196 Dr Edmund Hey wrote: ‘The two key papers pointing to the possibility that a sulphite excipient in some 
formulations of perenteral dexamethasone may be neurotoxic are: Baud et al. (1999, 2001). Interestingly no 
drug company has, even now, sought a licence from the regulatory authorities to recommend betamethasone, 
or any other steroid, for use in cases of threatened early labour. As a result such use remains an unlicensed 
use of a licensed product – a situation that the general public ﬁnd quite bafﬂing. It is easy to see why the 
drug companies have not spent the money necessary to get their licences modiﬁed when the basic product 
is no longer patent protected, but less easy to see why the regulators [the Food and Drug Administration 
(FDA) in the US and the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK] have 
not pressed to get this anomaly rectiﬁed. The use of steroids in pregnancy receives hardly a mention in the 
otherwise excellent British National Formulary (BNF). The most that it is prepared to offer is the negative 
comment that “there is no evidence of intra-uterine growth restriction following short-term treatment (such 
as prophylactic treatment for neonatal RDS)”. [BNF 49 (2005): 359.] Lack of action by the regulatory 
authorities must have contributed, over the years, to the under-use, and the over-use, of this drug.’ Note on 
draft transcript, 27 August 2005.
brain does not stop developing until age 25, which seems a perfectly reasonable 
justiﬁcation for raising the age at which you can vote.195 But babies develop, they 
develop for a long, long time and something like steroids has an enormously 
potent effect on all the systems of the body, and yet we think we can just look 
at RDS and ignore the potential long-term effects. I think we are beginning 
to realize that we cannot do that, that interventions which show short-term 
beneﬁts, like neonatal dexamethasone, may be countered by long-term harm. 
Not just that there is no beneﬁt in the long term, but that the long-term effects 
may be in the opposite direction. This means that long-term follow-up studies 
of these trial cohorts become essential and yet the current situation of data 
protection and conﬁdentiality issues in the UK, I would suggest, is making it 
more and more difﬁcult, and more and more expensive in terms of being able 
to follow up people. 
Hey: I would just add one thing that you didn’t raise. One of the issues about 
which steroids may have adverse effects is that some of the steroids have 
sulphides added to them as a preservative, but nobody reads the label, they 
think betamethasone is betamethasone. You can get betamethasone with a 
sulphide preservative in it and that was what was used in the recent French 
observational study.196 Liggins managed to choose the very best steroid in the 
very best dose that required just two injections. The preparation he used was 
also preservative free.
Brocklehurst: I think there is an issue here about preparations, because I 
remember the investigators from the Canadian study got in touch with us about 
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our TEAMS trial, and asked, ‘How did you get a placebo for your betamethasone, 
because ours is cloudy?’ We replied that ours was completely clear. The original 
trial doesn’t specify what the betamethasone preparation was and we were using 
the betamethasone that was available in this country, and in the UK you can 
only buy betamethasone in a solution, not a suspension. 
Gamsu: This is why, of course, with the advice of Glaxo we chose the three-dose 
regimen of betamethasone phosphate to try to achieve the same sort of levels as 
the 12-hourly regime that was used in New Zealand and also the placebo that 
was used was the vehicle and has the same appearance as the steroid that was 
used. And, of course, there’s a slight caveat about the use of cortisone acetate as 
the placebo in the Liggins trial, in which way it inﬂuenced things, if it did at 
all, one cannot say.
Hey: Perhaps we had better clarify that. Rather than having a negative placebo 
in the original trial, they [Liggins and Howie] used a corticosteroid that was 
only one-seventieth as powerful, because it didn’t cross the placenta. 
Gamsu: It did cross but in much smaller quantities. 
Hey: But by choosing that, they had something that looked visually identical. 
So one of the good things about the original trial was that they were genuinely 
blinded and I keep on hearing stories about how the second biggest trial, the 
US NIH Collaborative Group trial, is seriously ﬂawed because there were 
unblinding issues. 
Harding: If I could just comment on that? Mont did actually check the effects 
of the cortisone acetate, the placebo, on the babies, and in, I don’t know how 
many, women, but he measured cord blood steroid levels and showed that twice 
the dose used as placebo had no effect on cord blood steroid levels and that 
reassured him that that was an appropriate placebo. 
To come back to Peter Brocklehurst’s point about how come they chose the best 
dose and the best drug, I don’t think we know that they did. Nobody’s looked 
and almost all of the issues that Peter has raised – the repeat steroids, which 
dose, which drug, how often, at what gestation, to which pregnancy – all of 
those things were raised by Liggins and Howie in their original publications 
and said these were the things that needed work, including long-term follow-
up. When Stuart Dalziel, the key person in the 30-year follow-up, presents this 
data, he starts off by saying, ‘Why do we do this?’ He then puts up a quotation 
from the original papers, and says, ‘Because they told us we had to 30 years 
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ago’.197 To complete that story, recently at a meeting at the National Women’s 
Hospital, Stuart said, ‘I expect that it will be my PhD student in 20 years’ time 
who will have to do the 50-year follow-up’. 
Hey: I think this is a good point on which to ﬁnish. Thank you all very much 
for your attendance. There will be an opportunity for you to see a transcript of 
what you have said. Much more importantly, I hope some of you have had your 
memories triggered or your curiosity disturbed and it may be that, for some of 
the things you have said, you can now go away and ﬁnd the paper, or the quote, 
or get the year right. This has just been a ﬁrst outing, to stir your grey cells. You 
have all got to go away now and see what more you can add to this story, having 
heard what others have jogged your memory about.
197 Dalziel et al. (2005a and b).
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Appendix 1
Letter from Professor Sir Graham (Mont) Liggins to Sir Iain Chalmers 
[6 April 2004]
Dear Iain,
As you say, it would be nice to be ﬁt enough to do this face-to-face. I will do 
my best to answer your queries. There is no video-recording of an appropriate 
interview. Nor can I provide pages from a lab book. Lacking your sense of 
history, all my records were consigned to the scrap heap when I retired. The best 
I can do is a slide of a photo [see Figure 7] taken of those very ﬁrst lungs showing 
partial inﬂation after fetal infusion with cortisol at 118 days of gestation. The 
lamb had delivered during the night. To my great surprise, I found it still alive 
in the morning, gasping but surviving. I was fully occupied with studies of 
parturitional physiology and was not inclined to pursue it further at that time. 
However, I did tell Mel Avery who was visiting NZ soon afterwards. She got 
on the phone and called one of her Fellows in her lab and told him to give 
cortisol to some fetal sheep. Our observation was published in 1969 and was 
soon followed by deLemos and Avery in 1970 which conﬁrmed the ﬁnding as 
well as providing direct evidence of accelerated appearance of surfactant as we 
had postulated.198
When I returned to a position as Senior Lecturer in Obstetrics and Gynaecology 
at the National Women’s Hospital in 1959 after six years of clinical work and 
no research in the UK, I realized that my academic appointment required me 
to do some research. I asked my friend, Bill Liley, of fetal transfusion fame how 
to choose a topic. He said to look for a major problem which was potentially 
soluble. The major problem was easy. Prematurity stood out above everything 
else. I naively thought that all I had to do was solve the ancient question of 
what controlled the onset of labour at term and the reason for premature onset 
would become apparent. I thought it might be a fetal activity although at the 
time it was generally believed maternal activity via release of oxytocin from her 
pituitary. But I had some circumstantial evidence to support my idea. Sheep 
browse on Veratrum californicum or skunk cabbage in the mountains.199 They 
don’t like it, but will eat it in times of drought. Binns et al. in 1960 described 
198 Liggins (1969); deLemos et al. (1970).
199 Keeler (1990). 
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how the lambs were cyclopian and had prolonged pregnancies.200 At autopsy 
they found defective pituitaries. With this titbit I set out to hypophysectomize 
fetal sheep. Having no money and no animal lab I called on friends at Ruakura 
Agricultural Research Station, 80 miles south of Auckland. They generously 
provided everything I needed. So over the next sheep season I worked out how 
to do fetal hypophysectomies and adrenalectomies. The following year I had a 
sabbatical and went off to the Vet School at the University of California at Davis, 
and put the techniques to the test. The results were dramatically successful. 
Pregnancies continued on and on after hypophysectomy.
Back in Auckland I needed a lab and money. The Hospital gave me an abandoned 
shed and the Wellcome Trust, courtesy of that wonderful man, Peter Williams, 
gave me money.201 My ﬁrst experiments were to test the idea that the effects of 
the pituitary were mediated by the fetal adrenal. Infusion of cortisol or ACTH 
caused premature delivery at any gestational age. With that lengthy background 
we have arrived at the subject of the seminar, although there is plenty more to 
the parturition story.
200 Binns et al. (1960). For the background of Dr Wayne Binns’ work, see James (1999).
201 See Appendix 3, pages 97–9. 
Figure 7: Lamb lungs showing partial inﬂation after fetal infusion with cortisol at 118 days 
of gestation, birth at 120 days, photographed at autopsy. The pale areas are tissue inﬂated 
with air.  The dark areas are uninﬂated lung.
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When I saw the inﬂated lungs [Figure 7] and correctly guessed that cortisol 
had induced one or more enzymes responsible for surfactant synthesis and/or 
release, it seemed very likely that this was not a species-speciﬁc response since 
cortisol was well known to induce a variety of enzymes in a variety of species. 
So no time was lost in enlisting the collaboration of my neonatal colleague, 
Ross Howie, who I knew to be meticulous almost to a fault. We worked out 
what we thought was a rigorous protocol, but as simple in design as possible. 
An immediate problem was what to give the mothers and how much of it. It 
happened that I had been studying the effects of corticosteroids on human fetal 
adrenal function by measuring urinary oestriol excretion, which is a product of 
the fetal zone of the fetal adrenal. So I knew the dose of corticosteroid required 
to cause marked inhibition of adrenal function. To simplify administration to 
the mothers in the trial a once daily dose was desirable so we chose a mixture of 
a long-acting and a short-acting corticosteroid. This created a problem since all 
long-acting preparations are insoluble and in suspension. The placebo had to be 
identical in appearance. We ﬁnally chose cortisone acetate which is a suspension 
but one-seventieth of the potency of our active agent. The choice of active agent 
came down to what drug company was willing to supply the active and placebo 
ampoules. Glaxo, originally a NZ company, came up trumps and the trial soon 
began. Glaxo could see that no proﬁt was to be made but were happy to do it 
for goodwill. It was by chance then that our choice of agent has turned out to be 
the best. Ethics committees hadn’t arrived in 1969, but all clinical studies had 
to be submitted to the Senior Hospital Medical Committee for approval. The 
main purpose was to let the staff know what was going on and to enlist their 
co-operation. There were no conditions. We had told them that verbal consent 
would be obtained. The staff gave their full support so that 287 mothers were 
recruited in 22 months. The trial ran within the clinical care of each mother and 
no funding was required.
We offered our manuscript ﬁrst to Nature, which promptly rejected it without 
sending it out for review on the grounds that it lacked general interest.202
Judging by the number of trials that soon followed there was a lot of interest 
amongst obstetricians particularly in the US. I got the impression on visits to 
the UK that paediatricians there were lukewarm, perhaps because there was a 
202 Professor Sir Graham Liggins wrote: ‘Yes, Lancet, not Nature.’ E-mail to Mrs Lois Reynolds, 2 September 
2005. See also Professor Liggins’ description of the event when the article appeared as a Citation Classic in 
1982, having been cited over 565 times in the ten years after publication, at http://garﬁeld.library.upenn.
edu/classics1982 /A1982NF37800001.pdf (visited 26 September 2005).
Prenatal Corticosteroids — Appendix 1
88
perception that their territory was being encroached on. Judging by the 20 years 
that it took the RCOG to come out in favour, despite your constant nagging, 
there was a problem with British obstetricians too, though I don’t understand it.
Best wishes, Mont
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Appendix 2
Prenatal glucocorticoids in preterm birth: a paediatric view of the  
history of the original studies by Ross Howie, 2 June 2004
For the Wellcome Trust Centre seminar, London, 15 June 2004 
Firstly, my warmest greetings to Mel Avery, who was in at the very beginning 
of the whole surfactant story. My only regret for her is that she is not yet in at 
the end of it, at least as a major public health problem. If anyone had asked me 
at the time Mont Liggins and I ﬁrst published in 1972 how I thought the New 
Zealand work would be viewed in the year 2004, I would have replied that 
by then advances in our understanding and management of preterm delivery 
and its associations would surely have made it irrelevant.203 Which only goes to 
show, yet again, how naive it can be to try to divine the future.
I write with reservations, which had better be stated before they become too obvious. 
This account is largely from memory, and after more than 30 years faculties tend 
to blur. I have been long out of touch, and have been unable to consult most of 
my papers (in storage after a recent house move) or to visit libraries. But as there 
appear to be some misconceptions abroad about the early history of the work it 
may be useful to have something on record, however scrappy.
At the outset, it may be worth reminding others that the project was only a 
sideline of the main work of both Mont Liggins on the one hand and myself on 
the other. Mont has his much more widely ranging research into reproductive 
endocrinology for which he is so justly renowned. My own main interest was 
in health rather than science, especially in helping develop newborn services in 
New Zealand, and I just happened to be around at the time. But I helped design 
the trial, supervised the collection of data and did all the work of analysing 
them. If I hadn’t been around, I imagine trials would not have been done in 
Auckland and would not have been as large, at least from one centre.
A word on the setting. Possibly few single centres in the world could have carried 
out such a trial at that time. It needed one with a large number of births that 
was also academically well enough developed. Overseas, academic units tended 
to have relatively few births, and the large obstetric services tended not to have 
close academic ties. In Auckland, the National Women’s Hospital (NWH) then 
203 Liggins and Howie (1972).
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had about 5000 deliveries a year, among which were concentrated mothers and 
babies of the highest risk from about 15 000 in the region. The hospital had 
within it the Postgraduate School of Obstetrics and Gynaecology, which had 
a background of research starting with Bill Liley and his rhesus work, which 
Mont Liggins rejoined shortly after.204 
Nor, in other places, did it seem common for obstetricians and paediatricians 
to talk much with each other. The two disciplines had differences of outlook 
and values that were not always easy to bridge, but a good collaboration had 
been established at NWH. This was thanks very largely to successive heads of 
the Postgraduate School, Harvey Carey and Dennis Bonham, to the then senior 
paediatrician, Jack Matthews, and to Bill Liley. Drs Liley and Matthews had 
set up a Rhesus Committee about 1960, which brought together the obstetric, 
paediatric and other staff likely to be involved with the rhesus deliveries. 
From his coming in 1964, Dennis Bonham (fresh from his monumental work 
with Neville Butler in the British Perinatal Mortality Survey) reinforced this 
approach.205 In my medical school years (1952–56) I never heard the word 
‘perinatal’ and the outlook the word implies was in many places some time in 
the future.206
At the time Mont was doing his relevant basic research in the late 1960s, the 
death rate of babies in the newborn period was at least ﬁve times the present. 
By far the leading cause of death then was respiratory failure in babies born 
early. I was the only person in Auckland (and for that matter in the whole of 
the country) who could ventilate babies. I did not do it very well: techniques 
were crude, equipment limited, and nursing staff and other support short. This 
204 For Liley’s rhesus work, see Christie and Tansey (eds) (2005): 11–12, 17, 53–4. 57.
205 Bonham (1961).
206 ‘On the history of the word ‘perinatal’, I [Ross Howie, writing in June 2004] wonder whether anyone in 
the Wellcome Trust Centre can enlighten us. The coining of the word was a landmark that surely deserves 
recognition. A quick check of the US NLM website PubMed for occurrences of the words ‘perinatal’ and 
‘perinatale’ in titles of journal articles showed none earlier than 1952, when there were three. I tentatively 
concluded that the ﬁrst use of the word may have been in Europe in a language not English, French or 
German, but possibly Dutch, Scandinavian or Eastern European. At this point I found myself out of my 
depth and in need of more expert help.’ Dr Ross Howie later wrote: ‘Sir Iain Chalmers passed my query 
on to the noted US pioneer, Dr William Silverman, who replied: “The origin of the word ‘perinatal’ can be 
traced to Peller (1948), who coined the term to mean ante-, intra-, and postpartum, the period around and 
including the time of birth”. [Silverman (1961): 4.]’ E-mail to Mrs Lois Reynolds, 22 August 2005.
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was to my oft- and forcibly expressed regret, strongly supported by my two 
paediatric colleagues, Jack Matthews and Leo Phillips. The facilities of modern 
newborn care are now taken for granted, but it was a long and hard ﬁght to get 
them. In those days I felt I spent altogether too much time up at nights looking 
after babies, and was very ready to welcome any development that might reduce 
that need – never to mention, of course, beneﬁt to the babies in sparing them 
the tender mercies of intensive care.
The development came in a way that, if not familiar to members of your seminar, 
will presumably be explained by Mont himself. I still remember the excitement 
I felt at my ﬁrst evidence of it, when he handed me the lungs of twin lambs 
for pressure–volume studies. The lambs had been delivered very early: one had 
been infused with glucocorticoids and the other not. Lungs of the infused lamb 
were perfectly stable after inﬂation: pink, ﬂuffy and ﬂoated in water [see Figure 
7]. In total contrast, the lungs of the other remained solid and liver-like, and 
sank. After Mont had conﬁrmed the effect in further animal studies, he looked 
to set up the ﬁrst human trials and called me in. He looked after the maternal 
side and I that of the babies. 
My side was not, I thought, likely to be simple, as anyone with any knowledge 
of the ﬁeld will appreciate. Babies born unﬁnished, sent ‘before [their] time into 
this breathing world’ form, collectively, probably the most complex situation in 
human biology.207 It is complex partly because of the variety of associations of 
preterm delivery, but more because of the effects on every body system, not just 
the breathing; effects varying with gestational age and many other factors. It was 
not to be expected that one size would ﬁt all.
If the therapy worked at all, it seemed a priori that it would work under some 
conditions and not others, and under yet others might be hazardous. In the 
words of Claude Bernard, what is true in general is likely to be false in particular. 
I was also conscious of the history of so many ‘advances’ in medicine, which 
have come in phases: the ﬁrst of initial and uncritical enthusiasm, followed by 
one of debunking, and ﬁnally – if the development is worth while – one of a 
more sober balance. We were keen to see the project through all these phases 
and ﬁnd out as much as possible of the limitations of the therapy before others 
did. I set myself up at the outset as a chief sceptic, and have remained so.
We felt that only a very large study could hope to give results of any reliability. 
As a result the trial may have been kept going for longer than would meet with 
207 William Shakespeare’s Richard III, Act 4, Scene 1. See also Anonymous (1976). 
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the approval of an ethics committee today, but the results may be on a ﬁrmer 
footing as a result.
The analysis was carried out using Hollerith punch cards.208 I wonder how many 
people at the meeting are ancient enough to have had any experience of them. 
Our equipment could be described (politely) as somewhat temperamental, 
especially the card sorter, which at times would chew up one in every 500 cards 
put through the machine. The work could be tedious and time consuming, 
but I felt I had a handle on the data and could fairly promptly recognize and 
rectify ‘garbage out’. I have had no experience of analysis of research data by 
computer, but sometimes wonder whether those who by this means can get 
almost instantaneous results today have the same feel for their raw material. 
Incidentally, I was fascinated to note that in that fons et origo of high technology, 
the US, punch cards were used in their last Presidential election.209 I felt like 
offering my services as a technical consultant for the next one.
The ﬁrst paper attracted a lot of interest, among others from the World Health 
Organization, speciﬁcally its Human Reproduction Program. They proposed 
an international multicentre controlled trial, involving places like Bangkok and 
Leningrad (as it was then), with the aim of determining whether a treatment 
that appeared to work in Auckland would work as well in the possibly very 
different conditions of the other countries. Much as I would have liked to visit 
these exotic places, the prospect did not appeal. The conduct of a controlled 
trial must of course be meticulous, and I had found this difﬁcult enough in 
Auckland. Confusion of the most vital data in even a very few subjects, e.g. 
recording therapy as treatment when it was actually control, or recording the 
presence of RDS when it was actually absent, would have had the effect of 
eliminating genuine differences between treatment and control groups, and 
hence making the results valueless. We did not relish the prospect of WHO 
going to vast trouble and expense to ‘disprove’ our results. 
We asked them instead, and they very kindly agreed, to fund us to carry out long-
term follow-up studies. ‘Long-term’ to us then meant to six years. The 30-year 
follow-up would at the time have seemed an impossible dream. In this we were 
singularly well placed by having a happy association with Barton MacArthur, an 
educational psychologist in the University. He was (and still is) New Zealand’s 
208 For an example of an early Hollerith machine and punch card, see Ness et al. (2002): 35.
209 For the importance of the chad, or imperfectly punched card, in the 2000 election, see www.
usconstitution.net/elec2000.html#e (visited 25 October 2005).
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leading authority on tests of cognitive function in young children, and brought 
to his work a meticulousness and rigour unmatched among psychologists 
in my experience.210
Overseas I was often asked what management I would recommend for a mother 
in preterm labour. My standard answer was that I was there purely to present 
our work and ﬁndings and could not tell them what to do; it was hazardous to 
base management on the ﬁndings of only one trial. That may have disappointed 
some, who told me that researchers were expected to sell their research. If my 
low-key approach contributed to the delay in acceptance of the therapy, I have 
no apologies. The matter is not simple and it does no service to over-simplify. 
If, as has been suggested, the message was not clear, it seemed to me to be clear 
enough to those who wanted to hear it, and it had its main intended effect of 
encouraging further trials.
But I welcomed Patricia Crowley’s meta-analysis and the stimulus the history 
gave to the work of Iain Chalmers and others in setting up the Cochrane 
Collaboration. This was a major advance and long overdue, even if I think 
rather too much has come to be expected of ‘evidence-based medicine’. More 
recently I have welcomed another development, the 30-year follow-up by Stuart 
Dalziel, Jane Harding and Anthony Rodgers. If, apart from its main purpose, it 
gives support to David Barker’s ideas of considering fetal origins of disease (or 
health) I shall be more than happy.211
Another point of contention may be the effect of antenatal steroids on mortality. 
I have heard it said that the therapy has saved hundreds of thousands of lives. It 
would be pleasant to think so, but I wonder how this number was calculated: if 
the Auckland ﬁgures came into the reckoning I would have to doubt it. It may be 
more accurate to say ‘helped to save’. The reason, of course, is the development 
of newborn intensive care since the time of our trials. It is not to be expected 
that the therapy would save lives these days, at least in developed countries. On 
the other hand it should do so in some more advanced developing countries, in 
places where newborn services are at the level ours were in the early 1970s. 
I well remember January 1975 – just after the trials ﬁnished – as a watershed 
in the development of our own services. In 1974 I was away from the unit for 
two weeks in Geneva discussing our proposed follow-up studies with WHO, 
210 MacArthur et al. (1981, 1982).
211 Barker et al. (1989). 
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and found on my return to Auckland that during my absence two relatively 
large babies had died from uncomplicated RDS. Both, I was sure, would have 
survived if treated very simply with George Gregory’s technique of continuous 
positive airway pressure (CPAP).212 I hit the roof and sent in my resignation. 
For some reason the powers that were felt it necessary to talk me out of it, 
but we did achieve more staff. Our ﬁrst full-time clinical specialist, Sue Sayers, 
took up her post in 1975, and only then did ‘neonatal intensive care’ become a 
sustainable reality in our hospital.
In all developed countries to my knowledge, perinatal survival improved 
strikingly in the second half of the twentieth century.213 In New Zealand it 
improved possibly more than most due to a remarkable nationwide effort very 
ably led by the successive heads of the Postgraduate School of O&G, Harvey 
Carey and Dennis Bonham. In the 40 years after the hospital was established, 
the national perinatal mortality rate by the WHO deﬁnition of the time fell 
by nearly 80 per cent, from 34.6 per 1000 births in 1950 to 7.4 in 1990.214 
Steroid therapy was a welcome advance during this time, but it would be hard 
to attribute to it more than a fraction of the improvement.
But I am sure it has a place. In fact most advances in medicine are only 
marginal, but for those on the margins, as so many are, speciﬁc interventions 
may be crucial. And mortality is only a crude measure: nowadays the beneﬁt 
may be more in reducing morbidity (short- and long-term) and the workload 
of newborn services. Recently my wife and I had a family experience of its 
use: a daughter-in-law delivered at 31 weeks after antenatal steroid therapy, 
which I did not hesitate to support. Our grandson had a completely uneventful 
course and is now a lively two-year-old, developing well. Whether his outcome 
in relation to the steroid therapy was post hoc or propter hoc I have no idea, but 
I was happy with the odds.
If some of what I have written seems provocative, I can at least claim that is in a 
good early National Women’s Hospital tradition. It is one that various pressures 
have caused to be sadly less in evidence during the past 20 years. If there was any 
greatness in that hospital in its early days (as I believe there was), much of it was 
212 See notes 30 and 31.
213 See Christie and Tansey (eds) (2001): 28. 
214 Perinatal mortality as stated then: fetal deaths after 28 weeks’ gestation plus ﬁrst-week neonatal deaths, 
expressed per 1000 total births.
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due to an environment of questioning conventional wisdom and challenging 
authority, and doing so constructively and with rigour. It was one especially 
fostered by the second head of the Postgraduate School, Harvey Carey (1955–
62), who encouraged, for example, Bill Liley and fetal transfusion (everyone 
knew that blood could not be absorbed intact from the peritoneal cavity), and 
Mont Liggins with the work that was the basis of the advance related in this 
account (everyone thought that it was the mother that determined the onset of 
parturition). I felt privileged indeed to be part of the hospital in those times.
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Appendix 3
Premature sheep and dark horses: Wellcome Trust support  
for Mont Liggins’ work, 1968–76 by Tilli Tansey215
In February 1968 the Trustees of the Wellcome Trust made a grant of £15 000 
‘to enable Professor Liggins to investigate the mechanisms responsible for the 
initiation of human parturition’. Three years later, a summary of the work carried 
out under the grant made remarkable reading – a number of sensitive hormone 
assays had been developed; the role of the fetus in initiating parturition in the 
sheep and rabbit had been extensively examined and several causative factors 
and pathways identiﬁed. 
 
Two discoveries stood out in particular:
7. We made the original observation of the phenomenon of induction of 
pulmonary surfactant in fetal lungs [of sheep] by glucocorticosteroids. 
This has subsequently been conﬁrmed in sheep by Kotas and Avery and 
extended by them to rabbits.216 
8. We performed the ﬁrst clinical trial of antepartum corticosteroid 
treatment in the prevention of respiratory distress syndrome in the 
human neonate. A controlled, blind trial involving over 300 women in 
premature labour has shown a reduction in the incidence of respiratory 
distress in babies born at 26–32 weeks of gestation from 75 per cent in 
the control group to 8.3 per cent in the treated group (p<0.02).
 
The impact and furtherance of those discoveries have, of course, been the 
subject of this meeting.
The Wellcome Trust went on to support Liggins and his team for a further 
ﬁve years; with a grant of £23 050 to cover research expenses and assistance 
for further work in ‘a study of the hormonal control of ovine parturition’. This 
215 Details taken from ‘Liggins G C’, File 4078, Records of the Wellcome Trust, consulted and reproduced 
by permission of the Wellcome Trust and Sir Graham Liggins.
216 Kotas and Avery (1971).
Prenatal Corticosteroids — Appendix 3
98
was supplemented by £3185 in 1974 to cover the effective loss to the original 
grant by a revaluation of the New Zealand dollar. That grant too provided 
outstanding results. Liggins’ ﬁnal report to the Wellcome Trust in 1976 lists 
‘a new physiological system’ – the fetal control of parturition; ‘a new disease’ 
– placental sulphatase deﬁciency; and ‘a new treatment’ – the prenatal use of 
corticosteroids. As the report emphasizes: 
 
Our discovery of acceleration by corticosteroids of maturation of 
lung function in fetal lambs and our subsequent application of this 
phenomenon to prevention of the Respiratory Distress Syndrome in the 
human neonate by fetal treatment with corticosteroids is now beginning 
to have a worldwide impact on the incidence of this disorder.
 
In 1971 when the second grant was being considered, the Wellcome Trust 
suggested that ﬁnancial liability for Liggins and his group might be passed to 
the New Zealand Medical Research Council. Discussions between ofﬁcers and 
a Trustee (Sir John McMichael) of the Trust, staff of the NZ MRC, and Liggins 
and colleagues in the University of Auckland resulted in a transfer of ﬁnancial 
responsibility for the work in 1976. The ﬁnal correspondence between Liggins 
and the Director of the Wellcome Trust, Dr Peter Williams, is illuminating.
18 February 1977
Dear Dr Williams,
I want to add my personal thanks to you to the more formal appreciation 
conveyed in my ﬁnal Report. It is difﬁcult to convey the extent of my 
gratitude to you for the support you gave me as a ‘dark horse’ which has 
had such a profound effect on my career.
Kindest regards, 
Yours sincerely, 
Mont Liggins
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28 February 1977
Dear Professor Liggins,
I am writing to thank you very much for your kind comments both 
to myself and the Trustees about the support for your work. It is very 
satisfactory to know that such a ‘dark horse’ came in as a front runner.
It is possible that I may be visiting New Zealand later in the year in 
which case I would hope to be able to come and see you and get a ﬁrst 
hand account of your work.
With kind regards,
Yours sincerely,
Peter Williams
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Appendix 4
Prenatal corticosteroid therapy: early Auckland publications,  
1972–94 
Ross Howie, January 2005
This has been compiled for the historical record because of continuing interest, 
and because most of the trial reports were published in books or conference 
proceedings, and hence are not included in the online database PubMed. The 
list includes reports of the initial follow-up studies, but not abstracts, or trials of 
TRH with betamethasone.
Liggins G C, Howie R N. (1972) A controlled trial of antepartum glucocorticoid 
treatment for prevention of the respiratory distress syndrome in premature 
infants. Pediatrics 50: 515–25.
Liggins G C, Howie R N. (1973) Prevention of respiratory distress syndrome 
by antepartum corticosteroid therapy. In Physiological Society, Barcroft 
Sub-Committee editorial board, Comline K S et al., Foetal and Neonatal 
Physiology: Proceedings of the Sir Joseph Barcroft Centenary Symposium, held 
at the Physiological Laboratory, Cambridge, 25–27 July 1972. Cambridge: 
Cambridge University Press, 613–17.
Howie R N, Liggins G C. (1973) Prevention of respiratory distress syndrome 
in premature infants by antepartum glucocorticoid treatment. In Villee C A, 
Villee D B, Zuckerman J. (eds) Respiratory Distress Syndrome. New York, NY: 
Academic Press, 369–80.
Howie R N, Liggins G C. (1974) Clinical trial of betamethasone for the 
prevention of the respiratory distress syndrome. Proceedings of the XIV 
International Congress of Paediatrics, Buenos Aires, 3–9 October, 1974. In 
For A Healthy Child in A Better World: Fourteenth International Congress of 
Paediatrics, Buenos Aires, 3–9 October 1974 and ﬁve other recent paediatric 
congresses. Annales Nestlé series no. 35. Zurich: Nestlé Scientiﬁc Services. 
Liggins G C, Howie R N. (1974) The prevention of RDS by maternal steroid 
therapy. In Gluck L. (ed.) Modern Perinatal Medicine. Chicago, IL: Year 
Book Medical Publishers: 415–24.
Howie R N, Liggins G C. (1976) Maturation of the lung: present understanding 
and practical implications. Bulletin of the Postgraduate Committee in Medicine 
of the University of Sydney special issue: 19–30.
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Liggins G C. (1976) Prenatal glucocorticoid treatment: prevention of respiratory 
distress syndrome. In Moore T D. (ed.) Lung Maturation and the Prevention 
of Hyaline Membrane Disease. Report of the 70th Ross Conference on Pediatric 
Research. Columbus, OH: Ross Laboratories, 97–103.
Howie R N, Liggins G C. (1978) Clinical trial of antepartum betamethasone 
therapy for prevention of respiratory distress in pre-term infants. In Anderson 
A, Beard R W, Brudenell J M, Dunn P M. (eds) Preterm Labour: Proceedings 
of the ﬁfth study group of the Royal College of Obstetricians and Gynaecologists, 
1977. London: The College, 281–9.
MacArthur B A, Howie R N, Dezoete J A, Elkins J. (1981) Cognitive and 
psychosocial development of four-year-old children whose mothers were 
treated antenatally with betamethasone. Pediatrics 78: 638–43.
Howie R N, Liggins G C. (1982) The New Zealand study of antepartum 
glucocorticoid treatment. In Farrell P M. (ed.) Lung Development: Biological 
and clinical perspectives. Vol. 2: Neonatal respiratory diseases. New York, NY; 
London: Academic Press, 255–65.
MacArthur B A, Howie R N, Dezoete J A, Elkins J. (1982) School progress and 
cognitive development of 6-year-old children whose mothers were treated 
antenatally with betamethasone. Pediatrics 70: 99–105.
Howie R N. (1984) Pharmacological acceleration of lung maturation. In Raivio 
K O, et al. (eds) Respiratory Distress Syndrome: Proceedings of the Eighth Sigrid 
Juselius Symposium, Helsinki, 9–12 August 1982. New York, NY; London: 
Academic Press, 385–96. 
MacArthur B A, Howie R N, Dezoete J A, Elkins J, Liang A Y. (1989) Long-
term follow-up of children exposed to betamethasone in utero. In Tejani N. 
(ed.) Obstetrical Events and Developmental Sequelae. Boca Raton, FL: CRC 
Press, 81–89.
MacArthur B A, Howie R N, Dezoete J A, Elkins J, Liang A Y. (1994) Long-
term follow-up of children exposed to betamethasone in utero. In Tejani 
N (ed). Obstetrical Events and Developmental Sequelae, 2nd edition. Boca 
Raton, FL: CRC Press, 81–9. [Largely unchanged from 1st edition.]
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Appendix 5
Protocol for the use of corticosteroids in the prevention of respiratory 
distress syndrome in premature infants 
From the 1975 UK Study
217
Purpose of the study
To investigate the effectiveness of betamethasone 21 phosphate (‘Betnesol’, 
Glaxo Laboratories Ltd) in preventing respiratory distress syndrome (RDS) in 
the premature fetus (< 34 weeks’ gestation).
Rationale
There is evidence from animal studies that surfactant is secreted into the fetal 
lungs if stimulated by corticosteroids. Liggins and Howie (Pediatrics 50: 515 
[1972]) produced data in humans which indicated that the risk of developing 
RDS was reduced by maternal injection of 12mg betamethasone daily for two 
days. There was no indication of obvious adverse effects to mother or fetus. The 
trial proposed here is to conﬁrm these clinical ﬁndings as well as to investigate 
more formally any likely adverse effects.
Selection of patients
The patient’s consent to participate in the trial should be sought according to 
the policy of the hospital. Patients will be classiﬁed into two main groups:
Group I Women at less than 34 weeks’ gestation (ie end of 33rd week) who 
are in clinical spontaneous premature labour either:
a)  With ruptured membranes 
 or  b)  Without ruptured membranes
Group II Women at less than 34 weeks’ gestation (ie end of 33rd week) who 
are not in premature labour but:
a) For whom early elective induction is indicated, and who show 
low lecithin concentrations or L/S ratios;
b) For whom early elective induction is indicated but for whom 
no data is available on lecithin concentrations or L/S ratios.
217 Gamsu et al. (1989).
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Exclusions from study
1) Patients in whom steroid treatment is contra-indicated.
2) Patients for whom a delay of >24 hours before delivery is not 
in the interest of mother or fetus.
3) Diabetics.
4) Amnionitis. (If amnionitis is diagnosed after admission of 
patient to the trial an indication of how the diagnosis was 
made should be recorded. Further trial data for such a patient 
should still be recorded.)
Patient number
During the year results will be subject to periodic review and the total number 
of patients to be included will depend on the signiﬁcance of these results.
Design of trial
Double-blind trial comparing intramuscular doses of ‘Betnesol’ with placebo.
Drugs and dosage
Intramuscular injections of ‘Betnesol’ or matching placebo will be administered 
in a dosage of 1ml (= 4mg betamethasone 21 phosphate) every eight hours over 
a 48-hour period (total of six doses). Only one course of ‘Betnesol’ or placebo 
treatment may be given.
Allocation of patients to either placebo or active groups will be done according 
to a random code. The ampoules will be provided in numbered boxes to 
facilitate this.
Procedure
1) Patients will be examined on admission. Each patient will be 
allocated a trial number, a data sheet and a box of ampoules 
bearing her trial number.
2) Relevant patient details will be noted on the data sheet.
3) Group I
a) Inhibition of uterine contractions will be attempted using 
salbutamol according to a standard scheme, (see Table 5). 
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If possible labour will be delayed for at least 48 hours. If 
delivery occurs in less than 48 hours all data should still 
be recorded.
b) Each patient will receive an intramuscular injection of 
‘Betnesol’ (4mg) or placebo according to a random code.
c) ‘Betnesol’ injection (4mg) or placebo will then be 
administered at eight hourly intervals over a period of 
48 hours.
d) Antibiotics will not be routinely administered in cases of 
spontaneous ruptured membranes.
e) If the patient goes into premature labour again after the 
sixth (last) injection of ‘Betnesol’ (or placebo) salbutamol 
may be re-used at the discretion of the physician, but on no 
account should further ‘Betnesol’ or placebo be given.
 4)  Group II(a)
i) In these patients amniocentesis will be carried out. Those who 
show a low lecithin concentration or L/S ratio according to 
the standards of each hospital, will receive an intramuscular 
injection of ‘Betnesol’ (4mg) or placebo. This will be 
repeated at eight hourly intervals over a 48 hour period (six 
injections). The standards for interpreting the amniocentesis 
results should be deﬁned at the beginning of the trial.
ii) 48 hours after the start of the treatment period (or as soon as 
possible thereafter) amniocentesis will again be carried out 
to determine the lecithin concentration or L/S ratio.
 5) Group II(b)
i) Amniocentesis is not applicable for these patients, therefore 
no data on L/S ratios or lecithin concentrations will 
be available. The patients will receive an intramuscular 
injection of ‘Betnesol’ (4mg) or placebo every eight hours 
for six injections.
6) Groups I, II(a) and II(b)
i) The clinician will decide clinically on the optimum time 
interval between completion of steroid treatment and 
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delivery (ideally between 48 hours and seven days after the 
start of ‘Betnesol’ or placebo treatment).
ii) Maturity will be assessed 24–48 hours after birth in a well 
baby; this assessment may be postponed in a baby who is 
very ill. Signs of hyaline membrane disease, as listed on 
the record form, will be noted. In the case of post mortem, 
tissues should be retained for inclusion body counts which 
will be performed centrally.
iii) Adrenal function of baby. Approximately 5ml of cord blood 
from the umbilical vein should be collected immediately 
after the end of the third stage of labour, preferably by syringe 
and needle, and placed in a heparinized bottle. If taken at 
night, whole blood may be stored in a fridge (4°C). All 
samples should subsequently be centrifuged and the plasma 
deep frozen (-20°C). Plasma 17-hydroxycorticosteroids 
will be estimated centrally or in the individual hospitals, 
depending on the facilities available.
iv) In some centres adrenal function of mothers will be monitored 
for several days following delivery (method to be decided).
Withdrawals
Any patient may be withdrawn from the trial at the discretion of the clinician. 
A reason for withdrawal should be stated on the data sheet.
Side-effects
Any side-effects attributed to the treatments used in this trial should be notiﬁed 
to Glaxo Laboratories immediately. This is a requirement of the Committee on 
Safety of Medicines.
In the event of any queries please contact: Dr C H Dash/Mrs B M Mullinger, 
Medical Department, Glaxo Laboratories Ltd, Greenford, Middlesex. 
Tel: 01-422 3434 Ext 363.
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Table 5: Use of salbutamol in Group 1 patients for the management of 
premature labour for trial of corticosteroids in the treatment of RDS. 
Patients: All patients in Group I presenting in spontaneous premature 
labour without evidence of amnionitis, thyrotoxicosis 
or cardiac disease. The physician should be satisﬁed that 
premature labour has commenced, ie regular contractions 
occurring at intervals of ten minutes or less. Salbutamol 
treatment will then be started immediately.
Assessment 
before 
salbutamol 
treatment:
Cervical dilatation and effacement will be recorded on the 
record form together with maternal blood pressure, pulse 
rate and fetal heart rate.
Composition 
of salbutamol 
infusion:
5ml = 5mg salbutamol injection should be added to 
500ml 5 per cent dextrose solution to give a concentration 
of 10μg salbutamol per ml equivalent to 15 drops from a 
normal giving set. 
Treatment: Patients will receive an infusion of salbutamol through a 
forearm vein. The infusion will be started at 10 drops per 
minute (6.7μg salbutamol/minute) and increased by 10-drop 
increments at ﬁve to ten minute intervals until contractions 
cease or an infusion rate of 50 drops per minute (33μg/min) 
is reached. If contractions have not ceased, the infusion will 
be increased by 10-drop increments at 20-minute intervals. 
Treatment should be stopped if any of the following occur:
1. An infusion rate of 80 drops per minute (53μg per 
minute salbutamol) does not reduce contractions in 
strength, duration or frequency;
2. The cervix has dilated signiﬁcantly after six hours of 
treatment;
3. A steady maternal pulse rate exceeding 140/min  
is reached.
Prenatal Corticosteroids — Appendix 5
108
Once contractions have ceased, the infusion will be 
maintained at this steady rate for one hour. The infusion rate 
will then be reduced by half and maintained at this lower 
rate for six hours. The infusion rate will then be reduced 
by half again and maintained for a further six hours, before 
starting oral treatment with 14mg salbutamol (Ventolin) 
tablets qds for one week.
In the event of unacceptable side-effects occurring such as 
tremor or palpitations, salbutamol dosage by infusion or 
oral routes may be reduced.
 
Figure 8: Example of salbutamol treatment  
Records: Uterine contractions, maternal pulse rate and blood pressure and fetal 
heart rate will be monitored regularly (or prior to each change in salbutamol 
dose), until the maintenance infusion rate is reached; thereafter records will be 
made at 30-minute intervals until infusion is stopped.
Repeat therapy: If contractions become re-established during or after infusion 
treatment, the infusion will be increased or re-started at the previous one hour 
maintenance level and reduced as before at six hourly intervals.
Treatment will not normally be repeated on more than four occasions or after 
36 weeks’ gestation without the direction of the clinician concerned.
Speciﬁc queries regarding the use of salbutamol may be addressed to:—
Clinical Research Unit, Allen and Hanburys Research Ltd, Ware, Herts   
Tel: Ware 3232 Ext 286
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Women’s National Hospital, 
Auckland, from 1959 as a New 
Zealand Medical Research Council 
Senior Research Fellow, then at 
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PhD FRCOG FRCP FFPH  
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to Queen Charlotte’s Hospital, 
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for the Department of Health 
in England and is Director of 
Research Methods Programme, for 
NHS R&D.
Sir Peter Medawar
OM FRS (1915–87) was 
Jodrell Professor of Zoology 
and Comparative Anatomy at 
University College London from 
1951 to 1962. He shared the 
1960 Nobel Prize in Physiology or 
Medicine with Macfarlane Burnet 
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the National Institute for Medical 
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for the European School of 
Osteopathy, Maidstone, Kent.
Professor Ann Oakley
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Thomas Coram Research Unit, 
University of London, in 1985 
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Director of the Social Science 
Research Unit at the University 
of London Institute of Education 
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University of Oxford, from 1973 
until his retirement in 1990, later 
Professor Emeritus; and Honorary 
Consultant Obstetrician and 
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physiology from Bedford College 
for Women, where she worked 
from 1933 to 1938. She spent 
two years at a London Blood 
Transfusion Unit at the beginning 
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